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ABSTRACT
Synthesis and Characterization of Novel Platinum(II) and Platinum(IV) Complexes
Containing 4,4′-Disubstituted-2,2′-bipyridine Ligands for the Treatment of Cancer
By
Van Vo
Dr. Pradip K. Bhowmik, Examination Committee Co-Chair
Dr. Bryan L. Spangelo, Examination Committee Co-Chair
Department of Chemistry
University of Nevada, Las Vegas

Three series of platinum(II) and platinum(IV) complexes containing 4,4′disubstituted-2,2′-bipyridine ligands have been synthesized and characterized by 1H
NMR,

13

C NMR spectroscopy, elemental analysis, mass spectroscopy, and differential

scanning calorimetry measurements. The MTS cell proliferation assay was used to
examine the in vitro anti-proliferative activities of these complexes in various human
breast, lung, and prostate cancer cells. The cell’s response to the complexes varies
between different cell lines; however, the low EC50 values determined from the MTS data
indicate that several of the complexes are much more potent than cisplatin.
Flow cytometric analysis of selected compounds revealed induction of apoptosis
and some necrosis. One of the complexes, Pt(II)-4C, was further studied by examining
its interaction with DNA and its effect on mitogen-activated protein kinase (MAPK)
signaling. Data from UV-Vis analysis with calf thymus DNA, gel electrophoresis with
plasmid pBR322 DNA, and inductively coupled plasma-atomic emission spectrometry
(ICP-AES) indicate that Pt(II)-4C is able to bind to DNA, cause unwinding of the
circular plasmid DNA, as well as covalently modify cellular DNA. Results from western
iii

blotting, flow cytometric immunofluorescence, and immunofluorescence microscopy
indicate activation of JNK, ERK, and p38. Cells treated with Pt(II)-4C in the presence
of JNK and p38 inhibitors had increased cell viability compared to cells treated with
Pt(II)-4C alone indicating that JNK and p38 are involved in Pt(II)-4C induced cell
death.
These results demonstrate the potential utilization of these novel complexes for
the treatment of cancer.
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CHAPTER 1

INTRODUCTION

1.1 General statement
This dissertation has been organized as manuscripts (Chapters 2–5). Chapter 2
corresponds to the contents of a published paper1 with the format modified to fit the
formatting requirements. Chapters 3–5 are manuscripts in preparation.
1.2 Background and Significance
1.2.1 Cancer and current treatment options
Currently, about 25% of the deaths in the United States are due to cancer, making
it the second leading cause of death. In 2014, an estimated 1.7 million new cancer cases
(855,000 males and 810,000 females) and 586,000 cancer deaths (310,000 males and
276,000 females) are projected to occur.2 Prostate and lung cancers are the top two
leading cancer types in males; whereas, breast and lung cancers are the top two leading
cancers in females.
Not only is cancer a leading cause of death in the U.S., but it is also a leading
cause of death worldwide. In 2012, there were an estimated 14.1 million new cases of
cancer and 8.2 million cancer-related deaths worldwide.3 With an estimated 1.7 million
new cancer cases diagnosed in 2012 (25% of all cancers), breast cancer is the most
frequent cancer among women and is the second most common cancer in the world.
Overall, with 522,000 deaths, breast cancer ranks as the fifth cause of death from cancer.
Lung cancer remains as the most commonly diagnosed and cause of cancer-related death

1

in the world with an estimated 1.8 million new cases and 1.6 million deaths in 2012. In
2012, there were an estimated 1.1 million new cases of prostate cancer worldwide,
making it the second most common cancer in men and the fourth common cancer overall.
Additionally, it is the fifth leading cause of cancer-related death (307,000 deaths) in
men.3
If the trends for the global cancer rates remain the same, it is projected that the
number of new cases of cancer will increase to 22.2 million and the number of cancerrelated deaths will increase to 13.2 million by the year 2030.4 These are an increase of
about 60% compared to the estimates from 2012, which is a cause for concern.
Cancer treatment varies depending on the type of cancer and its stage. The three
classical approaches to cancer treatment are surgery, radiotherapy, and chemotherapy. If
the cancer is localized, surgery is usually the first approach; however, if surgery cannot
be performed or does not successfully remove all of the diseased cells, then radiotherapy,
chemotherapy, or a combination of the three is used. For certain breast and prostate
cancers, hormonal therapy is an alternative treatment option. Additionally, with the
recent technological advances and a better understanding of cancer cell biology, more
selective treatment options such as targeted therapy and immunotherapy are now
available.5,6
1.2.2 Platinum (Pt)-based chemotherapy
1.2.2.1 Cisplatin and related compounds
Many new innovative methods of cancer treatment are continuously being
introduced; however, chemotherapy remains a standard treatment option. A
chemotherapeutic drug that is commonly prescribed for the treatment of many cancers is
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cisplatin (CDDP), a square-planar Pt(II) compound coordinated to two ammonia and two
chloride ligands in cis configuration (Figure 1-1). Cisplatin was first synthesized by
Peyrone in 1844 and Rosenberg accidentally discovered its antitumoral property in 1965,
which sparked an interest in the development of platinum complexes as chemotherapeutic
drugs in the 1960s.7–11 Cisplatin gained approval for clinical treatment by the U.S. Food
and Drug Administration (FDA) in the late 1970s and is now widely used in the treatment
of many malignancies, including glioblastoma multiforme, cancers of the bladder, lung,

Figure 1 – 1. Structures of cisplatin and platinum(II) complexes in clinical use.

breast, uterus and cervix, and testicular cancer.11,12 Research on platinum drugs has
resulted in the synthesis of thousands of platinum complexes; however, only a few have
been approved for clinical use. Along with cisplatin, two other Pt(II) complexes,
carboplatin and oxaliplatin, are approved for use worldwide (Figure 1-1). Additionally,
five other Pt(II) complexes are used in selected countries; lobaplatin and dicycloplatin in
China, nedaplatin and miriplatin in Japan, and heptaplatin in Korea.9–11,13–16
3

Figure 1 – 2. General structure of Pt(II) and Pt(IV) complexes.

As many researchers remain focused on improving Pt(II) complexes, some are
expanding into the development of Pt(IV) complexes. Unlike Pt(II) complexes which
have four coordinating ligands attached to the Pt center (giving it a +2 oxidation state),
Pt(IV) complexes have six coordinating ligands (giving it a +4 oxidation state) (Figure 12). These complexes are generally prepared by oxidation of Pt(II) compounds with Cl2 or
H2O2 and further modified by reactions with various reagents to produce the desired axial
ligands.13,17,18 They are described as prodrugs because these compounds require
activation through intracellular enzymatic reduction to Pt(II). The use of Pt(IV)
complexes as prodrugs is of interest due to advantages of the Pt(IV) structure over Pt(II).
They have a low-spin d6 octahedral geometry, which make these compounds more inert
to substitution reactions than its Pt(II) counterparts. The decreased reactivity leads to a
reduction in side effects and the potential for oral administration. The added coordination
of the axial ligands of Pt(IV) complexes allow for greater flexibility in strategies that
improve solubility and target selectivity.13,19 Along with cisplatin, several Pt(IV)
complexes (cis-[Pt(NH3)2Cl4], trans-[Pt(NH3)2Cl4] and [Pt(en)Cl4]) were described by
Rosenberg et al.; however, they were less effective than cisplatin.20 Since then,
Iproplatin, tetraplatin, and satraplatin are several other Pt(IV) complexes which have
entered clinical trials (Figure 1-3). Tetraplatin was abandoned in Phase I clinical trials
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due to severe neurotoxicity. Iproplatin was abandoned because it was less effective than
cisplatin and carboplatin. Satraplatin can be administered orally and is less toxic than
cisplatin, but there is no improvement in overall survival benefit. It is still undergoing
clinical trials in combination with other chemotherapeutic agents.13,19–21

Figure 1 – 3. Structures of some platinum(IV) complexes that have entered clinical trials.

Presently, about 50% of cancer chemotherapeutic regimens consist of platinum
(Pt)-based drugs; however, treatment with platinum drugs is accompanied by severe side
effects such as nephrotoxicity, neuropathy, ototoxicity, and myelosuppression.
Additionally, other drawbacks such as intrinsic or acquired resistance and limited activity
against some major types of cancer have impeded the clinical utility of these
drugs.9,10,13,20,21 To circumvent these drawbacks, the quest for improved platinum drugs
continues with the goal of discovering compounds with greater efficacy and reduced
toxicity.
1.2.2.2 Cellular response to platinum drugs
The cytotoxic effect of cisplatin is mainly due to the formation of DNA adducts
even though only a small percentage (5–10%) of the intracellular cisplatin concentration
is found in the nucleus.22 When administered into the body, cisplatin is kept inactivated
by the high chloride ion concentration in the extracellular space. Once inside the cell
where the chloride ion concentration is low, cisplatin is activated by substitution of the
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labile chloride ligands with water molecules and then undergoes nucleophilic attack of
the N7 position of guanine (and adenine to a lesser extent) to form irreversible cisplatinDNA cross-links.7,8,12,13,22 Although the overall structure of the DNA double helix stays
the same, the arrangement of several bases are disrupted because of unwinding and a high
degree of bending toward the major groove.13,23,24 Cisplatin-induced DNA damage elicits
various cellular responses such as cell cycle arrest, activation of repair mechanisms,
stress response, and cell death pathways. The two pathways that are of interest for this
dissertation are the p53 and the mitogen-activated protein kinases (MAPK).
The p53 protein is a tumor suppressor that is involved in many processes
including activation of DNA repair, cell cycle arrest, and initiation of apoptosis. 25 During
normal cellular conditions, p53 has a short half-life and is kept at a low level by the
Mdm2 ubiquitin ligase. However, the interaction of p53 with Mdm2 decreases when
stimulated by stress signals, which allows for the accumulation and phosphorylation of
p53.25,26 Activated p53 can then interact with other proteins such as p21 (cell cycle
protein) or Bax (apoptotic protein).26 Current data from the literature indicate that the role
of p53 in cisplatin treated cells varies depending on the cell line and duration of
treatment. In some reports, cisplatin-induced apoptosis is described as requiring
functional p53; however, the opposite is reported by some authors indicating that cells
with wild-type p53 are resistant to cisplatin treatment and sensitivity is achieved by
inhibition of its expression.22,26
The MAPKs are proteins that are activated by various stimuli to regulate cellular
processes such as proliferation, differentiation, movement, survival, and programmed
death.22,26 Three major MAPK members are extracellular signal-regulated kinases (ERK),
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c-Jun N-terminal kinases (JNK), and p38 kinases. Generally, ERK has a role in cell
proliferation and development; however, JNK and p38 have roles in apoptotic signaling,
inflammatory responses, and protective responses.22 These proteins are activated through
phosphorylation by upstream kinases and, in turn, phosphorylate downstream targets to
activate them. ERK, JNK, and p38 have all been demonstrated to be activated by
cisplatin; however, similar to p53, their roles also vary between different cell lines and
duration of treatment. In some studies, in accordance with their roles, ERK activation
protects cells from apoptosis, whereas, activation of JNK and p38 leads to apoptotic cell
death; on the other hand, some studies demonstrated the opposite.22,26–28
1.3 Research objectives
Described herein is a multidisciplinary dissertation project involving various
fields of science including synthetic organic chemistry, inorganic chemistry, analytical
chemistry, and cancer biochemistry, for the development of novel chemotherapeutic
agents.
The nitrogen containing 2,2′-bipyridine compounds are attractive ligands to use
for the synthesis of platinum drugs because of their high redox stability and ease of
functionalization.29,30 Various metal complexes containing 2,2′-bipyridine have been
reported to have antitumor activity,31–39 but these compounds have drawbacks such as
requiring special glassware or reaction conditions, and having lower activity than
cisplatin. These drawbacks contributed to the motivation to develop platinum complexes
containing the 2,2′-bipyridyl moiety with improved efficacy.
The goals of this project are to synthesize and characterize novel Pt(II) and Pt(IV)
cisplatin analogues containing 4,4′-disubstituted-2,2′-bipyridine, examine the cytotoxicity

7

of the synthesized compounds using a variety of human cancer cell lines, and characterize
the mechanism of action of the novel platinum complexes on selected human cancer
cells. These goals are accomplished with the following aims:


Aim I: Synthesis and characterization of novel Pt(II) and Pt(IV) cisplatin
analogues
Rationale. Although platinum-based drugs are used in about 50% of cancer
chemotherapeutic regimens, drawbacks such as cellular resistance, toxic side
effects, and the narrow spectrum of activity warrant the need for development of
platinum drugs with superior characteristics. Additionally, the National Cancer
Institute has reported a shortage of chemotherapeutic drugs for several years.
Synthesis of new drugs will not only alleviate this shortage problem and
circumvent the drawbacks of current platinum drugs, but also allow patients to
have access to alternative treatment options.
o Study 1: Synthesis of new platinum compounds containing 4,4′-disubstituted2,2′-bipyridine using various organic reactions and purification methods (i.e.,
recrystallization, extraction, and column chromatography).
o Study 2: Characterize the chemical structures and confirm the purity of the
compounds using elemental analysis, 1H and 13C NMR (nuclear magnetic
resonance spectroscopy), and DSC (differential scanning calorimetry).



Aim II: Assessment of the cytotoxicity of the synthesized compounds in multiple
human cancer cell lines and determination of the cell death pathway (apoptosis vs.
necrosis) induced by the active platinum complexes.
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Rationale. Often a chemotherapeutic drug such as cisplatin is effective for some
type of cancers, but ineffective in others. Thus, it is necessary to examine the
cytotoxicity of the compounds in various cancer cells to determine the potency
and potential application of these compounds.
o Study 1: Determine the cytotoxicity profiles of the synthesized platinum
compounds in various human cancer cell lines using the MTS colorimetric
cell proliferation assay.
o Study 2: Detect changes in the cell cycle and cell death pathways (apoptosis
or necrosis) activated by the platinum complexes using DNA laddering assay,
flow cytometry, and fluorescence microscopy.


Aim III: Characterization of the mechanism of action of the novel cisplatin
analogues on selected human cancer cells
Rationale. Understanding the cellular effect of a drug is important when
developing treatment strategies and predicting possible side effects. There is still
much to be explored about the biological effects of cisplatin; however, it is known
that cisplatin binds to DNA and forms adducts that damage the DNA and
activates the apoptotic pathway. The synthesized platinum(II) complexes have a
platinum center that is similar to cisplatin [Pt(IV) complexes are expected to be
intracellularly reduced to Pt(II)] and may bind to DNA to cause damage in a
mechanism analogous to cisplatin.
o Study 1: Analyze the interaction of the novel platinum complexes with DNA
using UV-Vis spectroscopy with calf thymus DNA and gel electrophoresis
with plasmid pBR322 DNA.
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o Study 2: Determine the uptake of the novel platinum compounds and the level
of DNA binding in select human cancer cell lines using inductively coupled
plasma-atomic emission spectrometry (ICP-AES)
o Study 3: Identify the proteins mediating cell death responses activated by the
novel platinum compounds in select human cancer cell lines using western
blotting analysis, flow cytometry, and immunofluorescence microscopy.

Chapters 2–5 describe the synthesis of three novel Pt(II) and Pt(IV) complexes
and the structural characterization of these complexes by 1H NMR, 13C NMR
spectroscopy, elemental analysis, mass spectroscopy, and differential scanning calorimetry (DSC) measurements. The anti-proliferative activities of these compounds against
a panel of human cancer cell lines are also described and compared to that of cisplatin
and carboplatin. Additionally, the structure-activity relationship is explored to provide a
rational basis for the discovery of novel platinum compounds with increased
effectiveness and low toxic side effects. Furthermore, data from various experimental
techniques (UV-Vis spectroscopy and gel electrophoresis to study interactions with
DNA; ICP-AES for the detection of platinum uptake by cells and binding to DNA;
western blotting, immunofluorescence, and flow cytometry for analysis of changes in
protein expression) are presented to describe the interactions of these complexes with
biological molecules and gain insight into the mechanism of action, which will further aid
in the development of promising chemotherapeutic agents.
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CHAPTER 2
SYNTHESIS OF [PTCL2(4,4′-DIALKOXY-2,2′-BIPYRIDINE)]
COMPLEXES AND THEIR IN VITRO ANTICANCER PROPERTIES*
2.1 Abstract
A series of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes of the general
formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)] (where R = –(CH2)n–1CH3, n = 2–6,
8) were synthesized and characterized using 1H NMR, 13C NMR spectroscopy, elemental
analysis, mass spectroscopy, and differential scanning calorimetry measurements. The in
vitro anti-proliferative activities of these compounds were evaluated against human
cancer cell lines A549 (lung adenocarcinoma), DU145 (prostate carcinoma), MCF-7
(breast adenocarcinoma), and MDA-MB-435 (melanoma) using the MTS cell
proliferation assay. Several Pt(II) coordination compounds were found to have greatly
enhanced activity compared to cisplatin after a one hour treatment in all cell lines tested.
A structure-activity relationship was observed, that is, the activity increases as the carbon
chain length of the alkyl group increases. The activity was maximum when the carbon
chain length reached four or five carbons and decreased with the longer carbon chain
length. Fluorescence microscopy and flow cytometry data indicate that the main mode of
cell death is through apoptosis with some necrotic responses.

*

This chapter corresponds to the content of the published paper:

Vo V, Tanthmanatham O, Han H, Bhowmik PK, Spangelo BL. Synthesis of [PtCl2(4,4′dialkoxy-2,2′-bipyridine)] complexes and their in vitro anticancer properties.
Metallomics, 2013, 5, 973-987.
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2.2 Introduction
Cisplatin (CDDP) is a relatively small coordination compound of platinum (Pt)
that was approved by the US FDA in 1978 for the clinical treatment of various cancers.1–3
Thirty-five years since its FDA approval cisplatin has remained one of the most
commonly prescribed chemotherapeutic drugs.

However, the clinical application of

cisplatin is limited due to toxic side effects, such as kidney damage and cellular
resistance (either intrinsic or acquired).3–7 Due to these issues, numerous cisplatin
analogues have been synthesized and investigated with varying anti-neoplastic activity.
Currently, only two cisplatin analogues have been approved by the US FDA. The first
was carboplatin, which was approved in 1989, for the treatment of lung and ovarian
cancer. The second was oxaliplatin, approved in 2002, for the treatment of colorectal
cancer.1,6 Although these drugs have less toxic side effects than cisplatin, they are only as
effective or in some cases less effective than cisplatin. Additionally, side effects such as
myelosuppression have limited their usefulness.1,8
The first report for the synthesis of 2,2′-bipyridine dates back to 1888 by Fritz
Blau9 and then by Newkome et al.10 and it is now one of the most extensively studied
chelating agents. The 2,2′-bipyridine compounds are commonly used as bidentate
transition metal ligands because various functional groups can easily be attached and they
have high redox stability.11,12 These compounds are used in electron-transfer processes,
luminescent devices, and nanomaterials. Additionally, they have applications in areas
such as photonics and electrochemistry.10,11 Various metal complexes containing 2,2′bipyridine have been reported to have antitumor activity,13–21 some of the representative
Pt-complexes (1–10) are depicted in Fig. 2-1.
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Figure 2 – 1. Some representative chemical structures of known [Pt(II)Cl2(4,4′disubstituted-2,2′-bipyridine)] complexes.

Complex 1 was reported to have some activity against NCI-H460 lung cancer
cells, but was less active than cisplatin (determined by MTT assay with a 48 h
treatment).22 Complexes 2 and 3 were reported to be at least 100 times more lethal than
cisplatin as determined in clonogenic survival assays of MDA-MB-231 human breast
cancer cells and its two engineered derivatives treated for 1 h with the complexes. It was
also demonstrated that 3 was more lethal than cisplatin in human prostate (DU145) and
lung (A549) cancer cells.17 Complexes 4 and 5 were shown to be more lethal than
cisplatin in A549, DU145, and MDA-MB-435 (now classified as a melanoma cell line)
when tested using a clonogenic survival assay with a 1 h treatment duration.19 The
activity of complexes 6-10 has been tested in MCF-7 (breast cancer), MDA-MB-231, and
A549 cells.20 Complexes 6-8 exhibited anti-proliferative activity against MDA-MB-231,
but no significant activity against MCF-7 and A549 cells. Complexes 9 and 10 did not
have significant activity against any of the cell lines tested.
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Although complexes 2-5 were demonstrated to be effective, the synthesis of the
ligands for the more active complexes (3 and 5) involved the use of the strong base
lithium diisopropylamide (LDA) to deprotonate the starting 4,4′-dimethyl-2,2′-bipyridine
compound.19,23 This strong base is inconvenient to use, since it reacts violently with
water; thus, the reaction must be performed in a specialized glassware under argon or
nitrogen. Additionally, other properties (e.g., corrosivity and pyrophoricity) make this
base quite difficult to use.24 Synthesis of the ligands for complexes 6-10 require
fluorinated alcohols that are quite expensive. Additionally, the synthetic reaction has a
step that produces moisture-sensitive alkoxide as an intermediate.20,25 Working with the
moisture-sensitive compounds requires the additional step of drying all glassware and
reagents before use.
In an effort to find a more suitable replacement for current anticancer Pt
compounds, an improved method for a two-step synthesis of a series of [Pt(II)Cl2(4,4′dialkoxy-2,2′-bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)2,2′-bipyridine)] (where R = –(CH2)n–1CH3, n = 2–6, 8) was developed. This method does
not require the use of strong bases and gives high yields, resulting in cost-effective
preparation of prospective antitumor drugs. Platinum complexes of these novel chemical
structures have not, to our knowledge, been previously reported. Herein, we describe
their synthesis and characterization by 1H NMR,
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C NMR spectroscopy, elemental

analysis, mass spectroscopy, and differential scanning calorimetry (DSC) measurements.
The anti-proliferative activities of these compounds against a panel of human cancer cell
lines are described and compared to that of cisplatin—a gold standard for cancer therapy.
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2.3 Experimental
2.3.1 General
All starting materials including 4,4′-dimethoxy-2,2′-bipyridine and reagents for
the synthetic procedures were purchased from the commercial vendors (Sigma-Aldrich,
TCI, Alfa-Aesar, or Acros) unless otherwise noted. They were of high purity and were
used without further purification unless noted in the procedure. Minimum essential
medium (MEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsinEDTA, and penicillin-streptomycin were purchased from Life Technologies (Carlsbad,
CA). The RPMI 1640 medium was purchased from ATCC (Manassas, VA) and HEPES,
crystal violet, CDDP and dimethyl sulfoxide (DMSO) were purchased from SigmaAldrich. All reagents and enzymes used for flow cytometry were of analytical grade
qualities and were purchased from Sigma-Aldrich, unless otherwise noted.
2.3.2 Chemical characterization instrumentation
All of the NMR spectra were obtained utilizing a Varian spectrometer at 298 K or
the indicated temperature using deuterated dimethyl sulfoxide (DMSO-d6) or chloroform
(CDCl3) as the solvents: 1H NMR, 400 MHz; and
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C NMR, 100 MHz. Either residual

solvent or tetramethylsilane (TMS) were used as the internal chemical shift reference.
Thermal transitions were determined by using a TA Instruments DSC 2010 differential
scanning calorimeter in nitrogen at heating and cooling rates of 10 °C min-1. The
temperature axis of the DSC thermogram was calibrated with reference standards of high
purity indium and tin before use. An amount of 2–3 mg of compound was used in this
measurement. The Tonset and Tmax temperatures of a melting endotherm of a compound
were recorded from the DSC thermogram as Mp (Tonset–Tmax). Elemental analysis was
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determined by NuMega Resonance Labs Inc. (San Diego, CA) by using a Perkin Elmer
PE2400-Series II with a CHNS/O analyzer. Mass analysis was also determined by
NuMega Resonance Labs Inc. by using a Perkin Elmer PE-SCIEX API-150.
2.3.3 Preparation of 2,2′-bipyridine-4,4′-diol
The 2,2′-bipyridine-4,4′-diol was synthesized according to a previously published
procedure with a slight modification of the reaction condition.26 Briefly, 48 wt% HBr in
H2O (15.5 equiv.) was slowly added to a solution of 4,4′-dimethoxy-2,2′-bipyridine (1.0
equiv.) in glacial acetic acid and the resulting mixture was heated to reflux for a period of
72 h. The solvents were removed under vacuum resulting in the product residue that was
dissolved in H2O. Insoluble material was removed by filtration and the pH of the filtrate
was adjusted to neutral using NH4OH. The colourless solid product precipitated out and
was collected by vacuum filtration. It was then washed with plenty of H 2O and dried at
80 °C in vacuo. The compound was then used without further purification in the next
step.
2.3.4 Preparation of 4,4′-dialkoxy-2,2′-bipyridine
The appropriate alkyl halide (2.2 equiv.) was slowly added to a mixture of 2,2′bipyridine-4,4′-diol (1 equiv.) and Cs2CO3 or K2CO3 (2.2 equiv.) in DMF at ca. 60 °C.
The suspension was heated to reflux for 48 h then allowed to cool to room temperature.
The salt was removed by vacuum filtration and washed with DMF. Rotary evaporator
was used to remove the solvent from the solution resulting in the solid residue that was
washed with water and collected by vacuum filtration. Recrystallization from acetoneH2O afforded the pure product as shiny, colourless crystals.

20

4,4′-Diethoxy-2,2′-bipyridine (L-2C). Yield: 86%, white crystals. Mp 122–124
°C.27’28 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 8.46 (d, 1H, J = 5.7 Hz), 7.90
(d, 1H, J = 2.5 Hz), 6.99 (dd, 1H, J = 5.7, 2.6 Hz), 4.20 (q, 2H, J = 7.0 Hz), 1.37 (t, 3H, J
= 7.0 Hz). 13C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 165.9, 157.3, 150.9, 111.5,
106.8, 64.0, 14.8. ESI-MS: m/z 245.40 [M + H]+.
4,4′-Dipropoxy-2,2′-bipyridine (L-3C). Yield: 93%, white crystals. Mp 97–99
°C. 1H NMR (342 K, 400 MHz, DMSO-d6): δ (ppm) = 8.45 (d, 1H, J = 5.6 Hz), 7.90 (d,
1H, J = 2.5 Hz), 6.97 (dd, 1H, J = 5.6, 2.6 Hz), 4.11 (t, 2H, J = 6.5 Hz), 1.83–1.74 (m,
2H), 1.01 (t, 3H, J = 7.4 Hz). 13C NMR (302 K, 100 MHz, DMSO-d6): δ (ppm) = 165.5,
156.8, 150.4, 110.9, 106.3, 69.1, 21.7, 10.2. Anal. Calcd for C16H20N2O2 (272.34 g mol1

): C, 70.56; H, 7.40; N, 10.29%; found: C, 70.70; H, 7.80; N, 10.56%; ESI-MS: m/z

273.30 [M + H]+.
4,4′-Dibutoxy-2,2′-bipyridine (L-4C). Yield: 86%, white crystals. Mp 99–101
°C.29 1H NMR (332 K, 400 MHz, DMSO-d6): δ (ppm) = 8.46 (d, 1H, J = 5.6 Hz), 7.90 (d,
1H, J = 2.5 Hz), 6.98 (dd, 1H, J = 5.6, 2.6 Hz), 4.15 (t, 2H, J = 6.5 Hz), 1.78–1.71 (m,
2H), 1.51–1.42 (m, 2H), 0.95 (t, 3H, J = 7.4 Hz).
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C NMR (332 K, 100 MHz, DMSO-

d6): δ (ppm) = 166.1, 157.5, 150.9, 111.4, 107.1, 68.0, 30.9, 19.0, 14.0. Anal. Calcd for
C18H24N2O2 (300.40 g mol-1): C, 71.97; H, 8.05; N, 9.33%; found: C, 72.56; H, 7.81; N,
9.45%; ESI-MS: m/z 301.30 [M + H]+.
4,4′-Dipentyloxy-2,2′-bipyridine (L-5C). Yield: 78%, white crystals. Mp 85–86
°C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.45 (d, 1H, J = 5.6 Hz), 7.95 (d, 1H,
J = 2.5 Hz), 6.82 (dd, 1H, J = 5.7, 2.6 Hz), 4.12 (t, 2H, J = 6.5 Hz), 1.86–1.79 (m, 2H),
1.50–1.35 (m, 4H), 0.94 (t, 3H, J = 7.1 Hz).
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13

C NMR (298 K, 100 MHz, CDCl3): δ

(ppm) = 166.2, 157.9, 150.1, 111.3, 106.7, 68.1, 28.6, 28.1, 22.4, 14.0. Anal. Calcd for
C20H28N2O2 (328.45 g mol-1): C, 73.14; H, 8.59; N, 8.53%; found: C, 72.89; H, 8.90; N,
8.61%; ESI-MS: m/z 329.60 [M + H]+.
4,4′-Dihexyloxy-2,2′-bipyridine (L-6C). Yield: 65%, white crystals. Mp 95–96
°C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.45 (d, 1H, J = 5.7 Hz), 7.95 (d, 1H,
J = 2.5 Hz), 6.82 (dd, 1H, J = 5.7, 2.6 Hz), 4.12 (t, 2H, J = 6.5 Hz), 1.85–1.77 (m, 2H),
1.51–1.44 (m, 2H), 1.39–1.30 (m, 4H), 0.91 (t, 3H, J = 7.0 Hz).
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C NMR (298 K, 100

MHz, CDCl3): δ (ppm) = 166.2, 157.9, 150.1, 111.3, 106.7, 68.1, 31.5, 28.9, 25.6, 22.6,
14.0. Anal. Calcd for C22H32N2O2 (356.50 g mol-1): C, 74.12; H, 9.05; N, 8.98%; found:
C, 74.71; H, 8.83; N, 7.80%; ESI-MS: m/z 357.70 [M + H]+.
4,4′-Dioctyloxy-2,2′-bipyridine (L-8C). Yield: 79%, white crystals. Mp 91–93
°C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.45 (d, 1H, J = 5.7 Hz), 7.95 (d, 1H,
J = 2.6 Hz), 6.81 (dd, 1H, J = 5.7, 2.6 Hz), 4.12 (t, 2H, J = 6.5 Hz), 1.85–1.78 (m, 2H),
1.50–1.43 (m, 2H), 1.38–1.26 (m, 8H), 0.89 (t, 3H, J = 7.0 Hz).
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C NMR (298 K, 100

MHz, CDCl3): δ (ppm) = 166.2, 157.9, 150.1, 111.3, 106.7, 68.0, 31.8, 29.3, 29.2, 29.0,
26.0, 22.7, 14.1. Anal. Calcd for C26H40N2O2 (412.61 g mol-1): C, 75.68; H, 9.77; N,
6.79%; found: C, 75.63; H, 10.12; N, 6.90%; ESI-MS: m/z 413.9 [M + H]+.
2.3.5 Preparation of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes
The salt K2[PtCl4] (1.2 equiv.) was dissolved in 1–2 mL of H2O and then added to
a solution of 4,4′-dialkoxy-2,2′-bipyridine (1.0 equiv.) in acetone. The mixture was
heated to reflux for 24 h. The product (yellow solid) precipitated out either in hot
condition or upon cooling. Water was added to ensure the complete precipitation of the
product. The crude product was separated by vacuum filtration. The pure product was
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obtained by first washing with cold water and then hot hexane, unless otherwise noted.
[PtCl2(4,4′-dimethoxy-2,2′-bipyridine)] (Pt-1C). Yield: 92%, bright yellow
powder (by washing with hot methanol). Mp 311–316 °C. 1H NMR (298 K, 400 MHz,
DMSO-d6): δ (ppm) = 9.13 (d, 1H, J =6.8 Hz), 8.19 (d, 1H, J =2.8 Hz), 7.40 (dd, 1H, J =
6.9, 2.8 Hz), 4.05 (s, 3H).
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C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 168.2,

158.4, 149.5, 113.2, 111.1, 57.6. Anal. Calcd for C12H12Cl2N2O2Pt (482.23 g mol-1): C,
29.89; H, 2.51; N, 5.81%; found: C, 30.04; H, 2.75; N, 5.77%.
[PtCl2(4,4′-diethoxy-2,2′-bipyridine)] (Pt-2C). Yield: 97%, bright yellow
powder (by washing with hot acetone). Mp 318–322 °C. 1H NMR (332 K, 400 MHz,
DMSO-d6): δ (ppm) = 9.15 (d, 1H, J = 6.8 Hz), 8.14 (d, 1H, J = 2.8 Hz), 7.35 (dd, 1H, J
= 6.8, 2.7 Hz), 4.36 (q, 2H, J = 7.0 Hz), 1.41 (t, 3H, J = 7.0 Hz). 13C NMR (332 K, 100
MHz, DMSO-d6): δ (ppm) = 167.5, 158.6, 149.6, 113.4, 111.3, 66.1, 14.5. Anal. Calcd
for C14H16Cl2N2O2Pt (510.28 g mol-1): C, 32.95; H, 3.16; N, 5.49%; found: C, 33.30; H,
2.84; N, 5.80%; ESI-MS: m/z 548.80 [M + K]+.
[PtCl2(4,4′-dipropoxy-2,2′-bipyridine)] (Pt-3C). Yield: 95%, bright yellow
powder. Mp 269–272 °C. 1H NMR (342 K, 400 MHz, DMSO-d6): δ (ppm) = 9.15 (d, 1H,
J = 6.8 Hz), 8.13 (d, 1H, J = 2.8 Hz), 7.34 (dd, 1H, J = 6.8, 2.8 Hz), 4.27 (t, 2H, J = 6.5
Hz), 1.87–1.78 (m, 2H), 1.03 (t, 3H, J = 7.4 Hz). 13C NMR (302 K, 100 MHz, DMSOd6): δ (ppm) = 167.7, 158.5, 149.6, 113.4, 111.3, 71.6, 22.0, 10.5. Anal. Calcd for
C16H20Cl2N2O2Pt (538.33 g mol-1): C, 35.70; H, 3.74; N, 5.20%; found: C, 35.41; H,
3.89; N, 5.27%; ESI-MS: m/z 560.20 [M + Na]+.
[PtCl2(4,4′-dibutoxy-2,2′-bipyridine)] (Pt-4C). Yield: 93%, bright yellow
powder. Mp 229–230 °C. 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 9.13 (d, 1H,
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J = 6.9 Hz), 8.20 (d, 1H, J = 2.8 Hz), 7.40 (dd, 1H, J = 6.9, 2.8 Hz), 4.30 (t, 2H, J = 6.5
Hz), 1.83–1.76 (m, 2H), 1.53–1.44 (m, 2H), 0.97 (t, 3H, J = 7.3 Hz). 13C NMR (298 K,
100 MHz, DMSO-d6): δ (ppm) = 167.6, 158.5, 149.5, 113.4, 111.3, 69.9, 30.6, 19.0, 14.0.
Anal. Calcd for C18H24Cl2N2O2Pt (566.39 g mol-1): C, 38.17; H, 4.27; N, 4.95%; found:
C, 38.18; H, 4.61; N, 4.99%; ESI-MS: m/z 588.40 [M + Na]+.
[PtCl2(4,4′-dipentoxy-2,2′-bipyridine)] (Pt-5C). Yield: 92%, bright yellow
powder. Mp 173–175 °C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.81 (d, 1H, J =
6.8 Hz), 7.47 (d, 1H, J = 2.7 Hz), 6.73 (dd, 1H, J = 6.8, 2.7 Hz), 4.29 (t, 2H, J = 6.4 Hz),
1.92–1.85 (m, 2H), 1.54–1.38 (m, 4H), 0.97 (t, 3H, J = 7.2 Hz).
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C NMR (298 K, 100

MHz, CDCl3): δ (ppm) = 167.0, 158.0, 148.9, 112.7, 110.2, 70.1, 28.4, 27.9, 22.4, 14.0.
Anal. Calcd for C20H28Cl2N2O2Pt (594.44 g mol-1): C, 40.41; H, 4.75; N, 4.71%; found:
C, 40.46; H, 5.00; N, 4.58%; ESI-MS: m/z 616.80 [M + Na]+.
[PtCl2(4,4′-dihexyloxy-2,2′-bipyridine)] (Pt-6C). Yield: 61%, bright yellow
powder. Mp 176–179 °C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.78 (d, 1H, J =
6.8 Hz), 7.47 (d, 1H, J = 2.7 Hz), 6.71 (dd, 1H, J = 6.8, 2.7 Hz), 4.29 (t, 2H, J = 6.4 Hz),
1.91–1.84 (m, 2H), 1.56–1.48 (m, 2H), 1.41–1.33 (m, 4H), 0.93 (t, 3H, J = 7.0 Hz). 13C
NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 167.0, 158.0, 148.8, 112.7, 110.2, 70.2, 31.5,
28.7, 25.5, 22.6, 14.1. Anal. Calcd for C22H32Cl2N2O2Pt (622.49 g mol-1): C, 42.45; H,
5.18; N, 4.50%; found: C, 42.53; H, 5.40; N, 4.68%; ESI-MS: m/z 644.40 [M + Na]+.
[PtCl2(4,4′-dioctyloxy-2,2′-bipyridine)] (Pt-8C). Yield: 61%, bright yellow
powder (recrystallized from CHCl3-CH3OH). Mp 169–172 °C. 1H NMR (298 K, 400
MHz, CDCl3): δ (ppm) = 8.83 (d, 1H, J = 6.8 Hz), 7.47 (d, 1H, J = 2.8 Hz), 6.74 (dd, 1H,
J = 6.8, 2.7 Hz), 4.30 (t, 2H, J = 6.4 Hz), 1.92–1.85 (m, 2H), 1.56–1.48 (m, 2H), 1.41–
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1.28 (m, 8H), 0.91 (t, 3H, J = 7.0 Hz). 13C NMR (298 K, 100 MHz, CDCl3): δ (ppm) =
167.1, 158.0, 148.9, 112.7, 110.2, 70.2, 31.8, 29.3, 29.2, 28.8, 25.9, 22.7, 14.1. Anal.
Calcd for C26H40Cl2N2O2Pt (678.60 g mol-1): C, 46.02; H, 5.94; N, 4.13%; found: C,
46.26; H, 6.04; N, 4.29%; ESI-MS: m/z 701.20 [M + Na]+.
2.3.6 Cell culture
Human cancer cell lines A549 (lung adenocarcinoma), DU145 (prostate
carcinoma), MCF-7 (breast adenocarcinoma), and MDA-MB-435 (melanoma) were
obtained from American Culture Type Collection (ATCC). The A549, MCF-7, and
MDA-MB-435 cells were grown in MEM supplemented with 10% FBS, 25 mM HEPES
buffer (pH 7.4), penicillin (100 U mL-1) and streptomycin (100 µg mL-1). The DU145 cell
line was grown in RPMI 1640 supplemented with 10% FBS, 25 mM HEPES buffer (pH
7.4), penicillin (100 U mL-1) and streptomycin (100 µg mL-1). All cell lines were
maintained at 37 °C in a humidified, 5% CO2 atmosphere.
2.3.7 Preparation of stock solutions
CDDP stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in
5% glucose, ligands and synthesized Pt-complexes were dissolved in DMSO.
2.3.8 Cell viability assay
Cells were cultured at a density of 2 x 103 cells per well in flat bottomed 96-well
plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50%
confluence. The cells were then treated with solvent or the appropriate drugs for 1 h,
washed thrice with 100 µL PBS, and incubated in 100 µL of fresh medium. After 2 d,
the medium was replaced with 120 µL of medium containing CellTiter 96® Aqueous One
Solution Reagent (MTS reagent) (Promega, Madison, WI). After 4 h in culture the cell
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viability was determined by measuring the absorbance at 490 nm using a Tecan Infinite
M1000 microplate reader. The 48 h treatment was done in a similar method, except the
cells were not washed after treatment and the MTS reagent was immediately added.
Viability of treated groups was calculated as a percent of control and graphed with
GraphPad Prism.
2.3.9 Flow cytometry
2.3.9.1 Propidium iodide (PI) staining
Cells (~50% confluent) were incubated at 37 °C in a humidified, 5% CO2
atmosphere for 1 h with the indicated concentration of Pt-4C. After 1 h, cells were
washed with 5 mL PBS and fresh medium added. Cells were incubated at 37 °C in a
humidified, 5% CO2 atmosphere for 12, 24, and 48 h, at which point cells were harvested,
counted and centrifuged at 500 x g for 5 min. Cells were then washed two times with 5
mL PBS, fixed by resuspending in 0.1 mL PBS and 1 mL of cold 95% ethanol with
gentle vortexing. Fixed cells were stored at 4 °C until analysis. For analysis, fixed cells
were washed once with 1-2 mL PBS and centrifuged at 500 × g for 5 minutes. Cells were
resuspended in 100 µL of 1.0% Triton X-100 buffer solution. The RNAse solution (100
µL of a 1.0 mg mL-1) was added and allowed to stand at room temperature for 10-15 min.
While in the dark, 200 µL of a 100 µg mL-1 PI stain was added to make a final
concentration of 50 µg mL-1 and gently vortexed. Cell mixture was incubated at room
temperature for 30 min. Cytometry acquisition was done on Becton Dickinson FACS
Calibur with the argon laser set at 488 nm on the linear Flow Channel 2 (FL-2) with
Doublet Discriminatory Module (DDM) and threshold set on FL-2.
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2.3.9.2 Annexin V-FITC/PI staining
Cells (40-50% confluent) were incubated at 37 °C in a humidified, 5% CO2
atmosphere for 1 h with the indicated concentration of Pt-4C. After 1 h, cells were
washed with 5 mL PBS and fresh medium was added. Cells were incubated at 37 °C in a
humidified, 5% CO2 atmosphere for 12, 24, and 48 h, at which point cells were harvested
and counted. Next, the cells were centrifuged at 500 × g for 5 min and washed once with
5 mL Ca2+ and Mg2+ free PBS. Pellets were then washed in 2.0 mL 1X Annexin-V
Binding buffer (BD Bioscience, San Jose, CA) and centrifuged at 500 × g for 5 min. The
pellets were treated with Annexin-V-FITC conjugate (BD Bioscience, San Jose, CA) and
incubated in the dark for 15 min. Just before acquisition, the volume of cells-conjugate
mixture was adjusted by addition of 1X Annexin-V binding buffer. Acquisition to
discriminate between apoptotic and necrotic cells was done by staining the cell-conjugate
mixture with 10 µL of PI (50 µg mL-1) solution (BD Bioscience, San Jose, CA).
Acquisitions were done on FACS Calibur Cytometer on the FL1 (Annexin) and FL3 (PI)
channels with threshold and Duplet Discriminating Module (DDM) set at FL1. The level
of shift in events distribution in the Annexin-V only and Annexin-V-PI populations in
comparison to control is indicative of degree of effectiveness of the treatment agents. A
quantitative measure of these event shifts was accomplished by gating.
2.3.10 Fluorescence microscopy
A number of 5000 or 10 000 cells per well were seeded in a 4 well chamber slide
with a final volume of 0.5 mL. Cells were incubated at 37 °C for ~72 h and then treated
with EC50 concentration of Pt-4C for 1 h at 37 °C. Cells were washed twice with 0.5 mL
PBS and fresh medium (0.5 mL) was added. Cells were incubated at 37 °C for 2 h. While
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in the dark, medium was removed, cells were washed with 0.5 mL PBS, and then 0.5 mL
of 2 µg mL-1 Hoechst 33342 and 10 µg mL-1 PI stain (in PBS) was added for a final
concentration of 1 µg mL-1 Hoechst 33342 and 5 µg mL-1 PI. Cells were incubated for 15
min at room temperature. Images were acquired within 5 min with a Nikon Eclipse
microscope, model TE2000-U. Three random areas on each slide were imaged for bright
field, cells stained with Hoechst, and cells stained with PI (9 images were obtained for
each slide: 3 for bright field, 3 for Hoechst staining, and 3 for PI staining).
2.3.11 DNA laddering
Cells (~50% confluent) were treated with 10-35 µM Pt-4C for 1 h. 24 h post
treatment, cells were collected, washed with PBS, and the pellet resuspended in 500 µL
of lysis buffer (100 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS, 0.5% Triton X-100,
200 mM NaCl, 100 µg mL-1 proteinase K). After 2 h of incubation at 56 °C, 500 µL of 2propanol was added, mixed by inversion, and DNA was precipitated overnight at -20 °C.
The DNA was pelleted by centrifugation at 16 000 × g for 15 min at 4 °C. The pellet was
washed once with 70% ethanol and air dried by inverting the tube on a tissue for 10 min.
The DNA was dissolved in 20 µL of TE Buffer (10 mM Tris, 1 mM EDTA) containing
0.2 mg mL-1 RNAse A and incubated at 37 °C for 1 h. The DNA concentration was
determined with the NanoDrop ND-1000 Spectrophotometer and 2 µg of DNA was
analyzed on a 2% agarose gel in TBE buffer (2 mM EDTA, pH 8.0; 89 mM Tris; 89 mM
boric acid). The gel was stained with 1 µg mL-1 ethidium bromide for 30 min, rinsed with
water, and exposed to UV light.
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2.3.12 Statistical analysis
GraphPad Prism 4 was used to graph viability curves. ModFit version 3.0 was
used for the flow cytometry analysis. Microsoft Office Excel was used to run Student’s ttest; values with p < 0.05 were considered significant. Student’s t-tests were used to
verify significant differences among the EC50 values.
2.4 Results and discussion
2.4.1 Synthesis and characterization
Except for 4,4′-dimethoxy-2,2′-bipyridine (henceforth referred to as L-1C), which
was purchased from a commercial vendor, all ligands were synthesized by reacting a
respective primary alkyl halide with a mixture of 2,2′-bipyridine-4,4′-diol and Cs2CO3 or
K2CO3 in DMF on heating to reflux for 48 h. For the synthesis of L-2C—L-4C with high
yields, Cs2CO3 was used instead of the usual K2CO3 because the latter base gave
relatively low yields. However, the synthesis of L-5C, L-6C and L-8C with K2CO3 gave
respectable yields. The platinum complexes were formed by adding an aqueous solution
of K2[PtCl4] to a solution of the ligand in acetone and on heating to reflux for 24 h
(Scheme 2-1). All ligands are white and produce a colourless solution when dissolved in

Scheme 2 – 1. Scheme for the synthesis of Pt(II)-complexes (Pt-2C—Pt-6C, Pt-8C).
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Figure 2 – 2. Chemical structures of CDDP and the synthesized [Pt(II)Cl2(4,4′-dialkoxy2,2′-bipyridine)] complexes.

organic solvents; however, all the platinum complexes are yellow solids and generate a
yellow solution when dissolved in organic solvents. Thus, the progress of the reaction
was monitored visually by the appearance of a yellow solution or precipitate. The
chemical structures of cisplatin and the synthesized platinum complexes are shown in
Fig. 2-2. L-2C27,28 and L-4C29 were previously synthesized using an alternative method
with longer synthetic steps and produces a dinitro intermediate that is potentially
explosive. The synthesis and the in vitro cytotoxicity of the platinum complex Pt-1C
have been reported previously.19 The synthesis of Pt-2C has also been previously
reported for its electrochemical and electronic properties;30 however, no literature on
activity against cancer cells is available to date. The Pt-complexes, Pt-3C—Pt-6C and
Pt-8C, have not been reported in the literature.
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Figure 2 – 3. The aromatic region of ligands and platinum(II)-complexes from 1H NMR
spectra. Spectra were recorded in DMSO-d6 and CDCl3 at the temperatures indicated in
the Experimental section (* solvent peak).
All of the compounds were characterized by 1H and
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C NMR spectroscopy,

elemental analysis, mass spectrometry, and DSC measurements. Elemental and mass
spectrometry analyses of the complexes were in excellent agreement (within 0.5% for
elemental analyses and 5 ppm for mass spectrometry) with the expected values; thus,
validating the molecular formulae of these compounds. The 1H and 13C NMR spectra of
the compounds L-2C—L-4C, and Pt-2C—Pt-4C were recorded in DMSO-d6, whereas
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those of the compounds L-5C—L-8C, and Pt-5C—Pt-8C were recorded in CDCl3. The
spectra of all of the compounds displayed the expected proton and carbon resonances.
The 1H NMR chemical shifts of the aromatic region of the ligands and platinum
complexes are depicted in Fig. 2-3 and summarized in Table 2-1. The chemical shifts of
the protons at the 6,6′ positions are the most downfield, protons at the 5,5′ positions are
the most upfield and protons at the 3,3′ positions are in between. When 4,4′-dialkoxy2,2′-bipyridine was coordinated to platinum(II), all aromatic proton peaks of the
complexes in DMSO-d6 are shifted downfield compared to the ligand while only the peak
corresponding to the protons at the 6,6′ positions of complexes recorded in CDCl3 are
shifted downfield, and peaks corresponding to the 5,5′ and 3,3′ positions are shifted
upfield. Similarly, the carbon signals at the 5,5′ positions, those of 3,3′ position and
methylene carbon signal next to the oxygen in both the deuterated solvents were shifted
downfield to varying degrees, but the carbon signals at 6,6′ positions in these solvents
were slightly shifted to upfield (Fig. 2S-1, Appendix 1). The difference in the direction of
the chemical shifts is due to differences in the interaction of the compounds with the
organic solvents of varying polarity used (Table 2-1).
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Table 2 – 1. Chemical shifts (ppm) in the aromatic region of ligands and platinum(II)Cl2
complexes from 1H NMR spectra recorded in DMSO-d6 and CDCl3 at the temperatures
indicated in the Experimental section
Compound

Solvent

H-6,6′ (ppm)

H-5,5′ (ppm)

H-3,3′ (ppm)

L-2C (Pt-2C)
L-3C (Pt-3C)
L-4C (Pt-4C)
L-5C (Pt-5C)
L-6C (Pt-6C)
L-8C (Pt-8C)

DMSO-d6
DMSO-d6
DMSO-d6
CDCl3
CDCl3
CDCl3

8.46 (9.15)
8.45 (9.15)
8.46 (9.13)
8.45 (8.81)
8.45 (8.78)
8.45 (8.83)

6.99 (7.35)
6.97 (7.34)
6.98 (7.40)
6.82 (6.73)
6.82 (6.71)
6.81 (6.74)

7.90 (8.14)
7.90 (8.13)
7.90 (8.20)
7.95 (7.47)
7.95 (7.47)
7.95 (7.47)

Thermal transitions of the synthesized compounds were determined by DSC
measurements. Each of the DSC thermograms for ligands L-2C—L-8C displayed a
single endotherm in the first heating cycle and a single exotherm in the first cooling cycle
corresponding

to

its

melting

and

crystallization

transitions,

respectively.

Correspondingly, there were a melting endotherm in the second heating cycle and a
crystallization exotherm in the second cooling cycle. L-2C had the highest melting at 124
°C and L-5C had the lowest at 86 °C. L-3C, L-4C, L-6C, and L-8C had melting points
ranging between 93-100 °C with no apparent trends. Platinum complexes had varying
DSC thermograms. The DSC thermograms of Pt(II) complexes produced rather complex
thermal properties. For example, Pt-2C and Pt-3C showed a single endotherm in the first
heating cycle (Fig. 2S-2, Appendix 1), but no exotherm in the first cooling cycle.
Correspondingly, there was no melting endotherm in the second heating cycle and no
exotherm in the second cooling cycle. These complexes once melted could not crystallize
and, therefore, formed amorphous phases. Pt-4C showed a sharp single endotherm
(melting) in the first heating cycle, but showed a broad, exotherm in the first cooling
cycle. Correspondingly, it showed a slightly broad endotherm at a lower temperature
33

when compared with that in the first heating cycle, but showed a broad exotherm in the
second cooling cycle (not shown). Pt-5C showed two sharp endotherms in the first
heating cycle and two broad exotherms in the first cooling cycle. Correspondingly, it
showed two endotherms in the second heating cycle and two broad exotherms in the
second cooling cycle. The first low- temperature endotherm was related to the crystal-tocrystal transition and the high-temperature one was related to its melting transition (Fig.
2S-2, Appendix 1). Pt-6C showed three endotherms in the first heating cycle, but no
exotherms in the first cooling cycle. During the second heating cycle, once it traversed
through the glass transition temperature, it showed a cold crystallization exotherm and
three endotherms. Again, there were no exotherms in the second cooling cycle. The two
low-temperature endotherms were related to the crystal-to-crystal transitions and the
highest-temperature endotherm was related to its melting transition. The observed
crystal-crystal transitions of these two Pt(II)-complexes are in excellent agreement with
those of other Pt(II)-complexes.31 Pt-8C showed a sharp melting endotherm in the first
heating cycle and a sharp exotherm in the first cooling cycle. Correspondingly, it showed
a sharp melting transition in the second heating cycle and a sharp crystallization
exotherm in the second cooling cycle (Fig. 2S-2, Appendix 1). It was found that the
melting transitions of the Pt(II)-complexes were much higher than those of the ligands
and decrease as the carbon number of the alkoxy group increases in the series examined.
2.4.2 Biological properties
2.4.2.1 In vitro cytotoxic activity
Lung cancer is one of the leading causes of cancer death not only in the U.S., but
also worldwide; thus, the activity of the ligands and Pt compounds were first tested in the
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Figure 2 – 4. Cytotoxic activity of the synthesized ligands and Pt(II)Cl2 complexes vs.
CDDP and carboplatin against A549 human lung cancer cells. Cells were treated with
the ligands, CDDP, or the platinum analogs at various concentrations for (A, B) 1 h or (C,
D) 48 h and the viability was determined using the MTS assay. Data points represent
mean ± SD of at least three independent experiments done in quadruplicates.

human lung cancer cell line A549 and compared to cisplatin and carboplatin using an
MTS colorimetric assay to determine cell viability. For a 1 h treatment, L-1C—L-5C had
little to no effect on A549 cell viability (Fig. 2-4 A). Carboplatin also did not have any
effect on the cells when treated for 1 h (Fig. 2-4 B). Cisplatin caused a concentrationdependent decreased in A549 cell viability with a reduction of about 50% at 1000 µM.
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Similar to carboplatin, the analogues containing 1 (Pt-1C) or 2 (Pt-2C) carbon chain
length had no effect on the cells. When the carbon chain length was increased to three
(Pt-3C), the cell viability decreased with increasing concentrations. The analogues
containing four (Pt-4C) and five (Pt-5C) carbon chain lengths had similar activities and
caused further decrease in cell viability compared to the Pt-3C. When the chain length
was increased to 6 carbons (Pt-6C), the activity was reversed compared to Pt-4C and Pt5C and was similar to Pt-3C (Fig. 2-4 B). A549 cells remained unaffected by L-1C, L2C, and L-4C when the treatment was extended to 48 h; however, L-3C and L-5C
decreased cell viability by 40% and 60%, respectively, at 100 µM (Fig. 2-4 C). The Pt1C analogue was still without effect when treatment was extended to 48 h; however, Pt2C was very effective and caused almost complete reduction of cell viability at 100 µM
(Fig. 2-4 D). The activities of Pt-4C and Pt-5C were comparable to the 1 h treatment.
Interestingly, the activities of Pt-3C and Pt-6C were now increased to levels similar to
Pt-4C and Pt-5C. The activities of CDDP and carboplatin were also increased in the 48 h
treatment compared to the 1 h treatment; however, both drugs were still less effective
than Pt-2C—Pt-6C. The effective concentrations that result in 50% cell viability (EC 50)
for the complexes are given in Table 2-2. As shown, the EC50 of CDDP and carboplatin
are much higher than Pt-2C—Pt-6C. L-6C, L-8C, and Pt-8C were not tested due to poor
solubility in common solvents used for in vitro testing.
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Table 2 – 2 Effective concentrations that gives 50% cell death (EC50) determined from
A549 MTS assay data of at least three independent experiments
Compound

EC50 (µM) for 1 h

EC50 (µM) for 48 h

CDDP
Carboplatin
Pt-1C
Pt-2C
Pt-3C
Pt-4C
Pt-5C
Pt-6C
Pt-8C

1000 ± 0
> 1000
>100
>100
48 ± 3 a
17 ± 1 a
18 ± 1 a
66 ± 16 a
ND

500 ± 100
300 ± 30a
>100
66 ± 7 a
17 ± 1 a
15.4 ± 0.5 a
16.5 ± 0.5 a
19.1 ± 0.8 a
ND

Data represent mean ± SD from three independent experiments done in quadruplicates.
a

P<0.05 compared to CDDP.

The MTS cell viability results demonstrated a concentration and time-dependent
effect of complexes of CDDP, carboplatin, and Pt-2C—Pt-6C against human A549 lung
cancer cells. It is apparent that most of these complexes have higher activity than
cisplatin and carboplatin. The trend of the activity of the complexes at 1 h exposure in
A549 cells is Pt-4C ≈ Pt-5C > Pt-3C ≈ Pt-6C > CDDP > Pt-2C ≈ carboplatin ≈ Pt-1C.
The activity of the complexes increases as the carbon number on the alkoxy group
increases, which peaked with the complexes having four (Pt-4C) and five carbon chains
(Pt-5C) and then decreased with the complex having a six carbon chain (Pt-6C). It is
interesting to note that a difference of one carbon number caused the activity to increase
or decrease by 3 or 4 times. This may be attributed to changes in molecular weight and
lipophilicity, which could affect cellular uptake of the compounds.32,33
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Figure 2 – 5. Cytotoxicity of various human cancer cells (A) DU145, (B) MCF-7, and
(C) MDA-MB-435 treated for 1 h with CDDP (■) or Pt-4C (♦). Data points represent
mean ± SD of at least two independent experiments done in quadruplicates.
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Based on the results of A549 cells, one of the highly effective compounds, Pt-4C,
was used for further testing. To determine if Pt-4C has a broad spectrum of activity
against other types of oncogenic cells, the activity of this complex was tested against a
prostate cancer cell line (DU145), a melanoma cell line (MDA-MB-435), and a breast
cancer cell line (MCF-7). Similar to A549, Pt-4C also had a concentration-dependent
effect against all cell lines tested in a 1 h treatment (Fig. 2-5). The EC50 varied slightly
among the different cell lines (Table 2-3); the EC50 of Pt-4C was in the low micromolar
range, whereas, the EC50 of cisplatin was 25–63 times higher depending on the cell line.
The MDA-MB-435 cell line was the most sensitive to Pt-4C treatment, followed by
DU145. The MCF-7 cell line had the highest EC50 and was the least sensitive to Pt-4C.
These results indicate that this compound is much more potent compared to cisplatin and
has a broad spectrum of activity.

Table 2 – 3 EC50 (µM) values of Pt-4C determined from MTS assay data of at least two
independent experiments done in quadruplicates
Cell line
A549
DU145
MCF-7
MDA-MB-435

Cancer type
lung
prostate
breast
melanoma

CDDP
1000 ± 0
500 ± 200
910 ± 90
110 ± 40

Pt-4C
17 ± 1 a
8 ± 2a
32 ± 5 a
4 ± 1a

Data represent mean ± SD from three independent experiments done in quadruplicates.
compared to CDDP.

a

P<0.05

2.4.2.2 Evaluation of apoptosis
2.4.2.2.1 Cell cycle analysis by flow cytometry.
The MTS data indicate that these Pt-complexes induce cell death in various
human cancer cells. There are two major forms of cell death: apoptosis and necrosis.
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Apoptosis is a genetically-driven programmed cell death characterized by features such
as cell shrinkage and chromatin condensation and fragmentation.34 Necrosis results from
physical injuries and may result from exposure to chemotherapeutic drugs. Necrotic cells
swell up and lyse, releasing cellular contents and cause inflammatory responses.
Apoptosis is the main mode of cell death in cells treated with cisplatin (human ovarian
cancer cell line A2780,35 human cervix carcinoma cell line HeLa,36 ovarian cancer cells
OV200837). We hypothesized that the Pt-4C complex would also induce apoptosis; thus,
Pt-4C treated cells were analyzed by flow cytometry using propidium iodide (PI) and
Annexin V/PI double staining to detect apoptotic features.
The effect of Pt-4C on the cell cycle distribution of A549, DU145, and MCF-7
cells was examined by flow cytometry with PI staining (Fig. 2- 6). Cells were treated for
1 h with EC50 concentration of Pt-4C and harvested 24 and 48 h after treatment. The cells
were fixed, stained with PI and analyzed with a flow cytometer which measures the PI
fluorescence. In A549 (Fig. 2-6 A), Pt-4C treatment did not induce any cell cycle arrest.
However, it caused a decrease in all stages of the cell cycle and an increase in the sub-G1
population. The effects of Pt-4C on the cell cycle distribution of DU145 cells (Fig. 2-6
B) and MCF-7 cells (Fig. 2-6 C) were similar to A549 cells. Both MCF-7 and DU145 had
a higher percentage of cells in sub-G1 after 48 h compared to 24 h.

40

Control

Pt-4C

A
24 h

48 h

B
24 h

48 h

C
24 h

48 h

Figure 2 – 6. Flow cytometry with PI staining (A) A549, (B) DU145, and (C) MCF7.
Cells were treated with EC50 Pt-4C for 1 h then harvested 24 and 48 h after treatment.
Cells were fixed, stained with PI and analyzed with a flow cytometer.
representative plots of three independent experiments.
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Data are

2.4.2.2.2 Detection of membrane changes by flow cytometry
Analysis of the PI staining of Pt-4C treated cells demonstrate that the EC50
concentration of Pt-4C did not induce cell cycle arrest in A549, DU145, and MCF-7
cells, but caused a time-dependent increase in the sub-G1 population. The PI fluorescence
intensity is proportional to DNA content; the sub-G1 peak represents cells with less DNA
content than the cells in the G1 phase and are usually described as apoptotic cells.20
However, cells undergoing necrosis have membrane damage and DNA content can leak
out causing them to have less DNA than cells in G1 phase. Thus, it is unclear if the subG1 peak represents cells undergoing apoptosis or necrosis. Consequently, Annexin V/PI
staining was used to determine apoptotic vs. necrotic cell death.
An event that happens in early apoptosis is flipping of phosphatidylserine to the
membrane surface which is recognized by Annexin V. The effect of Pt-4C in A549,
DU145, and MCF-7 cells was analyzed by flow cytometry with Annexin V to detect
early apoptosis and PI staining to detect late apoptosis or necrosis. Cells were treated
with EC50 concentration of Pt-4C for 1 h then harvested 12, 24, and 48 h post treatment.
Cells were stained with Annexin V and PI and analyzed with a flow cytometer. For all
time points, A549 cells treated with Pt-4C were decreased in quadrant four (Q4) and
increased in both quadrant two (Q2) and quadrant three (Q3) populations, indicating an
increase in early apoptotic and late apoptotic/necrotic cells with a corresponding decrease
in live cells (Fig. 2-7). The 24 h group had higher percentages of early apoptotic and late
apoptotic/ necrotic cells (cells in Q2 and Q3) than the 12 h group; however, the 48 h
group had lower percentages than 24 h. Similar to A549, DU145 cells treated with Pt-4C
were also decreased in Q4 and increased in both Q2 and Q3 compared to control,
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Control

Pt-4C

12 h

24 h

48 h

Figure 2 – 7. A549 Flow with Annexin V/PI staining. A549 cells were treated with EC50
Pt-4C for 1 h then harvested 12, 24, and 48 h after treatment. Cells were stained with
Annexin V and PI and analyzed with a flow cytometer. Q1 is PI positive representing
necrotic cells, Q2 is Annexin V/PI positive representing late apoptotic/necrotic cells, Q3
is Annexin V positive and PI negative representing early apoptotic cells, and Q4 is
Annexin V/PI negative representing live cells.
independent experiments.
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Data are representative of three

Control

Pt-4C

12 h

24 h

48 h

Figure 2 – 8. DU145 Flow with Annexin V/PI staining. Cells were treated with EC50 Pt4C for 1 h then harvested 12, 24, and 48 h after treatment. Cells were stained with
Annexin V and PI and analyzed with a flow cytometer. Q1 is PI positive representing
necrotic cells, Q2 is Annexin V/PI positive representing late apoptotic/necrotic cells, Q3
is Annexin V positive and PI negative representing early apoptotic cells, and Q4 is
Annexin V/PI negative representing live cells. Data are representative plots of three
independent experiments.
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Control
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Figure 2 – 9. MCF-7 Flow with Annexin V/PI staining. Cells were treated with EC50 Pt4C for 1 h then harvested 12, 24, and 48 h after treatment. Cells were stained with
Annexin V and PI and analyzed with a flow cytometer. Q1 is PI positive representing
necrotic cells, Q2 is Annexin V/PI positive representing late apoptotic/necrotic cells, Q3
is Annexin V positive and PI negative representing early apoptotic cells, and Q4 is
Annexin V/PI negative representing live cells. Data are representative plots of three
independent experiments.
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indicating a decrease in live cells and an increased in early apoptotic and late
apoptotic/necrotic cells (Fig. 2-8). The percentages of cells in Q2 and Q3 (early apoptotic
and late apoptotic/necrotic cells) were higher in the 24 h group than the 12 h group and
the 48 h group had values similar to the 24 h group. MCF-7 cells treated with Pt-4C had
increased early apoptotic and late apoptotic/necrotic cells (Q2 and Q3) in the 12 and 24 h
groups, but only increased early apoptotic (Q3) cells in the 48 h group (Fig. 2-9). The
increase in early apoptotic and late apoptotic/necrotic cells (Q2 and Q3 populations) was
accompanied by a corresponding decrease in live cells (the Q4 population). These results
demonstrate that Pt-4C induces apoptosis in these cell lines and some necrotic responses
were also observed.
2.4.2.2.3 Analysis of morphological changes by fluorescence microscopy and DNA
laddering
The effect of Pt-4C in A549 cells was examined further by DNA laddering and
fluorescence microscopy. One of the features of apoptosis is cleavage of DNA into
fragments with increments of 180–200 bp which can be detected as a DNA ladder when
separated on an agarose gel. To observe this phenomenon, A549 cells were treated with
10–35 µM Pt-4C for 1 h and the DNA was extracted 24 h post treatment. The DNA was
separated on an agarose gel to detect a ladder pattern. The DNA of control cells did not
have the typical ladder pattern of apoptotic cells, whereas, the DNA of cells treated with
Pt-4C at concentrations ranging from 10–35 µM shows the laddering pattern (Fig. 2-10).
For analysis of cells using fluorescence microscopy, the cells were treated with the EC 50
concentration of Pt-4C for 1 h and then stained with Hoechst (Ho) and PI. PI is
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Figure 2 – 10. A549 apoptotic DNA laddering. Cells were treated for 1 h with varying
concentrations of Pt-4C and DNA was extracted 24 h post treatment.

Figure 2 – 11. A549 fluorescence microscopy. Cells were stained with Hoechst (Ho) and
propidium iodide (PI) 2 h post treatment with EC50 concentration of the Pt-4C for 1 h.
Bright fluorescence indicates positive staining. PI stains necrotic cells and Ho stains live
and apoptotic cells, with intense bright fluorescence indicating apoptotic cells. Images
are representative of at least two independent experiments.
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membrane impermeable and only stains cells with membrane damage. Ho is membrane
permeable and can stain both live cells and cells undergoing apoptosis; cells with intense
bright fluorescence indicate apoptotic cells. To determine the effect of Pt-4C in A549,
the cells were treated with the EC50 concentration of Pt-4C for 1 h, and then 2 h post
treatment the cells were stained with Ho and PI. Control cells show some positive Ho
staining, but no positive staining (Fig. 2-11). Cells treated with Pt-4C had more Ho and
PI positive staining than control; many Ho positive cells were also PI positive.
Additionally, bright field (BF) images showed altered cell morphology (shrunken and
rounding up) in Pt-4C treated cells compared to control. These results confirm that Pt-4C
induces apoptosis in A549 cells and are consistent with the mode of cell death induced by
other Pt(II) complexes reported in the literature.17,19,20
2.4.2.3 In vivo toxicity
Pt-4C was sent to Molecular Diagnostic Services Laboratory (San Diego, CA) for
in vivo toxicity testing in C57BL/6 female mice. The animals were divided into three
groups: group one had three animals and received one intraperitoneal (IP) injection of Pt4C at a dose of 12.5 mg kg-1 d-1; group two had three animals and received a dose of 12.5
mg kg-1 d-1 for three days; group three had one animal and was the vehicle control. One
animal from group two exhibited slight lethargy after the first injection, but quickly
recovered 2 h after the injection. All animals survived during the study period of 7 d post
injection and no abnormal observations were noted indicating that this compound is not
toxic in an animal model.
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2.5 Conclusions
A series of platinum(II) complexes containing 2,2′-bipyridyl with alkoxy
substituents of increasing carbon chain length at the 4,4′ positions were successfully
synthesized. The direct two step procedure generally gave moderate to high yields and
did not require expensive fluorinated reagents or the use of a potentially dangerous strong
base. These complexes were demonstrated to have a concentration and time-dependent
effect on various cancer cells. Furthermore, a structure-activity relationship was also
observed. Various methods employed indicate that one of the complexes, Pt-4C, induced
apoptosis in A549, DU145, and MCF-7 cells. It is likely that the other Pt-complexes
synthesized also induce cell death through apoptosis due to their similar chemical
structures. All of these exciting results demonstrate the potential utilization of our
platinum complexes as chemotherapeutic drugs in the treatment of a broad range of
cancers. However, further studies are needed to evaluate the prospective translation of
these compounds into clinical use.
Understanding the cellular effects of a drug is important when developing
treatment strategies and predicting possible side effects. There is still much to be
explored about the biological effects of cisplatin; however, it is known that cisplatin
binds to DNA and forms adducts that damage the DNA and activates the apoptotic
pathway.1,2,38–40 The newly synthesized Pt(II) complexes have a platinum center that is
similar to cisplatin and may bind to DNA to cause damage in a mechanism analogous to
cisplatin. Differences in cellular uptake and DNA binding may underlie the pronounced
improvement of the Pt-4C cytotoxicity profile compared to cisplatin.
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Determination of the mechanism of action requires an examination of the
signaling events that occur. Since Pt-4C induces apoptosis in A549, DU145 and MCF-7
cells, it is necessary to investigate the involvement of proteins in the apoptotic pathway.
A protein that is of interest is p53, a tumor suppressor protein that is involved in many
processes including activation of DNA repair, cell cycle arrest, and initiation of
apoptosis.41 The role of p53 in CDDP treated cells varies depending on the cell line and
duration of treatment.42–45 Thus, it is likely that p53 expression is affected by treatment
with Pt-4C and the other Pt-complexes. Interestingly, we have found that Pt-4C caused a
transient dose-dependent induction of p53 expression in A549 cells, which is currently
under investigation in our laboratory. Additionally, mitogen-activated protein kinases
(ERK, JNK, p38) are involved in signaling for cell survival and apoptosis. 42 Generally,
ERK has a role in cell proliferation and development, whereas JNK and p38 have roles in
apoptotic signaling. These proteins have been associated with CDDP treatment; however,
similar to p53, their roles also vary depending on the cell line and duration of
treatment.42,45–47 Thus, it will be interesting to examine the roles of these proteins in
response to treatment with Pt-4C.
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CHAPTER 3
CHARACTERIZATION OF THE DNA BINDING AND MAPK PROTEIN
ACTIVATION ACTIVITIES OF PT(II) COMPLEXES CONTAINING 4,4′DIALKOXY-2,2′-BIPYRIDINE LIGANDS

3.1 Abstract
The study of the anti-proliferative activities of our previously reported novel
platinum(II) complexes containing 4,4′-dialkoxy-2,2′-bipyridine ligands were expanded
to various lung, prostate, and breast cancer cell lines to examine differential responses to
these potential cancer drugs. The EC50 values obtained from MTS assays demonstrate a
generally improved cytotoxicity profile compared to cisplatin and carboplatin in all cell
lines. One of the complexes, Pt(II)-4C, was studied further for its ability to interact with
DNA and activation of important cell signaling pathways such as p53 and mitogenactivated protein kinase (MAPK) cascades.
UV-Vis analysis with calf thymus and gel electrophoresis with plasmid pBR322
DNA indicated that Pt(II)-4C can bind to DNA and cause unwinding of circular DNA.
Moreover, results from inductively coupled plasma-atomic emission spectroscopy (ICPAES) suggested that Pt(II)-4C can be taken up by A549 lung cancer cells and bind to
intracellular DNA.
Measurement of protein expression by immunofluorescence microscopy, flow
cytometric immunofluorescence, and western blotting show increased p53 expression in
Pt(II)-4C treated A459 cells and co-treatment with the p53 inhibitor, PFTα, resulted in
increased cell viability compared to Pt(II)-4C treatment alone. MAPK (JNK, ERK, and
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p38) activation was also observed in A549 and DU145 (human prostate cancer) cells
treated with Pt(II)-4C. Activation of MAPK was accompanied by phosphorylation of
histone H2AX (γH2AX). Treatment of A549 and DU145 cells with Pt(II)-4C in the
presence of MAPK inhibitors resulted in reduced levels of γH2AX.

Furthermore,

treatment of these two cell lines with Pt(II)-4C in the presence of the JNK and p38
inhibitors resulted in increased cell viability compared to Pt(II)-4C treatment alone.
Treatment of A549 with Pt(II)-4C in the presence of the ERK inhibitor resulted in
decreased cell viability compared to Pt(II)-4C treatment alone, but no effect was
observed in DU145 cells. These results indicate that JNK and p38 may be involved in cell
death signaling in response to Pt(II)-4C treatment.
3.2 Introduction
A chemotherapeutic drug that is commonly prescribed for the treatment of many
cancers is cisplatin (CDDP), a square-planar Pt(II) compound. Together with its two
analogues, carboplatin and oxaliplatin, platinum drugs constitute about 50% of all cancer
chemotherapeutic regimens.

However, treatment with these platinum drugs is

accompanied by severe side effects such as nephrotoxicity, neuropathy, ototoxicity, and
myelosuppression. Additionally, other drawbacks such as intrinsic or acquired resistance
and limited activity against some major types of cancer have impeded the clinical utility
of these drugs.1–5 Motivated to overcome these drawbacks, we have previously reported
on the synthesis of a series of platinum(II) [Pt(II)] complexes containing 4,4′-dialkoxy2,2′-bipyridine ligands (with the dialkoxy having one to six carbons) and their antiproliferative activity against the A549 lung cancer cell line (Chapter 2).6 The improved
anti-proliferative activity of these complexes compared to cisplatin warrant further
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investigation of these compounds. Since only one of the complexes was tested in other
cancer cells, it is necessary to expand the study of all the complexes in various cancer cell
types to have a better indication of their effectiveness in different types of cancers.
Furthermore, an understanding of the signaling pathways activated by these platinum
complexes will provide the foundation necessary for developing strategies to utilize these
compounds for the treatment of cancer.

Thus, we seek to determine the signaling

pathways activated within cancer cells in response to treatment by these novel platinum
complexes.
The cytotoxic effect of cisplatin is mainly due to the formation of DNA adducts
even though only a small percentage (5–10%) of the intracellular cisplatin concentration
is found in the nucleus.7 Cisplatin-induced DNA damage elicits various cellular responses
such as cell cycle arrest, activation of repair mechanisms, stress responses, and cell death
pathways. The two pathways that are of interest are the p53 and the mitogen-activated
protein kinase (MAPK) cascades.
The p53 protein is a tumor suppressor that is involved in many processes
including activation of DNA repair, cell cycle arrest, and initiation of apoptosis. 8 During
normal cellular conditions, p53 has a short half-life and is kept at a low level by the
Mdm2 ubiquitin ligase. However, the interaction of p53 with Mdm2 decreases when
stimulated by stress signals, which allows for the accumulation and phosphorylation of
p53.8,9 Activated p53 can then interact with other proteins such as p21 (cell cycle protein)
or Bax (apoptotic protein)9 to culminate in various cellular outcomes such as cell survival
and death.
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Loss of p53 function can occur due to mutations in about 50% of all cancers.10
The drug resistance of many cancers has been attributed to having mutant p53 and the
differential p53 status has been taken advantage of for the development of treatment
methods that are more specific by targeting p53.11 Current data from the literature
indicate that the role of p53 in cisplatin treated cells varies depending on the cell line and
duration of treatment. In some reports, cisplatin-induced apoptosis is described as
requiring functional p53; however, the opposite is reported by some authors indicating
that cells with wild-type p53 are resistant to cisplatin treatment and sensitivity is achieved
by inhibition of its expression.7,9
The MAPKs are proteins that are activated by various stimuli to regulate cellular
processes such as proliferation, differentiation, movement, survival, and programmed cell
death.7,9 Three major MAPK members are extracellular signal-regulated kinases (ERK),
c-Jun N-terminal kinases (JNK), and p38 kinases. Generally, ERK has a role in cell
proliferation and development; however, JNK and p38 have roles in apoptotic signaling,
inflammatory responses, and protective responses.7 These proteins are activated through
phosphorylation by upstream kinases and, in turn, phosphorylate downstream targets to
activate them. ERK, JNK, and p38 have all been demonstrated to be activated by
cisplatin; however, similar to p53, their roles also vary between different cell lines and
duration of treatment. In some studies, in accordance with their roles, ERK activation
protects cells from apoptosis, whereas, activation of JNK and p38 leads to apoptotic cell
death; on the other hand, some studies demonstrated the reverse.7,9,12,13
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Herein, the anti-proliferative activity of these complexes in various lung, prostate,
and breast cancer cell lines are described. Additionally, Pt(II)-4C interaction with DNA
and its effect on p53 and MAPK signaling are investigated.
3.3 Experimental
3.3.1 General
All general chemicals and reagents were purchased from common commercial
vendors (Sigma-Aldrich, TCI, Alfa-Aesar, or Acros) unless otherwise noted. Pt(II)
complexes were synthesized as described in Chapter 2. Minimum essential medium
(MEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsin-EDTA, and
penicillin-streptomycin were purchased from Life Technologies (Carlsbad, CA). The
RPMI 1640 medium was purchased from ATCC (Manassas, VA). Cisplatin, carboplatin,
HEPES, albumin from bovine serum (BSA), Tris-HCl, Trizma Base, and dimethyl
sulfoxide (DMSO) were purchased from Sigma-Aldrich.
3.3.2 Cell culture
Human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1),
lung (A549 and H520), and prostate (DU145 and PC-3) cancer cell lines were obtained
from American Culture Type Collection (ATCC). The A549, HCC38, MCF-7, MDAMB-231, SK-BR-3, T-47D, and ZR-75-1 cells were grown in MEM supplemented with
10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL-1) and streptomycin
(100 µg mL-1). The H520, DU145, and PC-3 cell lines were grown in RPMI-1640
supplemented with 10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL-1)
and streptomycin (100 µg mL-1). All cell lines were maintained at 37 °C in a humidified,
5% CO2 atmosphere.
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3.3.3 Cell viability assay
Cells were cultured at a density of 2–3.5 x 103 cells per well in flat bottomed 96well plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50%
confluence. The cells were then treated with solvent or the appropriate drugs (CDDP
stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 5% glucose,
synthesized Pt(II) complexes were dissolved in DMSO) for 1 h, washed three times with
100 µL PBS, and incubated in 100 µL of fresh medium. After 2 d, the medium was
replaced with 120 µL of medium containing CellTiter 96® Aqueous One Solution Reagent
(MTS reagent) (Promega, Madison, WI). The cells were incubated at 37 °C for 4 h and
the cell viability was determined by measuring the absorbance at 490 nm using a Tecan
Infinite M1000 microplate reader. The 48 h treatment was done in a similar method,
except the cells were not washed after treatment and the MTS reagent was immediately
added. Viability of treated groups was calculated as a percent of control and graphed with
GraphPad Prism.
The experiment was also done similarly for studies with p53 or MAPK inhibitors.
The cells were pre-treated with pifithrin-α (PFTα) (Sigma-Aldrich #P4359) SB202190
(p38 inhibitor, Sigma-Aldrich #S7067), PD-098,059 (ERK inhibitor, Sigma-Aldrich
#P215), or SP600125 (JNK inhibitor, Sigma-Aldrich #S5567) for the indicated time,
followed by co-treatment with the indicated concentrations of Pt(II)-4C, and posttreatment with the inhibitors.
3.3.4 UV-Vis spectroscopy
The ability of Pt(II)-4C to bind DNA was determined analyzing its interaction
with calf thymus DNA (CT-DNA) with UV-Vis spectroscopy. CT-DNA was purchased
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from Life Technologies (#15633-019, 10 mg/mL in Dnase, Rnase free water) and the
DNA concentration per nucleotide was determined from the UV absorbance at 260 nm
using the molar extinction coefficient ε260 = 6600 M−1cm−1. CT-DNA (100 µM) was
incubated with 0–140 µM of Pt(II)-4C (stock solution was dissolved in DMSO) in 10
mM Tris-HCl (pH 7.2) containing 10% DMSO for 1 or 24 h at 37 °C and the absorbance
was measured with the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo
Scientific). Pt(II)-4C solutions of each concentration in the same buffer were used as
blanks to eliminate the absorption of the Pt(II)-4C by itself. The study was also done by
using a constant concentration of Pt(II)-4C (100 µM) and increasing the concentration of
CT-DNA (0–100 µM). The same buffer system was used and samples with only CTDNA at each concentration was used as blanks to eliminate the absorbance from the CTDNA.
3.3.5 Agarose gel electrophoresis
A solution of pBR322 plasmid DNA (0.125 µg) (Life Technologies #15367-014,
supplied at 0.25 µg/µl in 10 mM Tris-HCl (pH 7.4), 5 mM NaCl, 0.1 mM EDTA) was
mixed with increasing concentrations (0–100 µM) of Pt(II)-4C and brought to 25 µL
with TE buffer (Tris-EDTA) containing 25% DMSO. Cisplatin was used as a control.
The samples were incubated at 37 °C in the dark for 24 h. After incubation, 5 µL of 6X
DNA loading buffer (0.25% bromophenol blue, 0.25% Orange G, 30% glycerol) was
added to each sample and 25 µL was electrophoresed through a 1% agarose gel immersed
in 1X TBE buffer (2 mM EDTA, pH 8.0; 89 mM Tris; 89 mM Boric Acid) for 50 min at
100 V. Finally, the gel was stained with ethidium bromide (EB) (1 µg mL-1) in the dark

63

for 30 min, followed by visualization on a Bio-Rad ChemiDoc XRS+ imaging system
with a UV-Vis transilluminator.
3.3.6 Cellular uptake and intracellular DNA binding of platinum
Cells were seeded in 100 mm culture dishes and incubated at 37 °C until ~70-80%
confluent. The cells were treated with the indicated concentrations of Pt(II)-4C for 4 h
and harvested by trypsinization. The cells were washed twice with 10 mL of PBS,
counted, and pelleted by centrifugation. For the cellular uptake study, the cell pellet was
stored at -20 °C until analysis.
For intracellular DNA binding analysis, the cell pellet was resuspended in 500 µL
of lysis buffer (100 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS, 0.5% Triton X-100,
200 mM NaCl, 100 µg mL-1 proteinase K). After 2 h of incubation at 56 °C, 4 µL of a 0.2
mg mL-1 RNAse A solution was added and the sample was incubated at room
temperature for 15 min. The DNA was precipitated by addition of 2-propanol (500 µL),
mixed by inversion, and stored overnight at -20 °C. The DNA was pelleted by
centrifugation at 16 000 × g for 15 min at 4 °C. The pellet was washed with 70% ethanol
and air dried by inverting the tube on a tissue for 10 min. The DNA was dissolved in 150
µL of nuclease-free water and the DNA concentration was determined with the
NanoDrop ND-1000 Spectrophotometer.

The samples were stored at -20 °C until

analysis
For platinum analysis, 200 µL of high purity concentrated HNO3 was added to the
cell pellet and DNA samples, and the contents were transferred to borosilicate glass
tubes. After heating at 80 °C for 2 h to digest the samples, they were diluted with ultrapure water to a final concentration of 1% HNO3. The samples were filtered with 0.45 µm
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syringe filters and analyzed by inductively coupled plasma-atomic emission spectrometry
(ICP-AES). Platinum standards (0-50 µM) were used as an external calibration curve to
calculate the amount of platinum in the samples.
3.3.7 Western blot analysis
Cells were seeded in 100 mm dishes and grown to subconfluence. The cells were
treated with increasing concentration of Pt(II)-4C for the indicated time, harvested, and
collected. The cells were lysed by vigorously vortexing in 300 µL M-PER lysis buffer
(Thermo Scientific # 78503) containing 2X phosphatase inhibitor cocktail (Pierce
#88667), 2X protease inhibitor cocktail (Thermo Scientific # 78410), 1X EDTA (Thermo
Scientific # 78410). The lysate was centrifuged at 14 000 × g for 15 min at 4 °C and
supernatant was collected.

The protein concentration was determined using the

bicinchoninic acid (BCA) protein assay (Pierce # PI-23235) by following the
manufacturer’s instructions. The cell lysate was mixed with 1X LDS sample buffer (Life
Technologies #B0007) and 1X DTT (Life Technologies #B0009), placed in boiling water
for 5 min, and 30 µg of protein was separated on a Novex Bolt 4-12% Bis Tris Plus gel
(Life Technologies # BG04125BOX) with Bolt MES SDS Running Buffer (Life
Technologies # B0002). The protein was transferred onto a nitrocellulose membrane
(iBlot® Transfer Stack, Life Technologies # IB301001) using the iBlot® Gel Transfer
Device. The membrane was treated with SuperSignal Western Blot Enhancer Antigen
Pretreatment Solution (Thermo Scientific # 46640) for 10 min, washed according to the
manufacture’s instruction, blocked with 5% bovine serum albumin (BSA) in 1X Trisbuffered saline containing 0.05% Tween-20 (TBST) buffer for 1 h at room temperature.
After rinsing with TBST, the membrane was incubated with the appropriate primary
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antibody (dilution in SuperSignal Western Blot Enhancer Primary Antibody Diluent
(Thermo Scientific # 46640)) at 4 °C overnight.

After washing with TBST, the

membrane was incubated with the appropriate HRP-conjugated secondary antibody
(diluted1:2000 in 5% BSA) for 1 h at room temperature. Protein bands were detected
with Clarity Western ECL Substrate (Bio-Rad # 170-5061) and imaged on the Bio-Rad
ChemiDoc XRS+.
SAPK/JNK

Antibody (#9252),

Phospho-SAPK/JNK

(Thr183/Tyr185)

Antibody (#9251), p38 MAPK Antibody (#9212), Phospho-p38 MAPK (Thr180/Tyr182)
Antibody (#9211), p44/42 MAPK (Erk1/2) Antibody (#9102), Phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204) Antibody (#9101) were purchased from Cell Signaling
Technologies. Β-Actin Antibody (C4) (#sc-47778) and p53 Antibody (DO-1) (#sc-126)
were purchased from Santa Cruz Biotechnology.
3.3.8 Immunofluorescence microscopy
Cells (125,000) were seeded into 35 mm dishes containing #1.5 glass coverslips
and incubated for 48 h at 37 °C. The cells were treated with the indicated concentration
of Pt(II)-4C (or co-treated with the MAPK inhibitors) for the indicated time at 37 °C,
washed 2X with PBS, and fixed with 4% formaldehyde for 15 min at room temperature.
The cells were washed 3X with PBS, permeabilized with 0.2% Triton X for 5 min at
room temperature, washed 3X with PBS, and blocked with 5% BSA in PBS for 1 h at 37
°C. After blocking, the cells were washed 2X with PBS and incubated with mouse antiphospho-JNK (Santa Cruz Biotechnology #sc-6254), anti-phospho-ERK1/2 (Santa Cruz
Biotechnology #sc-81492), anti-phospho-p38 (Santa Cruz Biotechnology #sc-7973), antiphospho-Histone H2A.X (Ser139) (EMD Millipore #05-636), p53 Antibody (DO-1)
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(Santa Cruz Biotechnology #sc-126) primary antibodies (1:50 dilution in 5% goat serum)
at 4 °C overnight. The cells were washed 4X for 5 min each on a rocker, followed by
incubation with Alexa-Fluor 488 goat anti-mouse secondary antibody (Life Technologies
#A11029) [1:400 dilution in 5% goat serum (Santa Cruz Biotechnology #sc-2043)] at
room temperature 30 min. The cells were washed 4X for 5 min each on a rocker, briefly
rinsed with ultrapure H2O, and mounted on glass slides with Prolong Gold Antifade
Reagent with DAPI (Life Technologies #P36935). Images were taken with the Nikon
A1R confocal laser scanning microscopy system (CLSM) mounted on a Nikon Eclipse
Ti.
3.3.9 Flow cytometric immunofluorescence
Cells (100,000) were seeded in 60 mm dishes and grown for 3 d at 37 °C in a
humidified, 5% CO2 atmosphere. The cells were treated with the indicated concentration
of Pt(II)-4C for the indicated time and harvested. The cells were fixed by addition of
16% formaldehyde to a final concentration of 4% and incubated at room temperature for
10 min. The cells were pelleted and the supernatant was discarded. The cells were
permeabilized by resuspension in 500 µL of ice-cold methanol and incubated at 4 °C for
10 min. The samples were stored at -20 °C until staining. For staining, the cells were
pelleted and washed 2X with 1% BSA in PBS. The cells were pelleted, resuspended in
BD Stain Buffer (BS Biosciences #554656) containing the appropriate conjugated
primary antibody [p38 MAPK (pT180/pY182) Alexa 488 (BD Biosciences #612594),
JNK (pT183/pY185) PE N9-66 (BD Biosciences #562480), ERK1/2 (pT202/pY204)
PerCP-Cy5.5 20A (BD Biosciences # 560115), p53 (pS37) Alexa 647 J159-641.79 (BD
Biosciences #560280), the γH2AX antibody was purchased as a part of a Cell
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Proliferation kit (BD Biosciences #562253)], and incubated at 4 °C overnight. After
washing 2X with BD Stain Buffer, the cells were resuspended in PBS and analyzed on a
Becton Dickinson FACS Calibur.
3.3.10 Statistical analysis
GraphPad Prism 5 was used to graph viability curves. ModFit version 3.0 was
used for the flow cytometry analysis. Microsoft Office Excel was used to perform
unpaired Student’s t-test; values with p < 0.05 were considered significant. Student’s ttests were used to verify significant differences among the EC50 values.
3.4 Results and discussion
3.4.1 Cytotoxicity of Pt(II) complexes
The cellular response to a particular drug can vary between different types of
cancers. In order to thoroughly examine the effectiveness of the dialkoxy-2,2′-bipyridyl
Pt(II) complexes in different types of cancers, the anti-proliferative activities of all the
complexes were determined in a lung (H520), two prostate (DU145 and PC-3), and six
breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1) cancer cell
lines. The cells were treated with increasing concentrations of the complexes for 1 or 48 h
and the viability was measured using an MTS colorimetric cell proliferation assay. The
effective concentrations which resulted in 50% cell viability (EC50) were obtained from
the viability curves and tabulated in Tables 3-1–3-3. The novel Pt(II) complexes are
generally more effective than cisplatin with EC50 values ranging from 1–80 µM, while
the EC50 values of cisplatin are in the range of 20–900 µM. The EC50 values for the 1 h
treatment with the two short chains complexes, Pt(II)-1C and Pt(II)-2C, were not
obtainable in some cell lines (both complexes in H520 and MCF-7; Pt(II)-1C in PC-3
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and MDA-MB-231 cells) with the highest concentration (100 µM) tested. Interestingly,
the EC50 values tend to be higher in H520, MCF-7, and ZR-75-1, which all have wild
type p53.14,15
Currently, cisplatin does not have a major role in the clinical treatment of breast
cancers; however, some triple negative breast cancers (TNBC) are sensitive to platinum
drugs.16 Comparison of the EC50 values for complexes Pt(II)-1C–Pt(II)-6C and cisplatin
demonstrate that in most cases the new complexes are more effective than cisplatin in the
breast cancer cell lines tested. Moreover, the response is similar between cell lines with
differential hormone receptors expression (HCC38 and MDA-MB-231 are TNBC).17

Table 3 – 1. EC50 (µM) of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in H520,
DU145 and PC-3 post 1 or 48 h treatment
Lung cancer

Prostate cancer

H520

DU145

PC-3

Compound

1h

48 h

1h

48 h

1h

48 h

CDDP

200 ± 17

24 ± 2

400 ± 100

64 ± 8

200 ± 20

30 ± 1

Carboplatin

ND

ND

>1000

400 ± 100a

ND

ND

Pt(II)-1C

>100

30 ± 2

40 ± 10a

24 ± 2a,b

>100

40 ± 7

Pt(II)-2C

>100

21 ± 1

20 ± 5a

11 ± 4a,b

22 ± 5a

21 ± 7

Pt(II)-3C

40 ± 20 a

13 ± 5 a

6 ± 1a

4 ± 2a,b

5 ± 1a

5.1 ± 0.8a

Pt(II)-4C

20 ± 1 a

14 ± 6

12 ± 8a

5 ± 2a,b

11 ± 2a

7.4 ± 0.5a

Pt(II)-5C

23 ± 5 a

17 ± 3

8 ± 2a

6.0 ± 0.7a,b

7 ± 1a

7.3 ± 0.7a

Pt(II)-6C

>50

18 ± 1

2.1 ± 0.1a

1.9 ± 0.1a,b

2.24 ±0.03a

2.7 ± 0.1a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.
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Table 3 – 2. EC50 (µM) of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in various
human breast cancers post 1 h treatment
Compound

HCC38

MCF-7

MDAMB-231

SK-BR-3

T-47D

ZR-75-1

CDDP

300 ± 30

900 ± 60

50 ± 4

420 ± 80

900 ± 100

260 ± 10

Carboplatin

ND

>1000

ND

ND

ND

ND

Pt(II)-1C

80 ± 20a

>100

>100

19 ± 5a

20 ± 1a

67 ± 27a

Pt(II)-2C

18 ± 4a

>100

30 ± 20

2.2 ± 0.2a

5 ± 2a

58 ± 15a

Pt(II)-3C

5 ± 2a

100 ± 0a

4 ± 2a

1.81 ± 0.03a

2.4 ± 0.1a

8.9 ± 0.4a

Pt(II)-4C

12 ± 6a

22 ± 2a

4 ± 3a

5 ± 4a

12 ± 7a

21 ± 2a

Pt(II)-5C

13 ± 5a

21 ± 5a

4 ± 2a

2.8 ± 0.8a

9 ± 3a

8 ± 3a

Pt(II)-6C

16 ± 5a

80 ± 30a

6 ± 3a

1.84 ± 0.03a

3.2 ± 0.8a

7 ± 2a

Values represent the mean ± SD of at least two independent experiments done in quadruplicates.
ND = no data a P < 0.5 compared to CDDP. b P < 0.05 compared to carboplatin.

Table 3 – 3. EC50 (µM) of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in various
human breast cancers post 48 h treatment
Compound

HCC38

MCF-7

MDAMB-231

SK-BR-3

T-47D

ZR-75-1

CDDP

30 ± 8

35 ± 1

21 ± 3

23 ± 6

35 ± 6

30 ± 8

Carboplatin

ND

800 ± 100a

ND

ND

ND

ND

Pt(II)-1C

57 ± 2a

>100

>100

23 ± 2

21 ± 1a

26 ± 1

Pt(II)-2C

20 ± 3

>100

20 ± 6

1.8 ± 0a

2.2 ± 0.4a

16.5 ± 0

Pt(II)-3C

4.7 ± 0.5a

19 ± 4a,b

2.2 ± 0.1a

1.73 ± 0.01a

1.9 ± 0.1a

5 ± 1a

Pt(II)-4C

7.3 ± 3

13 ± 1a,b

2.4 ± 0.6a

2.1 ± 0.2a

2.3 ± 0.4a

6.0 ± 0.9a

Pt(II)-5C

10 ± 2

15 ± 7 a,b

4.1 ± 0.2a

2.4 ± 0.4a

3 ± 1a

6.6 ± 0.7a

Pt(II)-6C

14 ± 4

12 ± 4a,b

4 ± 1a

1.8 ± 0a

2.1 ± 0.2a

6.4 ± 0.4a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data a P < 0.5 compared to CDDP. b P < 0.05 compared to carboplatin.
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3.4.2 UV-Vis analysis of DNA binding
Absorption spectroscopy is one of the methods commonly used to examine the
characteristics of metal complex interaction with DNA. The interactions of metal
complexes with DNA can cause changes in the absorption spectra such as an increase
(hyperchromism)

or

decrease

(hypochromism)

in

absorbance,

or

a

redshift

(bathochromism) or blueshift (hypsochromism) of the wavelength. Hypochromism and
redshift are usually observed for an intercalative binding of the compound to DNA.
Damage to the DNA double helical structure such as breakage is usually identified by a
hyperchromic shift in the absorbance spectra.18 Various degrees of hyperchromic and
hypochromic shifts have been described for different platinum complexes.19–23 The
absorbance spectra for one of the platinum complexes reported with coordination to 2,2′bipyridine and substituted 1,10-phenanthroline ligands showed hypochromism.22
Additionally, another complex similar to our compounds, but containing dicarboxylic
acid substituents, also caused hypochromism in the absorbance spectra.23 Thus, it is
hypothesized that the dialkoxy-2,2′-bipyridyl Pt(II) complexes will also cause similar
effects.
Due to having consistently low EC50 values in all of the cell lines tested, Pt(II)4C was chosen for further studies. The UV-Vis analysis of the interaction of Pt(II)-4C
with CT-DNA was

first evaluated by incubation of the CT-DNA at a constant

concentration (100 µM) with increasing concentrations of Pt(II)-4C for 1 or 24 h at 37
°C. Addition of Pt(II)-4C to CT-DNA for 1 h caused an increase in the DNA absorbance
at 260 nm and, as illustrated in Figure 3-1 A, the increase in absorbance was
concentration dependent. Further incubation of the DNA with Pt(II)-4C for 24 h did not
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caused any dramatic changes to the absorption spectra (Figure 3-1 B). The experiment
was repeated by keeping the Pt(II)-4C concentration constant (100 µM) and varying the
concentrations of CT-DNA. The spectra for the 1 h incubation show an absorbance
maximum for Pt(II)-4C (in the absence of DNA) around 250 nm and a broad absorption
around 300 nm (Figure 3-2 A).

Addition of 10 µM CT-DNA caused significant

hyperchromism in the spectra and the Pt(II)-4C peak around 300 nm was shifted to 280
nm (blueshift). Further addition of CT-DNA caused slight increases in the absorbance of
Pt(II)-4C. Results obtained for the 24 h incubation was similar to the 1 h incubation,
except the characteristic absorption peaks of Pt(II)-4C in the absence of DNA was not
observed as for the 1 h treatment period (Figure 3-2 B).
The hyperchromism observed for Pt(II)-4C interaction with CT-DNA is
indicative of electrostatic attractions that may have caused separation of the DNA
structure.24 These results are in contrast to the hypochromism observed by Sun et al. for
the structurally related Pt(II) complex containing dicarboxylic acid substituted 2,2′bipyridyl.23
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Figure 3 – 1. Absorption spectra of CT-DNA (100 µM) with increasing concentration of
Pt(II)-4C. Samples were incubated at 37 °C for (A) 1 or (B) 48 h in 10 mM Tris-HCl
(pH 7.2) containing 10% DMSO. Pt(II)-4C solutions of each concentration in the same
buffer were used as blanks to eliminate the absorption of the Pt(II)-4C by itself. Spectra
are representative of at least three independent experiments.
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Figure 3 – 2. Absorption spectra of Pt(II)-4C (100 µM) with increasing concentration of
CT-DNA. Samples were incubated at 37 °C for (A) 1 or (B) 48 h in 10 mM Tris-HCl (pH
7.2) containing 10% DMSO. Samples with only CT-DNA in the same buffer at each
concentration were used as blanks to eliminate the absorbance from the CT-DNA.
Spectra are representative of at least three independent experiments.
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3.4.3 Gel electrophoretic analysis of DNA cleavage
Cleavage of circular plasmid DNA is another method used to determine the
effects of a compound on DNA. Plasmid DNA cleavage generates different forms of
DNA that have varying migration rates in gel electrophoresis. To utilize this
characteristic, the interaction of Pt(II)-4C was further studied by examining its
interaction with plasmid pBR322 DNA. Plasmid pBR322 can have three forms; Form I is
the intact supercoiled structure, Form II results when one of the DNA strands is cleaved
forming an opened circular structure, and Form III is the linear structure generated when
both DNA strands are cleaved. Form I migrates the fastest in agarose gel electrophoresis,
Form II migrates the slowest, and Form III migrates in between the two.21–23
The electrophoretic mobility shift of pBR322 incubated with increasing
concentrations of Pt(II)-4C is shown in Figure 3-3. After incubation for 24 h at 37 °C,
Pt(II)-4C did not affect the mobility of Form I at concentrations of 5 and 15 µM. At 25
µM of Pt(II)-4C, a slight decrease in the mobility of Form I was observed and this
pattern was more evident at 50 µM with a slight increase in intensity for the Form II
band. Treatment of pBR322 with 75 µM Pt(II)-4C resulted in three bands: a faint band
in the Form I region, an increased Form II band, and a smeared band in between. This
pattern is indicative of DNA cleavage by Pt(II)-4C. Cisplatin (100 µM) was used as a
control. Cisplatin treatment resulted in two bands with decreased intensity and a different
mobility pattern compared to DNA alone. Treatment with Pt(II)-4C resulted in different
mobility patterns compared to cisplatin indicating that the interaction of Pt(II)-4C with
DNA may be different than that of cisplatin.
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Figure 3 – 3. Gel electrophoretic analysis of the Pt(II)-4C complex interaction with
DNA. Plasmid pBR322 DNA (0.125 µg) was incubated for 24 h at 37 °C with increasing
concentrations of Pt(II)-4C in TE buffer (Tris-EDTA) containing 25% DMSO, subjected
to electrophoresis in a 1% agarose gel, stained with ethidium bromide, and visualized
with a UV-Vis transilluminator. Gel images are representative of at least two independent
experiments.

3.4.4 Intracellular accumulation of Pt(II)-4C
Analysis of intracellular platinum concentrations were measured by ICP-AES to
determine the extent of cellular uptake and DNA binding of Pt(II)-4C in A549 cells.
A549 cells treated for 4 h with increasing concentrations of Pt(II)-4C had increasing
accumulation of platinum in the cell (Figure 3-4 A), which was accompanied by a
proportional increase in platinum bound to DNA (Figure 3-4 B). These results correlate
well with the concentration dependent anti-proliferative effect of Pt(II)-4C in A549 cells
(Chapter 2).6
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Figure 3 – 4. Cellular uptake of Pt(II)-4C in A549 human lung cancer cells. A549 cells
were treated for 4 h with increasing concentrations of Pt(II)-4C and the amount of Pt (A)
taken up by the cells or (B) bound to DNA was measured by ICP-AES. Values for the
cell uptake are representative of two independent experiments and the values for Pt
bound to DNA are from one trial.
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3.4.5 Pt(II)-4C induced cell death in A549 cells is p53 dependent
The effects of Pt(II)-4C treatment on p53 signaling was examined in A549 cells
to determine the role of p53 in Pt(II)-4C induced cell death. Immunofluorescence
microscopy analysis of p53 expression in A549 cells treated with Pt(II)-4C showed
increased p53 signal compared to control cells (Figure 3-5 A) with p53 localized in the
nucleus. This result was confirmed by western blotting, in which A549 cells treated with
increasing concentrations of Pt(II)-4C had increasing p53 expression (Figure 3-5 B).
Additionally, measurement of phosphorylated p53 (p-p53) levels in A549 cells treated
with Pt(II)-4C by flow cytometry showed an increased shift in p53 signal compared to
control (Figure 4-5 C).

The change of p-p53 expression calculated from the flow

cytometry data indicated a 2–3 fold increase in activated p53 (Figure 4-5 D).
To determine the role of activated p53 in Pt(II)-4C induced cell death of A549
cells, p53 was inhibited by the chemical inhibitor PFTα. As shown in Figure 3-6,
treatment of A549 cells with Pt(II)-4C in the presence of PFTα resulted in increased cell
viability compared to cells treated with Pt(II)-4C alone. The partial reversal of Pt(II)4C induced cell death by inhibition of p53 suggests that p53 is involved in the cell death
signaling response to Pt(II)-4C treatment in A549. This result is consistent with reports
of the role of p53 in regulating apoptosis.9,25
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Figure 3 – 5. Expression of p53 in A549 cells. Expression of p53 was measured by (A)
immunofluorescence microscopy of cells treated for 2 h with 100 uM of Pt(II)-4C
(images are representative of two independent experiments done by taking images of at
least three different fields) and (B) western blotting of cells treated for 3 h with
increasing concentrations of Pt(II)-4C (representative of two independent experiments).
(C) Flow cytometric analysis of phosphorylated p53 in cells treated for 6 h with 100 µM
Pt(II)-4C (representative of three independent experiments). (D) Fold change (signal of
treated cells/signal of control) in p-p53 fluorescence signal taken from the flow cytometry
data.
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Figure 3 – 6. Effect of p53 inhibition on Pt(II)-4C induced cell death in A549 cells.
A549 cells were pre-treated with 50 µM PFTα (p53 inhibitor) for 1h, co-treated with
PFTα and increasing concentrations of Pt(II)-4C for 1 h, and the cell viability was
measured by the MTS assay after 48 h of incubation with PFTα.
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3.4.6 Pt(II)-4C induces activation of MAPK
The involvement of MAPK members in response to Pt(II)-4C was determined in
A549 and DU145 cells. First, activation of JNK, p38, and ERK were analyzed using
flow cytometry. The histogram of A549 and DU145 cells treated with 100 µM of Pt(II)4C showed a right shift of phosphorylated p38 (Figure 3-7 A and E), JNK (Figure 3-7 B
and F), and ERK (Figure 3-7 C and G) signals compared to control indicating activation
of p38, JNK, and ERK. The fold change calculated from the flow data indicate increases
of 4–25 times compared to control (Figure 3-7 D and H) with p-ERK being the highest.
Additionally, a concentration dependent increase in MAPK members was observed.
Western blotting analysis of proteins from A549 (Figure 3-8 A) and DU145
(Figure 3-8 B) cells treated with increasing concentrations of Pt(II)-4C also showed a
concentration dependent increase in p-JNK, p-p38, and p-ERK. The increase in
phosphorylated proteins observed for A549 cells started at 25 µM, while this increase
was observed at 5 µM in DU145 cells. These results correspond to the MTS data
showing a lower EC50 value for DU145 cells.
Activation of MAPK in A549 and DU145 cells treated with Pt(II)-4C was further
analyzed with immunofluorescence microscopy. Similar to the flow and western data,
immunofluorescence images showed an increase in p-p38, p-JNK, and p-ERK signals in
Pt(II)-4C treated A549 cells (Figure 3-9). Moreover, activated JNK and ERK appeared
to be localized to the nucleus, while activated p38 localization was cytoplasmic. Similar
results were obtained for DU145 cells (Figure 3-10).
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Figure 3 – 7. Flow cytometric immunofluorescence analysis of MAPK activation in
A549 and DU145 cells. (A) p-p38, (B) p-JNK, and (C) p-ERK levels in A549 cells
treated for 6 h with Pt(II)-4C. (E) p-p38, (F) p-JNK, and (G) p-ERK levels in DU145
cells treated for 1 h with Pt(II)-4C. Fold change for (D) A549 and (H) DU145 cells
calculated by taking the ratio of the fluorescence signals of treated cells to control.
Histograms are representative of three independent experiments done in triplicate.
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Figure 3 – 8. Western blot analysis of MAPK activation in A549 and DU145 cells. (A)
A549 treated for 3 h with increasing concentrations of Pt(II)-4C. (B) DU145 treated for
1 h with increasing concentrations of Pt(II)-4C. Images are representative of at least two
independent experiments.
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Figure 3 – 9. Immunofluorescence microscopy analysis of MAPK activation in A549
cells treated for 2 h with 100 µM Pt(II)-4C. Images are representative of two
experiments done by taking images of at least three different fields.
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Figure 3 – 10. Immunofluorescence microscopy analysis of MAPK activation in DU145
cells treated for 1 h with 30 µM Pt(II)-4C. Images are representative of two experiments
done by taking images of at least three different fields.
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3.4.7 Pt(II)-4C induced activation of H2AX is dependent on MAPK
DNA double-strand breaks (DSBs) cause the activation of histone H2AX through
its phosphorylation at Ser-139. Phosphorylated H2AX (γH2AX) is believed to play a
role in DNA damage repair and regulation of apoptosis.26 MAPK members have been
associated with phosphorylation of H2AX.27,28 Furthermore, phosphorylation of H2AX in
cisplatin treated cells has been observed29–32 and its phosphorylation by MAPK in cells
treated with oxaliplatin has also been reported.33
Since Pt(II)-4C causes DNA damage and activates MAPK, it is possible that
γH2AX will also be induced. As expected, immunofluorescence microscopy analysis
showed an increased γH2AX fluorescence in A549 (Figure 3-10) and DU145 (Figure 311) cells treated with Pt(II)-4C compared to control (also confirmed by flow cytometry,
Figure 3S-1 shown in the appendix). Co-treatment of A549 and DU145 cells with Pt(II)4C and chemical inhibitors of p38 (SB202190), JNK (SP600125), and ERK (PD098,059) resulted in decreased γH2AX fluorescence compared to Pt(II)-4C treatment
alone. In A549 cells, inhibition of p38 and JNK resulted in decreased γH2AX
fluorescence comparable to the control; however, the decreased γH2AX fluorescence
resulting from the inhibition of ERK was not as dramatic (Figure 3-11). This was not
observed for DU145 cells. These results indicate that Pt(II)-4C causes DSB and induces
phosphorylation of H2AX in a MAPK dependent manner.
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Figure 3 – 11. Effect of MAPK inhibitors on Pt(II)-4C induced H2AX phosphorylation
in A549 cells. Cells were pre-treated with 10 µM of MAPK inhibitors (PD: ERK
inhibitor, SB: p38 inhibitor, SP: JNK inhibitor) for 2 h, then co-treated with Pt(II)-4C
(50 µM) for 2 h, and phosphorylated H2AX (γH2AX) was measured by
immunofluorescence microscopy. Images are representative of two independent
experiments.
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Figure 3 – 12. Effect of MAPK inhibitors on Pt(II)-4C induced H2AX phosphorylation
in DU145 cells. Cells were pre-treated with 10 µM of MAPK inhibitors (PD: ERK
inhibitor, SB: p38 inhibitor, SP: JNK inhibitor) for 24 h, then co-treated with Pt(II)-4C
(30 µM) for 3 h, and phosphorylated H2AX (γH2AX) was measured by
immunofluorescence microscopy. Images are from one experiment done by taking
images of at least three different fields.
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3.4.8 The effect on MAPK inhibitors on Pt(II)-4C induced cell death
To determine the role of MAPK in Pt(II)-4C induced cell death, the cell viability
of A549 and DU145 cells treated with increasing concentrations of Pt(II)-4C in the
absence or presence of the MAPK inhibitors was measured by the MTS assay. As shown
in Figure 3-13 A, A549 cells treated with Pt(II)-4C in the presence of the ERK inhibitor
had decreased cell viability compared to Pt(II)-4C treatment alone, while treatment in
the presence of p38 and JNK inhibitors resulted in increased cell viability compared to
Pt(II)-4C treatment alone. Similar results were observed for DU145 cells (Figure 3-13
B), except inhibition of ERK had no effect on the Pt(II)-4C induced cell death
(comparable results were obtained even when the concentration of the inhibitors was
increased, Figure 3S-2 shown in the appendix) . These results indicate that Pt(II)-4C
induced cell death is dependent on functional p38 and JNK in both A549 and DU145
cells. Additionally, functional ERK protects A549 cells from Pt(II)-4C induced cell
death. It is surprising that while Pt(II)-4C caused ERK activation in DU145 cells and its
inhibition reduced the level of γH2AX formation, its inhibition did not affect Pt(II)-4C
induced cell death. Perhaps its activation is not sufficient enough to overcome the effects
of Pt(II)-4C.
The results obtained are consistent with the reported roles of ERK in protection
against apoptosis, and p38 and JNK as apoptosis inducers.
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Figure 3 – 13. Effects of MAPK inhibitors on Pt(II)-4C induced cell death. (A) A549
treated with increasing concentrations of Pt(II)-4C in the absence and presence of 40 µM
of MAPK inhibitors (PD: ERK inhibitor, SB: p38 inhibitor, SP: JNK inhibitor) for 48 h
and (B) DU145 treated with increasing concentrations of Pt(II)-4C in the absence and
presence of 10 µM of MAPK inhibitors for 48 h. Results are representative of at least
three independent experiments done in quadruplicates.

3.5 Conclusions
The present work demonstrate that Pt(II) complexes containing 4,4′-dialkoxy-2,2′bipyridyl ligands are more potent than cisplatin in various human breast, prostate, and
lung cancers. One of the complexes, Pt(II)-4C, causes intracellular DNA strand breaks,
activates p53 and MAPK signaling pathways, which may culminate in cell death. In
A549 cells, p53 and the MAPK members, p38 and JNK, are responsible for inducing cell
death in response to Pt(II)-4C, while ERK protects A549 from cell death. In DU145
cells, p38 and JNK are necessary for Pt(II)-4C induced cell death.
MAPK and p53 are two of the many pathways activated by cisplatin treatment.
They are involved in a complex network of signaling cascades that regulate cell survival
and death. For a more complete understanding of the effects of Pt(II)-4C, it would be
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interesting to investigate the signaling of downstream target molecules of p53 and
MAPKs such as proteins in the cell cycle, the repair pathway, and death pathways
(apoptosis and autophagy) to determine the effects of Pt(II)-4C.
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CHAPTER 4
SYNTHESIS AND CHARACTERIZATION OF PT(II) COMPLEXES CONTAINING
4,4′-DIOLIGOOXYETHYLENE-2,2′-BIPYRIDINE LIGANDS FOR CANCER
TREATMENT

4.1 Abstract
Five

[Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)]

complexes

were

synthesized and their anti-proliferative activities were determined in a panel of human
breast, lung, and prostate cancer cell lines. While in some cases, the synthesized platinum
complexes were less active than cisplatin, they were generally more effective than
carboplatin. A549 and MCF-7 cells were the least sensitive to treatment, and the SK-BR3 and T-47D lines were most sensitive.
Two of the complexes, Pt(II)-4O,2C and Pt(II)-5O,1C, have some water
solubility, but their activities were inferior to the non-water soluble compounds. Pt(II)4O,2C was further studied in A549 and DU145 for analysis of cell death induction due to
its activity and solubility. A549 and DU145 cells treated with Pt(II)-4O,2C had an
increase in phosphorylated H2AX, indicating that Pt(II)-4O,2C caused DNA damage.
Furthermore, results from analysis of PI, Annexin V/PI, Hoechst/PI, and PARP cleavage
indicated that Pt(II)-4O,2C induced apoptosis; however, some necrosis was also
observed.
4.2 Introduction
Since the discovery of its anti-tumoral property in the 1960s, cisplatin (a Pt(II)
complex) has facilitated worldwide interest in utilizing metal compounds for clinical
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applications.1,2 Currently, cisplatin and its two analogues (carboplatin and oxaliplatin) are
approved worldwide for the treatment of various cancers. Additionally, five other Pt(II)
complexes (lobaplatin, dicycloplatin, nedaplatin, miriplatin, and heptaplatin) are
approved in selected countries.2–8 While platinum drugs are used in about 50% of all
cancer chemotherapeutic regimens as single agents or in combination with other types of
treatment, complications such as intrinsic or acquired resistance and severe side effects
have restricted their usefulness.2,4,8 To minimize these inadequacies, many researchers are
putting efforts toward the development of compounds with improved efficacies and lower
toxic side effects.
Numerous metal compounds have now been developed as potential cancer drugs
through methods such as replacing the platinum center with other metals (i.e. ruthenium,
palladium, etc.), changing the leaving groups, altering the amine groups, oxidation of the
platinum center, and incorporation into a delivery system.1,7,9–11 With an aspiration to
develop alternative cancer drugs, we have previously reported on the synthesis and antiproliferative effects of some novel Pt(II) complexes in which the amine ligands are
replaced with 4,4′-dialkoxy-2,2′-bipyryl ligands (Chapter 2).12

As have been

demonstrated, these complexes are much more effective than cisplatin and carboplatin
when evaluated in the A549 human lung cancer cell line. Furthermore, one of the
complexes, Pt(II)-4C, was also more effective than cisplatin in the DU145 prostate
cancer line, the MCF-7 breast cancer line, and the MDA-MB-435 melanoma line. While
the in vitro data gave promising results, our attempts to test the toxicity of Pt(II)-4C in
mice revealed the challenges of solubilizing the compound. Due to the hydrophobic
nature of the compound, it had low solubility in some common organic solvents and
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virtually none in water. Thus, to improve these compounds, the dialkoxy substituents
were modified to have increasing oxygen which will result in increasing hydrogen
bonding and water solubility.
Herein, the synthesis of a series of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)]
(where R = –(CH2CH2O)n(CH2)mCH3, n = 1–4, m = 0–3) is presented and their antiproliferative activities against a panel of human breast, lung, and prostate cancers in
comparison to cisplatin are described.
4.3 Experimental
4.3.1 General
All starting materials and reagents for the synthetic procedures were purchased
from the commercial vendors (Sigma-Aldrich, TCI, Alfa-Aesar, or Acros) unless
otherwise noted. They were of high purity and were used without further purification
unless noted in the procedure. The compound used for synthesis of the ligands, 2,2′bipyridine-4,4′-diol, was synthesized as described in Chapter 2.12,13 Minimum essential
medium (MEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsinEDTA, and penicillin-streptomycin were purchased from Life Technologies (Carlsbad,
CA). The RPMI 1640 medium was purchased from ATCC (Manassas, VA). Cisplatin,
carboplatin, HEPES, albumin from bovine serum (BSA), propidium iodide, Hoechst
33342, methanol, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich.
All reagents and enzymes used for flow cytometry were of analytical grade qualities and
were purchased from Sigma-Aldrich, unless otherwise noted.
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4.3.2 Chemical characterization instrumentation
All of the NMR spectra were obtained utilizing a Varian spectrometer at 298 K or
the indicated temperature using deuterated dimethyl sulfoxide (DMSO-d6) or chloroform
(CDCl3) as the solvents: 1H NMR, 400 MHz; and

13

C NMR, 100 MHz. Either residual

solvent or tetramethylsilane (TMS) were used as the internal chemical shift reference.
Thermal transitions were determined by using a TA Instruments DSC 2010 differential
scanning calorimeter in nitrogen at heating and cooling rates of 10 °C min-1. The
temperature axis of the DSC thermogram was calibrated with reference standards of high
purity indium and tin before use. An amount of 2-3 mg of compound was used in this
measurement. The Tonset and Tmax temperatures of a melting endotherm of a compound
were recorded from the DSC thermogram as Mp (Tonset-Tmax). Elemental analysis (EA)
was determined by NuMega Resonance Labs Inc. (San Diego, CA) using a Perkin Elmer
PE2400-Series II with a CHNS/O analyzer.
4.3.3 Preparation of monoalkoxy glycol tosylate compounds
4.3.3.1 Procedure A
The tosylate was synthesized following the procedure of Keddie et al.14 with a
slight modification of the reaction condition. The desired glycol (1.1 equiv.) was
dissolved in CH2Cl2 and cooled to 0 °C. After addition of KOH (4 equiv.), a solution of
p-toluenesulfonyl chloride (1 equiv.) in CH2Cl2 was slowly added while maintaining the
temperature at 0 °C. When all of the p-toluenesulfonyl chloride was added, the mixture
was further stirred at 4 °C for 24 h. The resulting white suspension was filtered to remove
salt and water was added to the filtrate. The product was isolated by extraction with
CH2Cl2 and dried over Na2SO4. The solvent was removed using a rotary evaporator
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resulting in a colorless oily liquid. The final product was dried in vacuo overnight at 50
°C.
4.3.3.2 Procedure B
The tosylate was synthesized following the procedure of Lenz et al.15 with a slight
modification of the reaction condition. The desired glycol (1.1 equiv.) was added to a
solution of 7 M KOH (40-60 ml) and cooled to 0 °C. To the reaction flask, ptoluenesulfonyl chloride (1 equiv.) was slowly added and the mixture was stirred at 0 °C
for 3 h. The product was isolated by extraction with CH2Cl2 and dried over Na2SO4. The
solvent was removed using a rotary evaporator and the colorless oily liquid was washed
with hexane. The final product was dried in vacuo overnight at 50 °C.
OTs-2O,1C. Yield: 73% (prepared by procedure A). 1H NMR (298 K, 400 MHz,
CDCl3): δ (ppm) = 7.81 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 4.16 (t, J = 4.7 Hz,
2H), 3.58 (t, J = 4.8 Hz, 2H), 3.31 (s, 3H), 2.45 (s, 3H).
OTs-3O,2C. Yield: 81% (prepared by procedure B). 1H NMR (298 K, 400 MHz,
CDCl3): δ (ppm) = 7.80 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.17 (t, J = 4.9 Hz,
2H), 3.70 (t, J = 4.9 Hz, 2H), 3.61 – 3.55 (m, 2H), 3.54 – 3.45 (m, 4H), 2.45 (s, 3H), 1.19
(t, J = 7.0 Hz, 3H).
OTs-4O,2C. Yield: 91% (prepared by procedure B). 1H NMR (298 K, 400 MHz,
CDCl3): δ (ppm) = 7.78 (d, J = 7.9 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.14 (t, J = 4.8,
2H), 3.66 (t, J = 4.9, 2H), 3.61 – 3.52 (m, 8H), 3.49 (m, 2H), 2.42 (s, 3H), 1.18 (t, J = 7.0
Hz, 3H).
OTs-4O,4C. Yield: 76% (prepared by procedure B). 1H NMR (298 K, 400 MHz,
CDCl3): δ (ppm) = 7.79 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.15 (t, J = 4.9 Hz,
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2H), 3.68 (t, J = 4.9 Hz, 2H), 3.63 – 3.51 (m, 8H), 3.44 (t, J = 6.7 Hz, 2H), 2.44 (s, 3H),
1.60 – 1.49 (m, 2H), 1.41 – 1.27 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H).
OTs-5O,1C. Yield: 86% (prepared by procedure B). 1H NMR (298 K, 400 MHz,
CDCl3): δ (ppm) = 7.77 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.13 (t, J = 4.7 Hz,
2H), 3.66 (t, J = 4.9 Hz, 2H), 3.63 – 3.49 (m, 12H), 3.34 (s, 3H), 2.42 (s, 3H).
4.3.4 Preparation of 4,4′-dioligooxyethylene-2,2′-bipyridine
The appropriate tosylate (2.1 equiv.) was slowly added to a mixture of 2,2′bipyridine-4,4′-diol (1 equiv.) and Cs2CO3 (2.3 equiv.) in DMF, and the suspension was
heated to reflux for 48 h. The salt was removed by vacuum filtration and washed with
CH2Cl2. A rotary evaporator was used to remove the solvents from the solution. The
crude product was dissolved in CH2Cl2, filtered to remove any remaining salt, and
washed with hexane. The product was further purified by recrystallization in the noted
solvent or by extraction with CH2Cl2, dried over Na2SO4, and the solvent removed by a
rotary evaporator. The final product was dried in vacuo for 48 h.
L-2O,1C. Yield: 77%, white crystals (by recrystallization in acetone-hexane). Mp
99-101 °C. 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 8.44 (d, J = 5.6 Hz, 1H),
7.88 (s, 1H), 7.00 (d, J = 5.5 Hz, 1H), 4.24 (d, J = 4.2 Hz, 2H), 3.67 (t, J = 4.2 Hz, 2H),
3.29 (s, 3H). 13C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 165.85, 157.27, 150.94,
111.55, 106.79, 70.44, 67.58, 58.63. Anal. Calcd for C16H20N2O4 (304.35 g mol-1): C,
63.14; H, 6.62; N, 9.20%; found: C, 63.26; H, 6.85; N, 9.32%.
L-3O,2C. Yield: 79%, white solid. Mp 43–45 °C. 1H NMR (298 K, 400 MHz,
CDCl3): δ (ppm) = 8.45 (d, J = 5.6 Hz, 1H), 7.97 (d, J = 2.6 Hz, 1H), 6.86 (dd, J = 5.7,
2.6 Hz, 1H), 4.30 (t, J = 4.8 Hz, 2H), 3.90 (t, J = 4.7 Hz, 2H), 3.72 (t, J = 4.7 Hz, 2H),
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3.61 (t, J = 4.7 Hz, 2H), 3.58–3.46 (m, 2H), 1.21 (t, J = 7.0, 3H). 13C NMR (298 K, 100
MHz, CDCl3): δ (ppm) = 165.84, 157.81, 150.12, 111.47, 106.66, 71.00, 69.87, 69.39,
67.47, 66.71, 15.16. Anal. Calcd for C22H32N2O6 (420.50 g mol-1): C, 62.87; H, 7.67; N,
6.66%; found: C, 61.87; H, 7.45; N, 6.75%. EA results showed a possibility of the
hydrated form C22H32N2O6 • 0.5 H2O. Anal. Calcd for C22H32N2O6 • 0.5 H2O (429.51 g
mol-1): C, 61.52; H, 7.74; N, 6.52%; found: C, 61.67; H, 7.45; N, 6.75%.
L-4O,2C. Yield: 83%, pale yellow oil. 1H NMR (298 K, 400 MHz, CDCl3): δ
(ppm) = 8.44 (d, J = 5.6 Hz, 1H), 7.96 (d, J = 2.5 Hz, 1H), 6.85 (dd, J = 5.7, 2.6 Hz, 1H),
4.35–4.25 (m, 2H), 3.92–3.87 (m, 2H), 3.75–3.71 (m, 2H), 3.70–3.62 (m, 4H), 3.60–3.55
(m, 2H), 3.54–3.47 (m, 2H), 1.19 (t, J = 7.0 Hz, 3H).

13

C NMR (298 K, 100 MHz,

CDCl3): δ (ppm) = 165.85, 157.82, 150.12, 111.49, 106.63, 70.94, 70.75, 70.67, 69.82,
69.38, 67.48, 66.63, 15.17. Anal. Calcd for C26H40N2O8 (508.60 g mol-1): C, 61.40; H,
7.93; N, 5.51%; found: C, 60.33; H, 8.63; N, 5.71%. EA results showed a possibility of
the hydrated form C26H40N2O8 • 0.5 H2O. Anal. Calcd for C26H40N2O8 • 0.5 H2O (517.61
g mol-1): C, 60.33; H, 7.98; N, 5.41%; found: C, 60.33; H, 8.63; N, 5.71%.
L-4O,4C. Yield: 70%, pale yellow oil. 1H NMR (298 K, 400 MHz, CDCl3): δ
(ppm) = 8.44 (d, J = 5.7 Hz, 1H), 7.96 (d, J = 2.6 Hz, 1H), 6.85 (dd, J = 5.6, 2.5 Hz, 1H),
4.29 (t, J = 4.7 Hz, 2H), 3.89 (t, J = 4.9 Hz, 2H), 3.75–3.54 (m, 8H), 3.44 (t, J = 6.7 Hz,
2H), 1.62–1.50 (m, 2H), 1.41–1.27 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (298 K,
100 MHz, CDCl3): δ (ppm) = 165.87, 157.75, 150.09, 111.49, 106.69, 71.20, 70.94,
70.71, 70.67, 70.07, 69.36, 67.49, 31.71, 19.27, 13.93. Anal. Calcd for C30H48N2O8
(564.71 g mol-1): C, 63.81; H, 8.57; N, 4.96%; found: C, 62.09; H, 8.87; N, 4.91%. EA
results showed a possibility of the monohydrated form C30H48N2O8 • H2O. Anal. Calcd
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for C30H48N2O8 • H2O (582.73 g mol-1): C, 61.83; H, 8.65; N, 4.81%; found: C, 62.09; H,
8.87; N, 4.91%.
L-5O,1C. Yield: 84%, pale yellow oil. 1H NMR (298 K, 400 MHz, CDCl3): δ
(ppm) = 8.44 (d, J = 5.7 Hz, 1H), 7.96 (d, J = 2.5 Hz, 1H), 6.86 (dd, J = 5.6, 2.5 Hz, 1H),
4.29 (t, J = 4.8 Hz, 2H), 3.89 (t, J = 4.8 Hz, 2H), 3.77 – 3.59 (m, 10H), 3.57 – 3.49 (m,
2H), 3.36 (s, 3H).
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C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 165.96, 157.91,

150.23, 111.60, 106.76, 72.05, 71.03, 70.77, 70.76, 70.73, 70.63, 69.48, 67.59, 59.15.
Anal. Calcd for C28H44N2O10 (568.66 g mol-1): C, 59.14; H, 7.80; N, 4.99%; found: C,
58.75; H, 7.93; N, 5.31%.
4.3.5 Preparation of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes
A concentrated solution of K2[PtCl4] (1.0 equiv.) in H2O (1–2 mL) was added to a
solution of 4,4′-dioligooxyethylene-2,2′-bipyridine (1.0 equiv.) in acetone. The mixture
was then heated to reflux for 24 h and the acetone was removed by using a rotary
evaporator resulting in either a yellow suspension or a yellow wax-like solid. For
reactions resulting in a yellow suspension, the crude product was collected by vacuum
filtration and the final product was obtained by recrystallization in the noted solvent and
dried in vacuo at 70 °C for 24 h. For reactions resulting in a yellow wax-like solid, the
product was purified by extraction with CH2Cl2 and dried over Na2SO4. The solvent was
removed using a rotary evaporator and the solid residue was washed with hexane. The
final product was collected and dried in vacuo for 24 h.
Pt(II)-2O,1C. Yield: 86%, bright yellow solid (by recrystallization in CHCl3).
Mp 206–207 °C. 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 9.10 (d, J = 6.7 Hz,
1H), 8.21 (s, 1H), 7.39 (d, J = 6.6 Hz, 1H), 4.43 (t, J = 4.3 Hz, 2H), 3.74 (t, J = 4.2 Hz,
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2H), 3.33 (s, 3H).
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C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 167.45, 158.46,

149.46, 113.55, 111.32, 70.13, 69.28, 58.64. Anal. Calcd for C16H20Cl2N2O4Pt (570.25 g
mol-1): C, 33.69; H, 3.53; N, 4.91%; found: C, 33.76; H, 3.70; N, 4.93%.
Pt(II)-3O,2C.

Yield:

78%,

bright

yellow

solid

(by

extraction,

then

recrystallization in isopropanol). Mp 126–130 °C. 1H NMR (298 K, 400 MHz, CDCl3): δ
(ppm) = 8.86 (d, J = 6.8 Hz, 1H), 7.48 (d, J = 2.8 Hz, 1H), 6.85 (dd, J = 6.8, 2.7 Hz, 1H),
4.53–4.46 (m, 2H), 4.00–3.93 (m, 2H), 3.78–3.71 (m, 2H), 3.67– 3.59 (m, 2H), 3.57–3.50
(m, 2H), 1.21 (t, J = 7.0 Hz, 3H). 13C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 166.94,
157.77, 149.03, 113.20, 110.19, 70.94, 69.81, 69.24, 69.15, 66.71, 15.19. Anal. Calcd for
C22H32Cl2N2O6Pt (686.47 g mol-1): C, 38.49; H, 4.70; N, 4.08%; found: C, 38.26; H,
5.01; N, 4.10%.
Pt(II)-4O,2C. Yield: 72%, bright yellow solid (by extraction). Mp 94–98 °C. 1H
NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.84 (d, J = 6.8 Hz, 1H), 7.47 (d, J = 2.8 Hz,
1H), 6.86 (dd, J = 6.8, 2.7 Hz, 1H), 4.49 (t, J = 4.4 Hz, 2H), 3.95 (t, J = 4.5 Hz, 2H),
3.79–3.49 (m, 10H), 1.20 (t, J = 7.0 Hz, 3H).
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C NMR (298 K, 100 MHz, CDCl3): δ

(ppm) = 166.93, 157.69, 148.99, 113.24, 110.21, 70.82, 70.69, 70.60, 69.79, 69.27,
69.13, 66.65, 15.18. Anal. Calcd for C26H40Cl2N2O8Pt (774.59 g mol-1): C, 40.32; H,
5.21; N, 3.62%; found: C, 39.91; H, 5.61; N, 3.77.
Pt(II)-4O,4C. Yield: 93%, bright yellow solid (by extraction). Mp 109–114°C.
1

H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 9.04 (d, J = 6.8 Hz, 1H), 7.42 (d, J = 2.8

Hz, 1H), 6.87 (dd, J = 6.8, 2.7 Hz, 1H), 4.39 (t, J = 4.5 Hz, 2H), 3.89 (t, J = 4.5 Hz, 2H),
3.70–3.48 (m, 8H), 3.38 (t, J = 6.7 Hz, 2H), 1.51–1.43 (m, 2H), 1.34–1.22 (m, 2H), 0.83
(t, J = 7.4 Hz, 3H).

13

C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 166.64, 157.33,
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148.13, 113.36, 110.18, 71.07, 70.62, 70.55, 70.48, 69.95, 69.12, 68.98, 31.60, 19.17,
13.86. Anal. Calcd for C30H48Cl2N2O8Pt (830.69 g mol-1): C, 43.38; H, 5.82; N, 3.37%;
found: C, 43.34; H, 6.30; N, 3.65%.
Pt(II)-5O,1C. Yield: 85%, wax-like yellow solid (by extraction). Mp 48–58 °C.
1

H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.79 (d, J = 6.8 Hz, 1H), 7.48 (d, J = 2.8

Hz, 1H), 6.84 (d, J = 6.8 Hz, 1H), 4.48 (t, J = 4.5 Hz, 2H), 3.94 (t, J = 4.4 Hz, 2H), 3.77 –
3.59 (m, 10H), 3.56 – 3.49 (m, 2H), 3.35 (s, 3H). 13C NMR (298 K, 100 MHz, CDCl3): δ
(ppm) = 167.06, 157.87, 149.11, 113.33, 110.36, 72.05, 70.94, 70.72 (3C overlapped),
70.64, 69.40, 69.25, 59.16. Anal. Calcd for C28H44Cl2N2O10Pt (834.65 g mol-1): C,
40.29; H, 5.31; N, 3.36%; found: C, 40.50; H, 5.51; N, 3.64%.
4.3.6 Cell culture
Human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1),
lung (A549 and H520), and prostate (DU145 and PC-3) cancer cell lines were obtained
from American Culture Type Collection (ATCC). The A549, HCC38, MCF-7, MDAMB-231, SK-BR-3, T-47D, and ZR-75-1 cells were grown in MEM supplemented with
10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL-1) and streptomycin
(100 µg mL-1). The H520, DU145, and PC-3 cell lines were grown in RPMI-1640
supplemented with 10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL-1)
and streptomycin (100 µg mL-1). All cell lines were maintained at 37 °C in a humidified,
5% CO2 atmosphere.
4.3.7 Cell viability assay
Cells were cultured at a density of 2–3.5 x 103 cells per well in flat bottomed 96well plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50%
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confluence. The cells were then treated with solvent or the appropriate drugs (CDDP
stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 5% glucose,
synthesized Pt(II) complexes were dissolved in DMSO) for 1 h, washed three times with
100 µL PBS, and incubated in 100 µL of fresh medium. After 2 d, the medium was
replaced with 120 µL of medium containing CellTiter 96® Aqueous One Solution Reagent
(MTS reagent) (Promega, Madison, WI). The cells were incubated at 37 °C for 4 h and
the cell viability was determined by measuring the absorbance at 490 nm using a Tecan
Infinite M1000 microplate reader. The 48 h treatment was done in a similar method,
except the cells were not washed after treatment and the MTS reagent was immediately
added. Viability of treated groups was calculated as a percent of control and graphed with
GraphPad Prism.
4.3.8 Flow cytometry
4.3.8.1 Propidium iodide (PI) staining
Cells (~50-60% confluent in 60 mm dishes) were treated as indicated with the
platinum compound. After the treatment duration, the floating cells were collected, and
both attached and floating cells were washed 2X with PBS. The cells were resuspended
in fresh medium and incubated as indicated. The cells were harvested (both the floating
and attached cells were collected), counted, and pelleted. The cells were then washed two
times with 5 mL PBS, fixed by resuspending in 0.1 mL of PBS and 1 mL of ice-cold 95%
ethanol with gentle vortexing. Fixed cells were stored at 4 °C until analysis. For analysis,
fixed cells were washed once with 1–2 mL of PBS and centrifuged at 500 × g for 5
minutes. The cell pellet was resuspended in 100 µL of a 1.0% Triton X-100 buffer
solution, and 100 µL of a 1.0 mg mL-1 RNAse solution was added and allowed to stand at
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room temperature for 10–15 min. While in the dark, 200 µL of a 100 µg mL-1 PI stain
was added to make a final concentration of 50 µg mL-1 and gently vortexed. The cell
mixture was incubated at room temperature for 30 min and flow cytometry acquisition
was done on a Becton Dickinson FACS Calibur with the argon laser set at 488 nm on the
linear Flow Channel 2 (FL-2) with Doublet Discriminatory Module (DDM) and threshold
set on FL-2.
4.3.8.2 Annexin V-FITC/PI staining
Cells (~50–60% confluent in 60 mm dishes) were treated as indicated with the
platinum compound. After the treatment duration, the floating cells were collected, and
both attached and floating cells were washed 2X with PBS. The cells were resuspended
in fresh medium and incubated as indicated. The cells were harvested (both the floating
and attached cells were collected), counted, and pelleted. The cells were then washed two
times with 5 mL of Ca2+ and Mg2+ free PBS. The pellets were then washed in 2.0 mL of
1X Annexin-V Binding buffer (BD Bioscience, San Jose, CA) and centrifuged at 500 × g
for 5 min. The pellets were treated with Annexin-V-FITC conjugate (BD Bioscience, San
Jose, CA) and incubated in the dark for 15 min. Just before acquisition, the volume of
cells-conjugate mixture was adjusted by addition of 1X Annexin-V binding buffer.
Acquisition to discriminate between apoptotic and necrotic cells was done by staining the
cell-conjugate mixture with 10 µL of PI (50 µg mL-1) solution (BD Bioscience, San Jose,
CA). Acquisitions were done on a FACS Calibur Cytometer on the FL1 (Annexin) and
FL3 (PI) channels with threshold and Duplet Discriminating Module (DDM) set at FL1.
The level of shift in events distribution in the Annexin-V only and Annexin-V-PI
populations in comparison to control is indicative of degree of effectiveness of the
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treatment agents. A quantitative measure of these event shifts was accomplished by
gating.
4.3.8.3 Flow cytometric immunofluorescence
Cells (200,000–250,000) were seeded in 60 mm dishes and incubated at 37 °C in
a humidified, 5% CO2 atmosphere for 2 d to reach ~50–60% confluence. The cells were
treated with the platinum complexes as indicated, the floating cells were collected, and
both attached and floating cells were washed 2X with PBS. The cells were resuspended
in fresh medium and incubated as indicated. After incubation, both the floating and
attached cells were collected and fixed by incubation in 4% formaldehyde for 10 min at
room temperature. The fixed cells were pelleted and permeabilized by incubation in 500
µL of ice-cold methanol at 4 °C for 10 min. The samples were stored at -20 °C until
analysis. For analysis, the cells were pelleted and washed 2X with 1% BSA in PBS. The
cells were resuspended in BD Stain Buffer (BS Biosciences #554656) containing the
appropriate conjugated primary antibody [PE Mouse Anti-Cleaved PARP (Asp214) and
Alexa Fluor 647 Mouse Anti-H2AX (pS139) antibodies were purchased as a part of a
Cell Proliferation Kit (BD Biosciences #562253)], and incubated at 4 °C overnight. After
washing 2X with 1% BSA, the cells were resuspended in PBS and analyzed on a Becton
Dickinson FACS Calibur.
4.3.9 Confocal microscopy
Cells (100,000–125,000) were seeded into 35 mm dishes and incubated for 48 h at
37 °C. The cells were treated as indicated, and while in the dark, the cells were washed
twice with 1 mL PBS. After washing, 1 mL of a 2 µg mL-1 Hoechst 33342 and 10 µg mL1

PI solution (in PBS) was added and the cells were incubated for 15 min at room
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temperature. Images were acquired within 5 min with a Nikon A1R confocal laser
scanning microscopy system (CLSM) mounted on a Nikon Eclipse Ti. At least three
random areas on each dish were imaged.
4.3.10 Statistical analysis
GraphPad Prism was used to graph viability curves. ModFit version 3.0 was used
for the flow cytometry analysis. Microsoft Office Excel was used to perform unpaired
Student’s t-test; values with p < 0.05 were considered significant. Student’s t-tests were
used to verify significant differences among the EC50 values.
4.4 Results and discussion
4.4.1 Synthesis and characterization
A method similar to the synthesis of the [Pt(II)Cl 2(4,4′-dialkoxy-2,2′-bipyridine)]
complexes

was

used

to

synthesize

the

[Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-

bipyridine)] complexes (Scheme 4-1), except the ligands were synthesized using tosylate
compounds as alkylating agents instead of alkylhalides. The tosylates were prepared from
the desired glycols (containing increasing number of oxyethylene linkages and varying
terminal carbon number) by following previously described procedures.14,15 All of the
tosylate compounds were colorless liquids and the yields were moderate to high (73–

Scheme 4 – 1. Synthesis of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)]
complexes.
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Figure 4 – 1. Structures of monoalkoxy glycol tosylate compounds.

91%). The structures of these tosylate compounds (Figure 4-1) were confirmed by proton
NMR and used for the preparation of the ligands without further analysis.
The ligands were synthesized by reacting the respective tosylate compound with a
mixture of 2,2′-bipyridine-4,4′-diol and Cs2CO3 in DMF on heating to reflux for 48 h.
The yields for the ligands range from 70-84%. The platinum complexes were prepared by
reacting the ligands with K2[PtCl4] for 24 h on reflux.

As was observed for the

previously synthesized Pt(II) complexes, the formation of the product was monitored by
the appearance of a yellow solid or solution. The structures of the synthesized platinum
complexes are shown in Figure 4-2. The yields of the platinum complexes were in the
range of 72–93%. All of the ligands and platinum complexes were characterized by 1H
and 13C NMR spectroscopy, EA, and DSC measurements.
1

H and

13

C NMR spectra of the ligands and platinum complexes displayed the

expected resonances. Formation of the ligand was marked by the disappearance of the
tosylate characteristic aromatic peaks and appearance of the bipyridyl aromatic peaks in
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Figure 4 – 2. Chemical structures of the synthesized [Pt(II)Cl2(4,4′-dioligooxyethylene2,2′-bipyridine)] complexes.

the 1H NMR spectra. Coordination of the ligands to the Pt was confirmed by observing
the shifting of the bipyridyl aromatic peaks towards downfield.
Elemental analysis of the ligands, L-2O,1C and L-5O,1C, matched with that of
the calculated values (within 0.5%); however, the carbon values for L-3O,2C and L4O,2C, were 1% less than the calculated values. When considering the possibility of
having hydration due to the many oxygen atoms in their structures, the EA results
matched the calculated values for a hydrated form of L-3O,2C and L-4O,2C with 0.5
mol of H2O. Further purification of L-4O,2C or re-synthesis did not improve the carbon
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result. The carbon for L-4O,4C was also less than the calculated value; however, the EA
result matched the calculated value for a monohydrated form of L-4O,4C. Elemental
analysis of all the platinum complexes matched well with the calculated values (within
0.5%).
The melting point of the ligands decreased as the oxygen number increased. The
DSC thermogram of L-2O,1C (contains two oxygens in each substituent) showed an
endothermic transition at 99–100 °C, which is an indication of a melting transition. This
melting transition was observed in the L-3O,2C (three oxygens in each substituent) DSC
thermogram at 43–45 °C. L-4O,2C, L-4O,4C, and L-5O,1C were all liquid compounds
and thus DSC analysis was not performed. Coordination to platinum caused an increase
in the melting temperature and, similar to the ligands, the melting points of the platinum
complexes decreased as the oxygen number increased. Pt(II)-2O,1C has the highest
melting temperature with a sharp endothermic transition at 206–207 °C. Pt(II)-5O,1C,
with the most oxygen in its structure, has a broad melting point at 48–58 °C. Pt(II)4O,2C and Pt(II)-4O,4C have the same number of oxygen atoms, but Pt(II)-4O,4C has
two more carbons on each end of the substituents than Pt(II)-4O,2C, which resulted in a
higher melting temperature.
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Figure 4 – 3. DSC thermograms of the [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′bipyridine)] complexes. The thermograms were obtained in the first heating cycles in
nitrogen at heating and cooling rates of 10 °C/min.
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The structure of Pt(II)-2O,1C is similar to Pt(II)-4C, except one of the carbons
in each chain of the alkoxy substituent is replaced by an oxygen. Although the solubility
of Pt(II)-2O,1C in common organic solvents is slightly improved, it was still poorly
soluble in water. Pt(II)-3O,2C, which has an additional oxygen on each substituent by
the addition of another oxyethylene linkage, is also poorly soluble in water. Pt(II)-4O,4C
is also poorly soluble, but Pt(II)-4O,2C and Pt(II)-5O,1C both have some solubility in
water (a 5 mM solution can be made).
4.4.2 Biological properties
4.4.2.1 In vitro cytotoxic activity
Three of the most commonly diagnosed cancers are breast, lung and prostate;
thus, the anti-proliferative activities of the synthesized complexes were examined in
human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1), lung
(A549 and H520), and prostate (DU145 and PC-3) cancer cell lines using the MTS cell
proliferation assay. The graphs of the results for a representative cell line from each type
of cancer treated for 1 or 48 h with cisplatin, carboplatin, or the synthesized platinum
complexes are shown in Figure 4-4 (DU145 cells), Figure 4-5 (MCF-7 cells), and Figure
4-6 (A549 cells). As shown in Figure 4-4, the viability of DU145 cells treated with the
highest concentration of cisplatin (1 mM) was reduced by about 60%, while carboplatin
had negligible effects. Pt(II)-2O,1C and Pt(II)-3O,2C were only tested up to a
concentration of 100 µM due to limited solubility and had about the same effect as
cisplatin at the concentrations tested. However, they were more effective than
carboplatin. It is interesting to note that, with only a change of one carbon to an oxygen,
the anti-proliferative activity of Pt(II)-2O,1C (EC50 for the 1 h treatment is 80 ± 20 ) is
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greatly reduced compared to Pt(II)-4C (EC50 for the 1 h treatment is 12 ± 8, Chapters 2
and 3). While Pt(II)-4O,2C and Pt(II)-5O,1C have water solubility, Pt(II)-4O,2C had
similar activity to cisplatin and Pt(II)-5O,1C was not as active. However, it is worth
noting that Pt(II)-4O,2C is more effective than carboplatin. Pt(II)-4O,4C was the most
effective; however, poor water solubility remains an issue. Similar results were observed
for the 48 h treatment. All of the complexes were more effective than carboplatin, except
Pt(II)-5O,1C, which had similar activity. Cisplatin was slightly more effective than
Pt(II)-2O,1C, Pt(II)-3O,2C, and Pt(II)-4O,2C.
Similar results were obtained for A549 and MCF-7. It should be noted that,
compared to DU145 cells, these cell lines are more resistant to cisplatin and all the other
platinum complexes. The EC50 values obtained from the MTS data for all the tested cell
lines are given in Tables 4-1 to 4-4. Comparison of the EC50 values indicates varying
degrees of activity across the different cell lines. A549 and MCF-7 are the most resistant
to treatment and SK-BR-3, ZR-75-1, and T-47D are generally more sensitive to the
synthesized platinum complexes than to cisplatin for the 1 h treatment.
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Figure 4 – 4. DU145 cell viability from MTS cell proliferation assays post (A) 1 h or (B)
48 h treatment.
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Figure 4 – 5. MCF-7 cell viability from MTS cell proliferation assays post (A) 1 h or (B)
48 h treatment.
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Figure 4 – 6. A549 cell viability from MTS cell proliferation assays post (A) 1 h or (B)
48 h treatment.
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Table 4 – 1. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes in
A549 and H520 post 1 or 48 h treatment
Lung cancer
A549

H520

1h

48 h

1h

48 h

CDDP

900 ± 200

500 ± 100

200 ± 17

24 ± 2

Carboplatin

>1000

300 ± 30

ND

ND

Pt(II)-2O,1C

>100

>100

>100

36 ± 3a

Pt(II)-3O,2C

>100

>100

>100

60 ± 10

Pt(II)-4O,2C

>1000

330 ± 5

150 ± 100

197 ± 0a

Pt(II)-4O,4C

17 ± 4a

17 ± 3a,b

13.1 ± 0.9 a

12.1 ±0.5

Pt(II)-5O,1C

>1000

>1000

>1000

400 ± 100

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.

Table 4 – 2. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes
in DU145 and PC-3 post 1 or 48 h treatment
Prostate cancer
DU145

PC-3

1h

48 h

1h

48 h

CDDP

400 ± 100

64 ± 8

200 ± 20

30 ± 1

Carboplatin

>1000

400 ± 100a

ND

ND

Pt(II)-2O,1C

80 ± 20

60 ± 20b

90 ± 20a

70 ± 10a

Pt(II)-3O,2C

>100

100 ± 6a,b

>100

80 ± 8

Pt(II)-4O,2C

300 ± 60

250 ± 40a,b

300 ± 30a

310 ± 6a

Pt(II)-4O,4C

13 ± 2a

14.3 ± 0.2a,b

13 ± 1a

12 ± 1a

Pt(II)-5O,1C

>1000

800 ± 100

>1000

400 ± 70a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.
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Table 4 – 3. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes in
various breast cancer cells post 1 h treatment
HCC38

MCF-7

MDA-MB-231

SK-BR-3

T-47D

ZR-75-1

CDDP

300 ± 30

900 ± 100

50 ± 4

420 ± 80

900 ± 100

260 ± 10

Carboplatin

ND

>1000

ND

ND

ND

ND

Pt(II)-2O,1C

80 ± 6

Pt(II)-3O,2C

>100

a

a

>100

>100

40 ± 10

>100

>100

50 ± 20a
a

240 ± 20

24 ± 6

a

70 ± 20a

40 ± 9a
a

190 ± 20

>100
a

345 ± 6a

Pt(II)-4O,2C

240 ± 30

>1000

210 ± 20

Pt(II)-4O,4C

13 ± 1a

30 ± 2a

14.4 ± 0.4a

8 ± 6a

12.1 ±0.3a

19 ± 1a

Pt(II)-5O,1C

>1000

>1000

>1000

800 ± 200

1000 ± 30

>1000

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.

Table 4 – 4. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes in
various breast cancer cells post 48 h treatment
HCC38

MCF-7

MDAMB-231

SK-BR-3

T-47D

ZR-75-1

CDDP

30 ± 8

34 ± 1

21 ± 3

23 ± 6

35 ± 6

30 ± 8

Carboplatin

ND

800 ± 100a

ND

ND

ND

ND

Pt(II)-2O,1C

70 ± 10a

>100

65 ± 3a

25 ± 5

25 ± 2

50 ± 20

Pt(II)-3O,2C

80 ± 20a

>100

>100

60 ± 10a

50 ± 8

90 ± 6a

Pt(II)-4O,2C

20 ± 6

500 ±100a,b

170 ± 7a

230 ± 70a

170 ± 10a

260 ± 50a

Pt(II)-4O,4C

12.5 ±0.4a

18 ± 4a,b

14.5 ±0.1a

8 ± 6a

12.2 ± 0.4a

18.2 ± 0.6

Pt(II)-5O,1C

100 ± 100

900 ± 100a

500 ± 90a

340 ± 20a

400 ± 50a

400 ± 100a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.
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Figure 4 – 7. Pt(II)-4O,2C induced phosphorylation of H2AX in A549 and DU145 cells.
(A) A549 cells were treated for 6 h with 1000 µM Pt(II)-4O,2C and analyzed 12 h post
treatment, (B) DU145 cells were treated for 2 h with 250 µM Pt(II)-4O,2C and analyzed
7 h post treatment. Data are representative of three independent experiments.

4.4.2.2 Detection of DNA damage
The MTS results indicate that these dioligooxyethylene bipyridyl Pt(II)
complexes have anti-proliferative effects in various cancer cells; thus, it is necessary to
determine the type of cell death. Cisplatin treatment is often associated with apoptosis, a
type of programmed cell death in which the cells go through various signaling cascades
resulting in characteristic features such as externalization of phosphatidylserine to the
membrane surface, activation of apoptotic proteins, membrane damage, cell shrinkage,
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and chromatin condensation and fragmentation. These types of events can be measured
by flow cytometry and fluorescence microscopy.
The cytotoxic effects of cisplatin result from the formation of DNA adducts,
which stimulate multiple events such as cell cycle arrest, DNA damage repair, various
stress response pathways, and death pathways. DNA damage by cisplatin induces
phosphorylation of histone H2AX, which recognizes the damage and recruits proteins to
repair the damage or to regulate the apoptotic pathway. Flow cytometry was used to
analyze levels of phosphorylated H2AX (γH2AX) in A549 and DU145 cells treated with
Pt(II)-4O,2C. Although the Pt(II)-4O,4C complex was the most effective, it was not
selected for further analysis due to its low solubility when diluted in medium; thus,
Pt(II)-4C,2C was selected due to its water solubility and comparable activity to cisplatin
in some of the cell lines tested. As shown in Figure 4-7, treatment with Pt(II)-4O,2C
resulted in an increase of phopho-H2AX in both A549 and DU145 cells. This indicates
that Pt(II)-4O,2C may cause DNA damage in A549 and DU145 cells.
4.4.2.3 Evaluation of apoptosis
The increased level of γH2AX induced by Pt(II)-4O,2C is an indication of DNA
damage; thus, the effects on the cell cycle was analyzed by measurement of PI
fluorescence using flow cytometry. PI is a membrane impermeable molecule that can
bind to DNA of cells with membrane damage, an event that occurs during late stage
apoptosis or necrosis. Measurement of the PI fluorescence by the flow cytometer will
give an indication of the DNA content in the cells. Different stages of the cell cycle are
correlated with the amount of DNA in the cell and the PI fluorescence intensity is
proportional to DNA content. A sub-G1 peak occurs when the cells have less DNA than
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cells in the G1 phase, which has been attributed to cells undergoing apoptosis.
As shown in Figure 4-8, the flow histogram of the DNA contents in the different
phases of the cell cycle did not show any significant changes in the cell cycle of both
A549 and DU145 cells after treatment with Pt(II)-4O,2C, except for a small increase in
the sub-G1 peak. This indicates that Pt(II)-4O,2C does not cause cell cycle arrest and
may induce apoptosis in A549 and DU145 cells.

Figure 4 – 8. Cell cycle analysis of A549 and DU145 cells treated with Pt(II)-4O,2C.
(A) A549 cells were treated for 6 h with 1000 µM of Pt(II)-4O,2C and analyzed 12 h
post treatment, (B) DU145 cells were treated with 250 µM of Pt(II)-4O,2C for 1 h and
analyzed 12 h post treatment. Data are representative of three independent experiments.
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Figure 4 – 9. A549 and DU145 flow cytometry analysis of Annexin V/PI staining.
(A) A549 cells were treated for 5 h with 1000 µM of Pt(II)-4O,2C and analyzed 12 h
post treatment, (B) DU145 cells were analyzed after treatment with 250 µM of Pt(II)4O,2C for 1 h. Q1 = PI+, represents necrotic cells; Q2 = Annexin V/PI+, representing
late apoptotic/necrotic cells; Q3 = Annexin V+, representing early apoptotic cells; Q4 =
AnnexinV/PI-, representing live cells. Data are representative of three independent
experiments.

To confirm that Pt(II)-4O,2C induces apoptosis, flow cytometry was used to
detect for signs of early apoptosis by analysis of Annexin V, which binds to exposed
phosphatidylserine (occurs in early apoptosis). The flow scatter plot of A549 cells treated
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with Pt(II)-4O,2C showed an increase in early apoptotic cells (Q3) and late
apoptotic/necrotic cells (Q2), and a corresponding decrease in live cells (Q4) (Figure 4-9
A). Similar results were observed for DU145 cells, except, the plot of DU145 cells
showed a 17% increase in necrotic cells (Q1) (Figure 4-9 A). These results indicate that
Pt(II)-4O,2C induced DNA damage leads to apoptosis.

Figure 4 – 10. Microscopy analysis of PI and Ho uptake. (A) A549 were treated for 5 h
with 1000 µM Pt(II)-4O,2C and (B) DU145 treated for 3.5 h with 250 µM Pt(II)-4O,2C
were stained with Ho and PI and images were capture with a confocal microscope.
Images are from one trial.
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To further analyze for cell death, A549 and DU145 cells treated with Pt(II)4O,2C were stained with Hoechst (Ho) and PI. Ho is membrane permeable and can stain
both live cells and cells undergoing apoptosis; cells with intense bright fluorescence
indicate apoptotic cells. PI, as mentioned earlier, is membrane impermeable and only
stains cells with membrane damage. As shown in Figure 4-10, an increase of both Ho and
PI positive cells were detected in A549 and DU145 cells treated with Pt(II)-4O,2C. Ho
positive indicates cells undergoing apoptosis, while, PI positive indicates that the cells
have membrane damage so they are either at late stage apoptosis or necrosis.

Figure 4 – 11. Pt(II)-4O,2C induced cleavage of PARP. (A) A549 were treated for 6 h
with 1000 µM Pt(II)-4O,2C and analyzed 12 h treatment and (B) DU145 treated with
250 µM Pt(II)-4O,2C for 2 h analyzed 7 h post treatment. Data are representative of
three independent experiments.
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The last method used for analysis of apoptosis is measurement of cleaved-PARP
by flow cytometry. PARP is a nuclear poly (ADP-ribose) polymerase that has been
associated with DNA repair. During apoptosis, PARP is cleaved by caspase-3; thus,
cleaved-PARP is an indication of apoptosis.16 As shown in Figure 4-11, both A549 and
DU145 cells treated with Pt(II)-4O,2C had increased levels of cleaved-PARP,
suggesting that Pt(II)-4O,2C induced apoptosis in these two cell lines.
4.5 Conclusions
A series of Pt(II) complexes containing 4,4′-dioligooxyethylene-2,2′-bipyridyl
ligands have been prepared and two of the complexes have some water solubility. Their
anti-proliferative activities were investigated in a panel of human lung, breast, and
prostate cancer cell lines. The results showed varying degrees of activity in the cell lines
tested. In some cell lines, the synthesized complexes were as effective as cisplatin or less
effective, while in others, the synthesized complexes were more potent than cisplatin.
The breast cancer cell lines, SK-BR-3, T-47D, and ZR-75-1 were the most sensitive to
the new platinum complexes, whereas, A549 and MCF-7 were most resistant, even to
cisplatin. Results from confocal microscopy and flow cytometry, revealed that Pt(II)4O,2C causes DNA damage in A549 and DU145 cancer cells and induced apoptosis.
It should be noted that there was no observable difference in the activity of
Pt(II)-4O,2C, which is water soluble, whether the stock solution used was dissolved in
DMSO or in 0.15 M NaCl. However, the activity of cisplatin was attenuated when the
tested stock solution was made in DMSO instead of NaCl due to inactivation of cisplatin
through displacement of the chloride leaving groups by DMSO (data not shown). This
indicates that Pt(II)-4O,2C is more stable than cisplatin. Even though Pt(II)-4O,2C is
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only as effective or less effective than cisplatin in some of the cell lines tested, it is still
more effective than carboplatin in some cases; thus, it could still be potentially useful for
clinical applications due to its increased solubility and stability which might result in less
side effects.
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CHAPTER 5
SYNTHESIS AND CHARACTERIZATION OF PT(IV) COMPLEXES CONTAINING
4,4′-DIALKOXY-2,2′-BIPYRIDINE LIGANDS FOR CANCER TREATMENT

5.1 Abstract
Seven [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes have been
synthesized and characterized by 1H NMR,

13

C NMR spectroscopy, elemental analysis,

and differential scanning calorimetry (DSC) measurements. The in vitro anti-proliferative
activities of these Pt(IV) complexes were examined in a panel of human breast, prostate,
and lung cancer cell lines. Comparison of the EC50 values showed varying degrees of
activities in the 10 cell lines tested; however, the Pt(IV) complexes are generally more
effective than cisplatin. A structure activity relationship was observed in which
complexes with increasing carbon number on the alkoxy substituents had increasing antiproliferative activity. These Pt(IV) complexes exhibited improved solubility in organic
solvents compared to the Pt(II) precursors.
Analysis of the cell death pathways by confocal microscopy and various staining
with flow cytometry showed an increase of phosphorylated H2AX in A549 and DU145
cells treated with Pt(IV)-4C and Pt(IV)-5C. This indicates that these complexes cause
DNA damage leading to activation of apoptosis, although some necrosis might be
involved.
5.2 Introduction
In 2012, there were 8.2 million cancer-related deaths and 14.1 million new cancer
cases worldwide.1 Furthermore, these values are projected to continue increasing to an
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estimated 22.2 million new cases and 13.2 million cancer-related deaths by 2030.2
Although new treatment techniques such as targeted therapy and immunotherapy are
being explored,3,4 the use of chemotherapeutic drugs has remained a mainstream.
In the 1960s, the accidental discovery of the anticancer activity of cisplatin
(CDDP), a platinum(II) [Pt(II)] complex, opened up a new area of research on metalbased drug discovery.5 Although numerous platinum complexes have been synthesized,
only a few have been approved for clinical use. Along with cisplatin, two other Pt(II)
complexes, carboplatin and oxaliplatin, are approved for use worldwide.6 Additionally,
five other Pt(II) complexes are used in China (lobaplatin and dicycloplatin), Japan
(nedaplatin and miriplatin), and Korea (heptaplatin).7–10 Currently, about 50% of cancer
chemotherapeutic regimens consist of platinum-based drugs.10,11 However, clinical
application of these platinum drugs is hindered due to toxic side effects and intrinsic or
acquired resistance.12 Consequently, new strategies to improved platinum compounds are
continually being introduced in hope of discovering compounds with greater efficacy and
reduced toxicity.
While many researchers remain focused on improving Pt(II) complexes, some are
expanding into the development of Pt(IV) complexes to act as prodrugs, which are
activated by intracellular enzymatic reduction to Pt(II). The general structure of Pt(IV)
complexes offers some advantages over their Pt(II) counterparts such as being more inert
to substitution reactions owing to their low-spin d6 electronic configuration and
octahedral geometry; reduction of side effects and the potential for oral administration;
and greater flexibility in strategies that improve solubility and target selectivity through
modification of the additional axial ligands.12–14 Additionally, Pt(IV) complexes could be
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used to selectively target tumor cells since tumors are known to be hypoxic, which leads
to a more reductive intracellular environment that favors the reduction of Pt(IV) to
Pt(II).12,15
Along with cisplatin, several Pt(IV) complexes (cis-[Pt(NH3)2Cl4], trans[Pt(NH3)2Cl4] and [Pt(en)Cl4]) were described by Rosenberg et al.; however they were
less effective than cisplatin.14 Since then, iproplatin, tetraplatin, and satraplatin (Figure 51) are several other Pt(IV) complexes which have entered clinical trials.10,13,14,16,17
Satraplatin, which can be administered orally, is the most successful example of Pt(IV)
complexes, but failed Phase III clinical trials. However, it is still undergoing clinical trials
in combination with other chemotherapeutic agents.10

Figure 5 – 1. Structures of some platinum(IV) complexes that have entered clinical trials.

We have previously reported on the synthesis of a series of Pt(II) complexes
containing 4,4′-dialkoxy-2,2′-bipyridine ligands (with the dialkoxy having one to six
carbons) and their anti-proliferative activities against the A549 lung cancer cell line
(Chapter 2).18 The improved anti-proliferative activity of these complexes compared to
cisplatin warrant further investigation of these compounds. However, these complexes
have poor solubility in water and only moderate solubility in common organic solvents
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and solubilizing agents. To increase solubility, the structures of these 4,4′-dialkoxy-2,2′bipyridy Pt(II) complexes were modified by introducing increasing oxygen atoms into the
dialkoxyl substituents. Although increased solubility was observed, the anti-proliferative
activities of these complexes were decreased (by comparison of the EC50 values in
Chapters 3 and 4). Thus, an alternative strategy to improve these [Pt(II)Cl2(4,4′-dialkoxy2,2′-bipyridine)] complexes was to convert them to Pt(IV) complexes owing to the
attractive advantages of Pt(IV) complexes.
Herein, we describe the synthesis and characterization by 1H NMR,

13

C NMR

spectroscopy, elemental analysis, and differential scanning calorimetry (DSC)
measurements of a series of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes.
Additionally, the anti-proliferative activities of these complexes in a panel of human
lung, prostate, and breast cancers will be discussed.
5.3 Experimental
5.3.1 General
All starting materials and reagents for the synthetic procedures were purchased
from commercial vendors (Sigma-Aldrich, TCI, Alfa-Aesar, or Acros) unless otherwise
noted. They were of high purity and were used without further purification unless noted
in the procedure. [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes were synthesized
as described in Chapter 2.18 Minimum essential medium (MEM), fetal bovine serum
(FBS), phosphate buffered saline (PBS), trypsin-EDTA, and penicillin-streptomycin were
purchased from Life Technologies (Carlsbad, CA). The RPMI 1640 medium was
purchased from ATCC (Manassas, VA). CDDP, carboplatin, HEPES, albumin from
bovine serum (BSA), propidium iodide, Hoechst 33342, methanol, and dimethyl
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sulfoxide (DMSO) were purchased from Sigma-Aldrich. All reagents and enzymes used
for flow cytometry were of analytical grade qualities and were purchased from SigmaAldrich, unless otherwise noted.
5.3.2 Chemical characterization instrumentation
All of the NMR spectra were obtained utilizing a Varian spectrometer at 298 K or
the indicated temperature using deuterated DMSO (DMSO-d6) or chloroform (CDCl3) as
the solvents: 1H NMR, 400 MHz; and

13

C NMR, 100 MHz. Either residual solvent or

tetramethylsilane (TMS) were used as the internal chemical shift reference. Thermal
transitions were determined by using a TA Instruments DSC 2010 differential scanning
calorimeter in nitrogen at heating and cooling rates of 10 °C min-1. The temperature axis
of the DSC thermogram was calibrated with reference standards of high purity indium
and tin before use. An amount of 2–3 mg of the compounds was used for measurements.
The Tonset and Tmax temperatures of a melting endotherm of a compound were recorded
from the DSC thermogram as Mp (Tonset–Tmax). Elemental analysis was determined by
NuMega Resonance Labs Inc. (San Diego, CA) by using a Perkin Elmer PE2400-Series
II with a CHNS/O analyzer.
5.3.3 Preparation of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes
The Pt(IV) complexes were prepared from the corresponding Pt(II) complexes
using a previously published procedure with slight modifications of the reaction
condition.19 [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] (1 equiv.) was suspended in 40 mL
of glacial acetic acid (>99%) and H2O2 (30%, 33 equiv.) was added. The bright yellow
suspension was protected from light and stirred at 298 K for 24 h to obtain a light yellow
solution. The solvent was removed completely and 30 mL of acetic anhydride was added
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to the pale yellow residue. A pale yellow suspension was obtained after stirring for 1–2 d
at 298 K. The solvent was removed and ice-cold H2O was added. The crude product (pale
yellow solid) was collected by vacuum filtration. Unless otherwise noted, the product
was purified by extraction with CHCl3, dried over Na2SO4, removal of the solvent with a
rotary evaporator, and then dried in vacuo at 80 °C.
[Pt(IV)Cl2(OAc)2(4,4′-dimethoxy-2,2′-bipyridine)] (Pt(IV)-1C). Yield: 87%,
pale yellow powder (obtained by washing the crude product with water without further
purification). Mp 249 C (decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm)
= 9.30 (d, 1H, J = 6.9 Hz), 8.37 (s, 1H), 7.58 (d, 1H, J = 7.0 Hz), 4.14 (s, 3H), 1.60 (s,
3H). 13C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 174.66, 170.03, 158.03, 149.74,
113.24, 111.20, 58.12, 22.38. Anal. Calcd for C16H18Cl2N2O6Pt (600.31 g mol-1): C,
32.01; H, 3.02; N, 4.67%; found: C, 32.07; H, 3.11; N, 4.61%.
[Pt(IV)Cl2(OAc)2(4,4′-diethoxy-2,2′-bipyridine)] (Pt(IV)-2C). Yield: 90%, pale
yellow powder. Mp 260 C (decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6): δ
(ppm) = 9.27 (d, J = 6.9 Hz, 1H), 8.35 (d, J = 2.9 Hz, 1H), 7.54 (dd, J = 7.0, 2.8 Hz, 1H),
4.43 (q, J = 6.8 Hz, 2H), 1.59 (s, 3H), 1.44 (t, J = 6.5 Hz, 3H).

13

C NMR (298 K, 100

MHz, DMSO-d6): δ (ppm) = 173.79, 168.41, 157.23, 148.83, 112.59, 110.47, 65.85,
21.54, 13.69. Anal. Calcd for C18H22Cl2N2O6Pt (628.37 g mol-1): C, 34.41; H, 3.53; N,
4.46%; found: C, 34.58; H, 3.89; N, 4.59%.
[Pt(IV)Cl2(OAc)2(4,4′-dipropoxy-2,2′-bipyridine)] (Pt(IV)-3C). Yield: 64%,
pale yellow powder. Mp 243 C (decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6):
δ (ppm) = 9.27 (d, J = 7.0 Hz, 1H), 8.37 (d, J = 2.9 Hz, 1H), 7.55 (dd, J = 7.1, 2.9 Hz,
1H), 4.34 (t, J = 6.5 Hz, 2H), 1.90–1.81 (m, 2H), 1.60 (s, 3H), 1.05 (t, J = 7.4 Hz, 3H).
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13

C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 174.66, 169.42, 158.09, 149.69,

113.44, 111.38, 72.12, 22.39, 22.04, 10.62. Anal. Calcd for C20H26Cl2N2O6Pt (656.42 g
mol-1): C, 36.59; H, 3.99; N, 4.27%; found: C, 36.47; H, 4.08; N, 4.60%.
[Pt(IV)Cl2(OAc)2(4,4′-dibutoxy-2,2′-bipyridine)] (Pt(IV)-4C). Yield: 67%,
pale yellow powder (further purified by recrystallization in CHCl3-hexane). Mp 219 C
(decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 9.25 (d, J = 7.0 Hz,
1H), 8.34 (d, J = 3.0 Hz, 1H), 7.54 (dd, J = 7.2, 2.8 Hz, 1H), 4.36 (t, J = 6.4 Hz, 2H),
1.83–1.76 (m, 2H), 1.58 (s, 3H), 1.53–1.44 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H).

13

C NMR

(298 K, 100 MHz, DMSO-d6): δ (ppm) = 174.67, 169.43, 158.09, 149.69, 113.46,
111.40, 70.45, 30.64, 22.41, 18.99, 14.06. Anal. Calcd for C22H30Cl2N2O6Pt (684.47 g
mol-1): C, 38.60; H, 4.42; N, 4.09%; found: C, 38.48; H, 4.75; N, 4.10%.
[Pt(IV)Cl2(OAc)2(4,4′-dipentoxy-2,2′-bipyridine)] (Pt(IV)-5C). Yield: 92%,
pale yellow powder. Mp 222 C (decomposed). 1H NMR (298 K, 400 MHz, CDCl3): δ
(ppm) = 9.57 (d, J = 6.9 Hz, 1H), 7.46 (d, J = 2.8 Hz, 1H), 7.16 (dd, J = 7.0, 2.7 Hz, 1H),
4.20 (t, J = 6.4 Hz, 2H), 1.91–1.84 (m, 2H), 1.82 (s, 3H), 1.54–1.34 (m, 4H), 0.96 (t, J =
7.1 Hz, 3H).

13

C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 177.23, 169.18, 158.72,

150.21, 111.62, 110.01, 70.49, 28.46, 28.03, 22.90, 22.43, 14.05. Anal. Calcd for
C24H34Cl2N2O6Pt (712.53 g mol-1): C, 40.46; H, 4.81; N, 3.93%; found: C, 40.46; H,
5.12; N, 4.05%.
[Pt(IV)Cl2(OAc)2(4,4′-dihexyloxy-2,2′-bipyridine)] (Pt(IV)-6C). Yield: 74%,
pale yellow powder (further purified by recrystallization in acetone-hexane). Mp 219 C
(decomposed). 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 9.58 (d, J = 6.9 Hz, 1H),
7.45 (d, J = 2.9 Hz, 1H), 7.15 (dd, J = 7.1, 2.9 Hz, 1H), 4.21 (t, J = 6.4 Hz, 2H), 1.92–
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1.85 (m, 2H), 1.83 (s, 3H), 1.56–1.43 (m, 2H), 1.42–1.32 (m, 4H), 0.93 (t, J = 6.7 Hz,
3H).

13

C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 177.12, 169.04, 158.54, 150.09,

111.44, 109.88, 77.32, 77.00, 76.69, 70.35, 31.33, 28.59, 25.46, 22.75, 22.50, 13.96.
Anal. Calcd for C26H38Cl2N2O6Pt (740.58 g mol-1): C, 42.17; H, 5.17; N, 3.78%; found:
C, 42.08; H, 5.44; N, 3.80%.
[Pt(IV)Cl2(OAc)2(4,4′-dioctyloxy-2,2′-bipyridine)] (Pt(IV)-8C). Yield: 85%,
pale yellow powder (further purified by recrystallization in acetone-hexane). Mp 203 C
(decomposed). 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) 9.57 (d, J = 6.9 Hz, 1H),
7.46 (d, J = 2.7 Hz, 1H), 7.15 (dd, J = 7.0, 2.7 Hz, 1H), 4.20 (t, J = 6.4 Hz, 2H), 1.93–
1.84 (m, 2H), 1.82 (s, 3H), 1.54–1.43 (m, 2H), 1.43–1.25 (m, 8H), 0.90 (t, J= 6.6 Hz,
3H).

13

C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 177.07, 169.04, 158.58, 150.07,

111.47, 109.86, 70.36, 31.73, 29.15, 29.11, 28.63, 25.78, 22.75, 22.61, 14.07. Anal.
Calcd for C30H46Cl2N2O6Pt (796.69 g mol-1): C, 45.23; H, 5.82; N, 3.52%; found: C,
45.07; H, 6.10; N, 3.55%.
5.3.4 Cell culture
Human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1),
lung (A549 and H520), and prostate (DU145 and PC-3) cancer cell lines were obtained
from American Culture Type Collection (ATCC). The HCC38, MCF-7, MDA-MB-231,
SK-BR-3, T-47D, ZR-75-1, and A549 cells were grown in MEM supplemented with 10%
FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL-1) and streptomycin (100 µg
mL-1). The H520, DU145, and PC-3 cell lines were grown in RPMI-1640 supplemented
with 10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL-1) and streptomycin
(100 µg mL-1). All cell lines were maintained at 37 °C in a humidified, 5% CO2
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atmosphere.
5.3.5 Cell viability assay
Cells were cultured at a density of 2–3.5 x 103 cells per well in flat bottomed 96well plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50%
confluence. The cells were then treated with solvent or the appropriate drugs (CDDP
stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 5% glucose,
synthesized Pt(IV) complexes were dissolved in DMSO) for 1 h, washed three times with
100 µL PBS, and incubated in 100 µL of fresh medium. After 2 d, the medium was
replaced with 120 µL of medium containing CellTiter 96® Aqueous One Solution Reagent
(MTS reagent) (Promega, Madison, WI). The cells were incubated at 37 °C for 4 h and
the cell viability was determined by measuring the absorbance at 490 nm using a Tecan
Infinite M1000 microplate reader. The 48 h treatment was done in a similar method,
except the cells were not washed after treatment and the MTS reagent was immediately
added. Viability of treated groups was calculated as a percent of control and graphed with
GraphPad Prism.
5.3.6 Flow cytometry
5.3.6.1 Propidium iodide (PI) staining
Cells (~50–60% confluent in 60 mm dishes) were treated as indicated with the
platinum compound. After the treatment duration, the floating cells were collected, and
both attached and floating cells were washed 2X with PBS. The cells were resuspended
in fresh medium and incubated as indicated. The cells were harvested (both the floating
and attached cells were collected), counted, and pelleted. The cells were then washed two
times with 5 mL PBS, fixed by resuspending in 0.1 mL of PBS and 1 mL of ice-cold 95%
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ethanol with gentle vortexing. Fixed cells were stored at 4 °C until analysis. For analysis,
fixed cells were washed once with 1–2 mL of PBS and centrifuged at 500 × g for 5
minutes. The cell pellet was resuspended in 100 µL of a 1.0% Triton X-100 buffer
solution, and 100 µL of a 1.0 mg mL-1 RNAse solution was added and allowed to stand at
room temperature for 10–15 min. While in the dark, 200 µL of a 100 µg mL-1 PI stain
was added to make a final concentration of 50 µg mL-1 and gently vortexed. The cell
mixture was incubated at room temperature for 30 min and flow cytometry acquisition
was done on a Becton Dickinson FACS Calibur with the argon laser set at 488 nm on the
linear Flow Channel 2 (FL-2) with Doublet Discriminatory Module (DDM) and threshold
set on FL-2.
5.3.6.2 Annexin V-FITC/PI staining
Cells (~50–60% confluent in 60 mm dishes) were treated as indicated with the
platinum compound. After the treatment duration, the floating cells were collected, and
both attached and floating cells were washed 2X with PBS. The cells were resuspended
in fresh medium and incubated as indicated. The cells were harvested (both the floating
and attached cells were collected), counted, and pelleted. The cells were then washed two
times with 5 mL of Ca2+ and Mg2+ free PBS. The pellets were then washed in 2.0 mL of
1X Annexin-V Binding buffer (BD Bioscience, San Jose, CA) and centrifuged at 500 × g
for 5 min. The pellets were treated with Annexin-V-FITC conjugate (BD Bioscience, San
Jose, CA) and incubated in the dark for 15 min. Just before acquisition, the volume of
cells-conjugate mixture was adjusted by addition of 1X Annexin-V binding buffer.
Acquisition to discriminate between apoptotic and necrotic cells was done by staining the
cell-conjugate mixture with 10 µL of PI (50 µg mL-1) solution (BD Bioscience, San Jose,
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CA). Acquisitions were done on a FACS Calibur Cytometer on the FL1 (Annexin) and
FL3 (PI) channels with threshold and Duplet Discriminating Module (DDM) set at FL1.
The level of shift in events distribution in the Annexin-V only and Annexin-V-PI
populations in comparison to control is indicative of degree of effectiveness of the
treatment agents. A quantitative measure of these event shifts was accomplished by
gating.
5.3.6.3 Flow cytometric immunofluorescence
Cells (200,000–250,000) were seeded in 60 mm dishes and incubated at 37 °C in
a humidified, 5% CO2 atmosphere for 2 d to reach ~50–60% confluence. The cells were
treated with the platinum complexes as indicated, the floating cells were collected, and
both attached and floating cells were washed 2X with PBS. The cells were resuspended
in fresh medium and incubated as indicated. After incubation, both the floating and
attached cells were collected and fixed by incubation in 4% formaldehyde for 10 min at
room temperature. The fixed cells were pelleted and permeabilized by incubation in 500
µL of ice-cold methanol at 4 °C for 10 min. The samples were stored at -20 °C until
analysis. For analysis, the cells were pelleted and washed 2X with 1% BSA in PBS. The
cells were resuspended in BD Stain Buffer (BS Biosciences #554656) containing the
appropriate conjugated primary antibody [PE Mouse Anti-Cleaved PARP (Asp214) and
Alexa Fluor 647 Mouse Anti-H2AX (pS139) antibodies were purchased as a part of a
Cell Proliferation Kit (BD Biosciences #562253)], and incubated at 4 °C overnight. After
washing 2X with 1% BSA, the cells were resuspended in PBS and analyzed on a Becton
Dickinson FACS Calibur.
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5.3.7 Confocal microscopy
Cells (100,000–125,000) were seeded into 35 mm dishes and incubated for 48 h at
37 °C. The cells were treated as indicated, and while in the dark, the cells were washed
2X with 1 mL PBS. After washing, 1 mL of a 2 µg mL-1 Hoechst 33342 and 10 µg mL-1
PI solution (in PBS) was added and the cells were incubated for 15 min at room
temperature. Images were acquired within 5 min with a Nikon A1R confocal laser
scanning microscopy system (CLSM) mounted on a Nikon Eclipse Ti. At least three
random areas on each dish were imaged.
5.3.8 Statistical analysis
GraphPad Prism was used to graph viability curves. ModFit version 3.0 was used
for the flow cytometry analysis. Microsoft Office Excel was used to perform unpaired
Student’s t-test; values with p < 0.05 were considered significant. Student’s t-tests were
used to verify significant differences among the EC50 values.
5.4 Results and discussion
5.4.1 Synthesis and characterization
The activity of Pt(IV) complexes are believed to be due to activation by
intracellular enzymatic reduction to Pt(II); thus, the reduction potential of the Pt(IV)
compound is important. This is governed by the axial ligands; chlorido ligands are most
easily reduced, followed by acetato ligands, and hydroxido ligands are the most difficult
to reduce.12 With this guideline taken into consideration and in combination with the fact
that satraplatin, the most successful Pt(IV) to date, has acetato axial ligands, acetato axial
ligands were selected for modification of the [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)].
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[Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)]

complexes

were

synthesized

as

previously described (Chapter 2)18 and used as precursors for the synthesis of the Pt(IV)
complexes. Pt(IV) complexes of the formula [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′bipyridine)] (where R = –(CH2)n–1CH3, n = 2–6, 8) were synthesized with yields ranging
from 64–92% by following the procedure (Scheme 5-1) of Mackay et al.19 with slight
modification of the reaction condition. The Pt(II) precursors were first converted to
unsymmetrical Pt(IV) complexes containing a mixture of OH and OAc axial ligands by
an oxidation reaction with H2O2 in acetic acid. The progress of the reaction was visually
monitored by the disappearance of the insoluble bright yellow solid of the Pt(II)
compounds into a light yellow solution. After removal of the solvent, the
[Pt(IV)Cl2(OAc)(OH)(4,4′-bis(RO)-2,2′-bipyridine)] complexes were then reacted with
acetic anhydride to form the desired [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′-bipyridine)]
complexes. This step in the reaction was visually monitored by the appearance of a pale
yellow suspension. Seven complexes were successfully synthesized and their chemical
structures are shown in Figure 5-2; these Pt(IV) complexes have not been reported in the
literature.

Scheme 5 – 1. Synthetic route for the preparation of [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′bipyridine)] complexes.
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Figure 5 – 2. Chemical structures of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy2,2′-bipyridine)] complexes.

All of the compounds were characterized by 1H and

13

C NMR spectroscopy,

elemental analysis, and DSC measurements. Elemental analyses of the complexes were in
excellent agreement (within 0.5%) with the expected values; thus, validating the
molecular formulae of these compounds. To compare the NMR chemical shifts of the
Pt(IV) complexes to that of the Pt(II) complexes, the Pt(IV) samples were prepared in the
same deuterated solvent as the corresponding Pt(II) precursors. The 1H and

13

C NMR

spectra of Pt(IV)-1C–Pt(IV)-4C were recorded in DMSO-d6, whereas those of Pt(IV)5C–Pt(IV)-8C were recorded in CDCl3. The spectra of all of the complexes displayed the
expected proton and carbon resonances; the 1H NMR chemical shifts of the Pt(II) and
Pt(IV) complexes are depicted in Figure 5-3. The appearance of a singlet peak between
1.6–1.8 ppm in the 1H spectra (peak e) and two additional peaks in the 13C spectra
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Figure 5 – 3. 1H NMR spectra of Pt(II) and Pt(IV) complexes recorded in (A) DMSO-d6
or (B) CDCl3 at room temperature.
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indicate the presence of the diacetato ligands attached to the Pt center. While the
chemical shifts of the protons in the alkyl region remained relatively the same between
the Pt(II) and Pt(IV) complexes, the chemical shifts of the aromatic protons (peaks a–c)
and the methylene protons next to the oxygen attached to the bipyridine ring (peak d) are
slightly shifted. All of the aromatic proton peaks (Figure 5-3 A, peaks a–c) and the
methylene protons peak (Figure 5-3 A, peak d) of the Pt(IV) complexes in DMSO-d6 are
shifted downfield compared to Pt(II); however, the methylene proton signal (Figure 5-3
B, peak d) of the Pt(IV) complexes recorded in CDCl3 is slightly shifted upfield and only
the peaks corresponding to the protons at the 6,6′ (peak c) and 5,5′ (peak b) positions are
shifted downfield. Similar to the proton signals, carbon signals of the Pt(IV) complexes
are shifted to varying degrees compared to Pt(II) complexes (the chemical shifts of the
Pt(II) complexes are given in the experimental section of Chapter 2 and the shifts for the
Pt(IV) complexes are given in the experimental section of this chapter).
The thermal characteristics of the synthesized Pt(IV) compounds were studied by
using DSC analysis. As depicted in the DSC thermogram (Figure 5-4), the thermal
transitions of all the synthesized Pt(IV) complexes had a similar trend, but there are slight
variations. Although all of the complexes had an exothermic peak indicating
decomposition, the Tonset–Tmax ranges for the decomposition temperatures of Pt(IV)-1C–
Pt(IV)-4C were lower than the melting ranges of the Pt(II) counterparts and the ranges
for Pt(IV)-5C–Pt(IV)-8C were higher than the melting ranges of the Pt(II) (Table 5-1).
All of the Pt(IV) complexes also had an endotherm at varying temperatures after
decomposition. Additionally, the DSC thermogram of Pt(IV)-1C displayed an endotherm
about 10 °C before the Tonset of decomposition, and Pt(IV)-5C and Pt(IV)-8C each had
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an endotherm immediately before Tonset of decomposition. Pt(IV)-6C also had a broad
low energy endotherm between 150–160 °C. The endotherms occurring before the
decomposition temperature may be due to crystal-to-crystal transitions. Since the
compounds decompose, only one heating cycle was done instead of performing both
heating and cooling cycles.

Pt(IV)-1C
Pt(IV)-2C
Pt(IV)-3C
Pt(IV)-4C
Pt(IV)-5C

Heat Flow

Pt(IV)-6C

50

Pt(IV)-8C

100

150

200

250

300

350

Temperature (C)
Figure 5 – 4. DSC thermograms of [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′-bipyridine)]
complexes obtained in the first heating cycles in nitrogen at a heating rate of 10 °C/min.

Table 5 – 1. Tonset–Tmax (°C) of the Pt(II) melting temperatures vs. the Pt(IV) decomposition
temperatures
Complex

Pt-1C

Pt-2C

Pt-3C

Pt-4C

Pt-5C

Pt-6C

Pt-8C

Pt(II)

311–316

318–322

269–272

229–230

173–175

176–179

169–172

Pt(IV)

239–249

256–259

242–243

215–219

220–222

217–219

197–203
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Coordination of the axial ligands to the Pt center improved the solubility of the
complexes in common organic solvents. DMSO solutions of the Pt(IV) complexes with
concentrations of 10 mM or higher were obtainable, whereas, the Pt(II) can only be made
at the highest concentration of 5 mM. The solubility of Pt(IV)-8C was markedly
improved compared to Pt(II)-8C, which was not evaluated for anti-proliferative activities
due to poor solubility in DMSO and other common organic solvents that could be used
for in vitro testing.
5.4.2 Biological properties
5.4.2.1 In vitro cytotoxic activity
The anti-proliferative activities of all the Pt(IV) complexes were determined in
two lung (H520), two prostate (DU145 and PC-3), and six breast (HCC38, MCF-7,
MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1) cancer cell lines. The cells were treated
with increasing concentrations of cisplatin, carboplatin, or the Pt(IV) complexes for 1 or
48 h and the viability was measured using an MTS colorimetric cell proliferation assay.
The graphs of the results for DU145 (Figure 5-5), A549 (Figure 5-6), and MCF-7 (Figure
5-7) are shown to represent each type of cancer.
For the 1 h treatment in DU145 cells (Figure 5-5 A), cisplatin caused a
concentration dependent decrease in cell viability (a 60% reduction by the highest
concentration of 1 mM) and carboplatin had no effect even up to 1 mM. The two
complexes with short alkoxy substituents, Pt(IV)-1C (one carbon) and Pt(IV)-2C (two
carbons), also did not have any effects at the concentrations tested (up to 100 µM for
Pt(IV)-1C and 50 µM for Pt(IV)-2C). Complexes Pt(IV)-3C–Pt(IV)-8C all caused a
concentration dependent decrease in DU145 cell viability and were more effective than
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cisplatin. Pt(IV)-3C was the least effective among the five active compounds, followed
by Pt(IV)-4C, with Pt(IV)-5C–Pt(IV)-8C having similar activities. When the treatment
time was extended to 48 h (Figure 5-5 B), the activities of all the platinum compounds
were increased. However, all of the Pt(IV) complexes were still more effective than
cisplatin except for Pt(IV)-1C, which was more effective than carboplatin.
Similar trends were observed for A549 (Figure 5-6) and MCF-7 (Figure 5-7)
cells, except these cells were not as sensitive to treatment with the platinum complexes as
DU145 cells. Also, Pt(IV)-3C and Pt(IV)-4C did not have any effects on A549 and
MCF-7 cells at the concentrations tested for the 1 h treatment, and Pt(IV)-1C and
Pt(IV)-2C had no effects for the 48 h treatment. The dramatic increased activities of
Pt(IV)-3C and Pt(IV)-4C for the 48 h treatment compared to the 1 h treatment is an
indication that the anti-proliferative activities of the platinum complexes are not due to a
surfactant effect since interactions of the hydrophobic alkyl chain with the cell membrane
would result in a faster response.
It should be noted that while the solubility of these Pt(IV) complexes in organic
solvents are increased compared to their Pt(II) precursors, they were still poorly soluble
in water; thus, Pt(IV)-1C–Pt(IV)-3C were limited to a highest concentration of 100 µM.
Interestingly, Pt(IV)-4C precipitates out of solution at concentrations of 30 µM or higher
when the stock DMSO solution was diluted in the culture medium; thus, testing of
Pt(IV)4C was limited to 25 µM. Pt(IV)-8C gave similar results regardless of whether the
stock solution was made in DMSO or ethanol, which suggests that the chloride leaving
groups were not displaced by DMSO and indicates that the Pt(IV)-8C structure is stable.
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The effective concentration that resulted in 50% cell viability (EC50) for all the
cell lines tested are given in Tables 5-2–5-5. Comparison of the EC50 values indicate that
the Pt(IV) complexes are generally more effective than cisplatin. A549 and MCF-7 are
the most resistant cell lines, while SK-BR-3 and T-47D are the most sensitive. Similar to
Pt(II) complexes (Chapters 2 and 3), the activity of the Pt(IV) complexes increases as the
carbon number on the alkoxy substituent increases. Pt(IV) complexes with short carbon
chains (1–3 carbons) are not as effective as their Pt(II) precursors and Pt(IV) complexes
with long carbon chains (5–8) are more effective than their Pt(II) precursors. Pt(II)-4C
and Pt(IV)-4C (four carbon chain) have similar activities.
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Figure 5 – 5. Cytotoxic activity of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′bipyridine)] complexes vs. CDDP and carboplatin against DU145 cells. Cells were
treated with CDDP or the platinum analogs at various concentrations for (A) 1 h or (B)
48 h and the viability was determined using the MTS assay. Data points represent mean ±
SD of at least two independent experiments done in quadruplicates.
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Figure 5 – 6. Cytotoxic activity of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′bipyridine)] complexes vs. CDDP and carboplatin against A549 cells. Cells were treated
with CDDP or the platinum analogs at various concentrations for (A) 1 h or (B) 48 h and
the viability was determined using the MTS assay. Data points represent mean ± SD of at
least two independent experiments done in quadruplicates.
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Figure 5 – 7. Cytotoxic activity of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′bipyridine)] complexes vs. CDDP and carboplatin against MCF-7 cells. Cells were
treated with CDDP or the platinum analogs at various concentrations for (A) 1 h or (B)
48 h and the viability was determined using the MTS assay. Data points represent mean ±
SD of at least two independent experiments done in quadruplicates.
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Table 5 – 2. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)]
complexes in A549 and H520 post 1 or 48 h treatment
Lung cancer
A549
CDDP
Carboplatin
Pt(IV)-1C
Pt(IV)-2C
Pt(IV)-3C
Pt(IV)-4C
Pt(IV)-5C
Pt(IV)-6C
Pt(IV)-8C

1h
900 ± 200
>1000
>100
>50
>50
>25
6.6 ± 0.3a
2.5 ± 0.2a
7.0 ± 0.4a

H520

48 h
500 ± 100
300 ± 30
>100
>50
23 ± 1a,b
14 ± 1a,b
2.2 ± 0.1a,b
2.2 ± 0.1a,b
3.0 ± 0.5a,b

1h
200 ± 17
ND
>100
>100
80 ± 20a
13 ± 5a
3 ± 1a
2.1 ± 0.2a
7 ± 5a

48 h
24 ± 2
ND
>100
61 ± 2a
8 ± 6a
2.2 ± 0.1a
1.0 ± 0.3a
1.0 ± 0.4a
1.2 ± 0.6a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.

Table 5 – 3. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes
in DU145 and PC-3 post 1 or 48 h treatment
Prostate cancer

CDDP
Carboplatin
Pt(IV)-1C
Pt(IV)-2C
Pt(IV)-3C
Pt(IV)-4C
Pt(IV)-5C
Pt(IV)-6C
Pt(IV)-8C

1h
400 ± 100
>1000
>100
>50
24 ± 7a
8 ± 7a
1 ± 1a
1.3 ± 0.2a
0.7 ± 0.3a

DU145
48 h
64 ± 8
400 ± 100a
80 ± 20b
10 ± 4a,b
1 ± 1a,b
0.9 ± 0.2a,b
0.34 ± 0.02a,b
0.5 ± 0.3a,b
0.2 ± 0.1a,b

1h
200 ± 20
ND
>100
>50
23.0 ± 0.3a
5 ± 3a
1.7 ± 0.2a
2.0 ± 0.3a
1.2 ± 0.5a

PC-3
48 h
30 ± 1
ND
>100
20 ± 2a
1.1 ± 0.4a
1.1 ± 0.4a
0.5 ± 0.2a
0.33 ± 0.04a
0.11 ± 0.02a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.
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Table 5 – 4. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in
various breast cancer cells post 1 h treatment
HCC38

MCF-7

CDDP

300 ± 30

900 ± 100

MDAMB-231
50 ± 4

Carboplatin

ND

>1000

Pt(IV)-1C

>100

Pt(IV)-2C

93 ± 10a

Pt(IV)-3C

26 ± 6

Pt(IV)-4C

a

SK-BR-3

T-47D

ZR-75-1

420 ± 80

900 ± 100

260 ± 10

ND

ND

ND

ND

>100

>100

>100

>100

>100

>100

>100

40 ± 10a

46 ± 8a

a

19 ± 2

a

24 ± 3

>50

a

24 ± 3a

>100

34 ± 7

17 ± 3a

>25

2.8 ± 0.1a

4.0 ± 0.7a

10 ± 1a

2.9±0.3a

Pt(IV)-5C

3 ± 1a

2.9 ± 0.13a

1.8 ± 0.1a

1.3 ± 0.6a

2.3 ± 0.3a

1.6 ± 0.1a

Pt(IV)-6C

2.3 ± 0.2a

2.4 ± 0.1a

1.1 ± 0.2a

0.36±0.02a

2.1 ± 0.4a

1.1 ± 0.4a

Pt(IV)-8C

3.0 ± 0.6a

4 ± 1a

2.1 ± 0.2a

0.33±0.05a

1.5 ± 0.5a

3.0 ± 1a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.

Table 5 – 5. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in
various breast cancer cells post 48 h treatment
HCC38

MCF-7

MDAMB-231

SK-BR-3

T-47D

ZR-75-1

CDDP

30 ± 8

34 ± 1

21 ± 3

23 ± 6

35 ± 6

30 ± 8

Carboplatin

ND

800 ± 100a ND

ND

ND

ND

Pt(IV)-1C

>100

>100

80 ± 20a

>100

32.0 ± 0.5
a

0.95 ± 0.03

>100
a

Pt(IV)-2C

30 ± 9

>100

28 ± 7

8.3 ± 0.7

17 ± 7

Pt(IV)-3C

8 ± 1a

29 ± 2a,b

6.1 ± 0.4a

0.9 ± 0.1a

0.59 ± 0.01a

1.21±0.04a

Pt(IV)-4C

2.1±0.2a

2.2 ±0.1a,b

1.0 ± 0.2a

0.44±0.02a

0.33 ± 0.07a

0.7 ± 0.2a

Pt(IV)-5C

2.1±0.3a

2.0 ± 0.1a,b

0.26±0.01a

0.30±0.03a

0.25±0a

0.55±0.07a

Pt(IV)-6C

1.8±0.5a

1.6 ± 0.2a,b

0.31±0.04a

0.21±0.03a

0.24 ± 0.01a

0.55±0.04a

Pt(IV)-8C

1.6±0.3a

1.3 ± 0.3a,b

0.9 ± 0.3a

0.22±0.03a

0.25 ± 0a

1.3 ± 0.1a

Values represent the mean ± SD of at least two independent experiments done in
quadruplicates. ND = no data. a P < 0.5 compared to CDDP. b P < 0.05 compared to
carboplatin.
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Figure 5 – 8. Pt(IV) complexes induced phosphorylation of H2AX in A549 and DU145
cells. (A) A549 cells were treated for 6 h with 25 µM Pt(IV)-4C or 7.5 µM Pt(IV)-5C
and analyzed 12 h post treatment, (B) DU145 cells were treated for 2 h with 10 µM
Pt(IV)-4C or 2.5 µM Pt(IV)-5C and analyzed 7 h post treatment. Data are representative
of three independent experiments.

5.4.2.2 Detection of DNA damage
Cisplatin is known to bind DNA and form adducts, which induces cell cycle
arrest, DNA damage repair, various stress response pathways, and death pathways. DNA
damage by cisplatin has been shown to induce phosphorylation of histone H2AX, which
is believed to be involved in recognition and repair of damaged DNA, and regulation of
the apoptotic pathway. Flow cytometry was used to analyze levels of phosphorylated
H2AX (γH2AX) in A549 and DU145 cells treated with Pt(IV)-4C and Pt(IV)-5C.
156

Representative histograms for each cell line are shown in Figure 5-8. As shown,
treatment with Pt(IV)-4C and Pt(IV)-5C resulted in an increase of γH2AX in both A549
and DU145 cells. The increase in γH2AX caused by Pt(IV)-4C treatment was not as high
as Pt(IV)-5C. Nonetheless, these results indicate that treatment with Pt(IV)-4C and
Pt(IV)-5C caused DNA damage in A549 and DU145 cells.
5.4.2.3 Evaluation of apoptosis
Cisplatin induced DNA damage has been associated with cell cycle arrest and
induction of apoptosis.

Since treatment with Pt(IV)-4C and Pt(IV)-5C caused an

increase in γH2AX in A549 and DU145 cells, their effects on the cell cycle was
examined. Flow cytometric analysis of propidium iodide provides information on DNA
content, which is correlated with the stages in the cell cycle. Additionally, appearance of
a sub-G1 peak is an indication of apoptosis. A549 cells treated with Pt(IV)-4C and
Pt(IV)-5C had a decreased percentage of cells in the G1 phase and a corresponding
increase in the sub-G1 peak, while the S and G2 phases remained relatively similar to the
control (Figure 5-9 A). Treatment of DU145 cells with Pt(IV)-4C and Pt(IV)-5C did not
affect the cell cycle and a sub-G1 peak was not detected (Figure 5-9 B). A sub-G1 peak
was not detected even when the treatment time was extended to 2 and 4 h; perhaps these
treatment duration are not enough to cause fragmentation and leakage of the DNA
content to produce a sub-G1 peak. Alternatively, the difference between the response of
A549 and DU145 may be due to differences in p53 status; A549 has wild type p53, while
DU145 has mutant p53. It is possible that lack of apoptotic features in DU145 cells is the
result of not having functional p53 to signal the apoptotic pathway.
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The sub-G1 peak is a measurement of cells with less DNA than cells in the G1
phase, which is attributed to leakage of DNA content from cells undergoing late
apoptosis or necrosis. Since the sub-G1 peak is not a clear indication of apoptosis, flow
cytometric analysis of Annexin V and PI double staining was performed. Annexin V
binds to exposed phosphatidylserine on the membrane surface, which is an event that
occurs in early apoptosis. Co-staining with PI, a membrane impermeable dye, allows for
differentiation between cells with intact membrane and cells with membrane damage,
which occurs in late stage apoptosis or necrosis. As shown in Figure 5-10, A549 and
DU145 cells treated with Pt(IV)-4C and Pt(IV)-5C had decreased AnnexinV/PI negative
cells (Q4, live cells) and a corresponding increase in Annexin V positive (Q3, early
apoptotic cells) and Annexin V/PI positive cells (Q2, late apoptotic/necrotic cells). These
changes were higher in Pt(IV)-5C treated cells than Pt(IV)-4C treated cells. A549 cells
treated with Pt(IV)-5C also had an increase in PI positive cells (Q1, necrotic cells)
(Figure 5-10 A). DU145 had higher increases of Annexin V/PI positive cells than
Annexin V positive cells suggesting that they may be in late stage apoptosis or necrosis
(Figure 5-10 B). Together, these results indicate that Pt(IV)-4C and Pt(IV)-5C induce
apoptosis in A549 and DU145 cells, although some necrosis was also observed.
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Figure 5 – 9. Cell cycle analysis of A549 and DU145 cells treated with Pt(IV)-4C and
Pt(IV)-5C. (A) A549 cells were treated for 5 h with 25 µM Pt(IV)-4C or 7.5 µM Pt(IV)5C and analyzed 12 h post treatment, (B) DU145 cells were treated for 1 h with 10 µM
Pt(IV)-4C or 2.5 µM Pt(IV)-5C and analyzed 12 h post treatment. Data are
representative of three independent experiments.
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Figure 5 – 10. Flow cytometry analysis of Annexin V/PI staining in A549 and DU145
treated with Pt(IV)-4C and Pt(IV)-5C. (A) A549 cells were treated for 5 h with 25 µM
Pt(IV)-4C or 10 µM Pt(IV)-5C and analyzed 12 h post treatment, (B) DU145 cells were
treated for 1 h with 10 µM Pt(IV)-4C or 2.5 µM Pt(IV)-5C analyzed 12 h post treatment.
Q1 = PI+, represents necrotic cells; Q2 = Annexin V/PI+, representing late
apoptotic/necrotic cells; Q3 = Annexin V+, representing early apoptotic cells; Q4 =
AnnexinV/PI-, representing live cells. Data are representative of three independent
experiments.

Analysis of hoechst (Ho) and PI staining by confocal microscopy was performed
to detect cell death. PI stains cells with membrane damage; whereas, Ho stains both live
and apoptotic cells, but apoptotic cells will have more intense Ho fluorescence. A549
cells treated with Pt(IV)-4C and Pt(IV)-5C had increased Ho fluorescence compared to
control (Figure 5-11). There was no difference between the PI fluorescence of Pt(IV)-5C
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treated cells compared to the control, but Pt(IV)-4C treated cells had increased PI
positive cells. Similar results were obtained for DU145 cells, except Pt(IV)-5C treated
cells had more PI positive staining than Ho staining compared to the control (Figure 512). Additionally, unlike A549, the PI positive cells in Pt(IV)-4C treated cells were
higher than Pt(IV)-5C treated cells. The increase in PI staining suggests that the cells
have membrane damage, which indicates that the cells were either at late stage apoptosis
or were undergoing necrosis. These results correspond to the flow results indicating that
Pt(IV)-4C and Pt(IV)-5C induce apoptosis and possibly some necrosis.

Figure 5 – 11. Confocal microscopy analysis of PI and Ho uptake in A549 cells treated
with Pt(IV)-4C and Pt(IV)-5C. A549 cells treated for 5 h with 25 µM Pt(IV)-4C or 7.5
µM Pt(IV)-5C were stained with Ho and PI and images were capture with a confocal
microscope. Images are from one trial.
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Figure 5 – 12. Confocal microscopy analysis of PI and Ho uptake in DU145 cells treated
with Pt(IV)-4C and Pt(IV)-5C. DU145 cells treated for 3.5 h with 10 µM Pt(IV)-4C or
2.5 µM Pt(IV)-5C were stained with Ho and PI and images were capture with a confocal
microscope. Images are from one trial.

Finally, detection of cleaved-PARP by flow cytometry was used as an indication
of apoptosis. PARP is a nuclear poly (ADP-ribose) polymerase that has been associated
with DNA repair. During apoptosis, PARP is cleaved by caspase-3.20 As shown in Figure
5-13, both A549 and DU145 cells treated with Pt(IV)-4C and Pt(IV)-5C had increased
levels of cleaved-PARP, suggesting that Pt(IV)-4C and Pt(IV)-5C induced caspase-3
mediated apoptosis in these two cell lines. The fold increase of cleaved-PARP in A549
(~7 fold for both compounds) were higher than DU145 (~2 fold for both compounds).
Similar to the flow data with PI staining, the differences between A549 and DU145 may
be due to treatment time or p53 status.
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Figure 5 – 13. Pt(IV)-4C and Pt(IV)-5C induced cleavage of PARP. (A) A549 cells
were treated for 5 h with 25 µM Pt(IV)-4C or 7.5 µM Pt(IV)-5C and analyzed 12 h post
treatment, (B) DU145 cells were treated for 2 h with 10 µM Pt(IV)-4C or 2.5 µM
Pt(IV)-5C analyzed 7 h post treatment. Data are representative of three independent
experiments.
5.5 Conclusions
We have synthesized a series of Pt(IV) derivatives with diacetato axial ligands
from our recently reported Pt(II) complexes containing 4,4′-dialkoxy-2,2′-bipyridyl
ligands. Solubility of these Pt(IV) complexes in DMSO was increased compared to the
Pt(II) precursor. In vitro testing of these Pt(IV) complexes in a panel of human lung,
breast, and prostate cancer cell lines suggested that these Pt(IV) complexes are generally
more effective than cisplatin. Similar to the Pt(II) precursors, a structure activity
relationship was observed in which the compounds had increasing anti-proliferative
activities with increasing carbon chain length of the dialkoxy substituents. The activities
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of Pt(IV)-5C–Pt(IV)-8C were similar, but in some cases Pt(IV)-8C was less active.
Pt(IV)-1C–Pt(IV)-3C were less active than the Pt(II) counterparts and Pt(IV)-4C had
similar activity to Pt(II)-4C. Pt(IV)-5C and Pt(IV)-6C were more active than their Pt(II)
counterparts in both the 1 h and the 48h treatment. Pt(II)-8C could not be tested due to
poor solubility, but the increased solubility of Pt(IV) complexes allowed for the testing of
Pt(IV)-8C, which had activity in both the 1 h and the 48 h treatment.
Analysis of cell death using confocal microscopy and flow cytometry staining
with various dyes and antibodies demonstrated that Pt(IV)-4C and Pt(IV)-5C induced
DNA damage in A549 and DU145 cells, which led to activation of apoptosis with some
necrotic response.
These findings demonstrate that the Pt(IV) complexes have the potential to be
used as anticancer drugs.

164

5.6 References
1.

Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo,
M.; Parkin, D. M.; Forman, D.; Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence
and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France:
International Agency for Research on Cancer; 2013. http://globocan.iarc.fr (accessed
March 9, 2014).

2.

Bray, F.; Jemal, A.; Grey, N.; Ferlay, J.; Forman, D. Global cancer transitions
according to the Human Development Index (2008–2030): a population-based study.
Lancet Oncol. 2012, 13, 790-801.

3.

Urruticoechea, A.; Alemany, R.; Balart, J.; Villanueva, A.; Viñals, F.; Capellá, G.
Recent advances in cancer therapy: an overview. Curr. Pharm. Des. 2010, 16, 3-10.

4.

Biemar, F.; Foti, M. Global progress against cancer—challenges and opportunities.
Cancer Biol. Med. 2013, 10, 183-186.

5.

Fricker, S. Metal based drugs: from serendipity to design. Dalton Trans. 2007, 43,
4903-4917.

6.

Harper, B. W.; Krause-Heuer, A. M.; Grant, M. P.; Manohar, M.; GarbutcheonSingh, K. B.; Aldrich-Wright, J. R. Advances in Platinum Chemotherapeutic. Chem.
Eur. J. 2010, 16, 7064-7077.

7.

Kamimura, K.; Suda, T.; Tamura, Y.; Takamura, M.; Yokoo, T.; Igarashi, M.;
Kawai, H.; Yamagiwa, S.; Nomoto, M.; Aoyagi, Y. Phase I study of miriplatin
combined with transarterial chemotherapy using CDDP powder in patients with
hepatocellular carcinoma. BMC Gastroenterology 2012, 12, 127.

8.

Li, G.-q.; Chen, X.-g.; Wu, X.-p.; Xie, J.-d.; Liang, Y.-j.; Zhao, X.-q. C. W.-q.; Fu,
L.-w. Effect of Dicycloplatin, a Novel Platinum Chemotherapeutical Drug, on
Inhibiting Cell Growth and Inducing Cell Apoptosis. PLoS ONE 2012, 7, e48994.

9.

Wang, X.; Guo, Z. Targeting and delivery of platinum-based anticancer drugs.
Chem. Soc. Rev. 2013, 42, 202–224.

10. Wheate, N. J.; Walker, S.; Craig, G. E.; Oun, R. The status of platinum anticancer
drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113– 8127.
11. Casini, A.; Reedijk, J. Interactions of anticancer Pt compounds with proteins: an
overlooked topic in medicinal inorganic chemistry? Chem. Sci. 2012, 3, 3135–3144.
165

12. Graf, N.; Lippard, S. J. Redox activation of metal-based prodrugs as a strategy for
drug delivery. Adv. Drug Deliv. Rev. 2012, 64, 993–1004.
13. Wexselblatt, E.; Gibson, D. What do we know about the reduction of Pt(IV) prodrugs? J. Inorg. Biochem. 2012, 117, 220-229.
14. Wong, D. Y. Q.; Ang, W. H. Development of Platinum(IV) Complexes as
Anticancer Prodrugs: The Story so Far. COSMO 2012, 8, 121-134.
15. Bharti, S. K.; Singh, S. K. Recent Developments in the Field of Anticancer
Metallopharmaceuticals. Int. J. PharmTech Res. 2009, 1, 1406-1420.
16. Marques, M. P. M. Platinum and Palladium Polyamine Complexes as Anticancer
Agents: The Structural Factor. ISRN Spectroscopy 2013, 2013, 1-29.
17. Muhammad, N.; Guo, Z. Metal-based anticancer chemotherapeutic agents. Curr.
Opin. Chem. Biol. 2014, 19, 144-153.
18. Vo, V.; Tanthmanatham, O.; Han, H.; Bhowmik, P. K.; Spangelo, B. L. Synthesis of
[PtCl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes and their in vitro anticancer
properties. Metallomics 2013, 5, 973-987.
19. Mackay, F. S.; Farrer, N. J.; Salassa, L.; Tai, H.-C.; Deeth, R. J.; Moggach, S. A.;
Wood, P. A.; Parsons, S.; Sadler, P. J. Synthesis, characterisation and
photochemistry of PtIV pyridyl azido acetato complexes. Dalton Trans. 2009, 13,
2315-2325.
20. Boulares, A. H.; Yakovlev, A. G.; Ivanova, V.; Stoica, B. A.; Wang, G.; Iyer, S.;
Smulson, M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis.
Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J.
Biol. Chem. 1999, 274, 22932-22940.

166

CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Conclusions
Platinum-based drugs are currently used worldwide for the treatment of various
cancers; however, severe side effects and intrinsic or acquired resistance have hindered
their clinical utility. Motivated to develop platinum drugs with improved efficacy and
lower toxicity, three series of platinum(II) and platinum(IV) complexes containing 4,4′disubstituted-2,2′-bipyridine ligands have been synthesized and investigated for possible
anti-tumoral activity.
The first series that was prepared consisted of seven [Pt(II)Cl2(4,4′-dialkoxy-2,2′bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)]
(where R = –(CH2)n–1CH3, n = 2–6, 8), five of which are novel compounds. The antiproliferative activities of these complexes were examined in a panel of 10 human cancer
cell lines from lung, prostate, and breast origin. Although the effects of these
[Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes varies between the different cell
lines, it can be generalized that all of the novel complexes are more effective than
cisplatin and carboplatin in the cell lines tested. The superior activity of these novel
platinum complexes are more evident in the short 1 h treatment than in the extended 48 h
treatment, suggesting that these novel platinum complexes may reach intracellular targets
faster than cisplatin.
The EC50 values for two of the complexes, Pt(II)-1C and Pt(II)-2C, could not be
determined in some cell lines due to their poor solubility which prevented testing at
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concentrations above 100 µM. However, comparison of the effects at the concentrations
tested revealed a correlation between structure and activity; the anti-proliferative activity
of the complexes increases as the carbon number on the alkoxy substituents increases
from one (Pt(II)-1C) to four (Pt(II)-4C) carbons. Pt(II)-5C (5 carbons) and Pt(II)-6C (6
carbons) generally have similar activity to Pt(II)-4C. Pt(II)-8C, which has eight carbons
on the alkoxy substituents, was not tested due to poor solubility.
Pt(II)-4C was selected for further investigation due to having consistently low
EC50 values in all of the cell lines tested. Examination of Pt(II)-4C interaction with DNA
by UV-Vis analysis with calf thymus DNA, gel electrophoresis with plasmid pBR322
DNA, and ICP-AES measurement of platinum in Pt(II)-4C cells revealed that Pt(II)-4C
is able to induce DNA damage. Results from western blotting, flow cytometric
immunofluorescence, and immunofluorescence microscopy indicate induction of
apoptosis and activation of p53, histone H2AX (γH2AX), and MAPK members (JNK,
ERK, and p38). Treatment of cells with Pt(II)-4C in the presence of MAPK inhibitors
resulted in decreased γH2AX compared to cells treated with Pt(II)-4C alone suggesting
that activation of H2AX is dependent on MAPKs. Furthermore, cells treated with Pt(II)4C in the presence of p53, JNK, or p38 inhibitors had increased cell viability compared
to cells treated with Pt(II)-4C alone. These results indicate that p53, JNK, and p38 are
involved in activation of the apoptotic pathway in response to Pt(II)-4C. Moreover,
Pt(II)-4C induced apoptosis may be regulated by γH2AX in a JNK and p38 dependent
manner.
The in vitro data indicate that these complexes have potential clinical utility, thus,
Pt(II)-4C toxicity was tested in mice. Mice injected with Pt(II)-4C at a dose of 12.5 mg
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kg-1 d-1 for 3 d survived the study period of 7 d post injection and did not show any
abnormal signs. This result indicates that Pt(II)-4C is not toxic in animal models at the
tested dose; thus, further in vivo studies are warranted. However, in vivo investigation of
Pt(II)-4C is complicated by its low solubility in common organic solvents and
solubilizing agents.
To improve the solubility of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes,
the second series of Pt(II) complexes were developed by modification of the dialkoxy
substituents to have increasing oxygen which will result in increasing hydrogen bonding
and water solubility. This series consist of five [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)]
(where R = –(CH2CH2O)n(CH2)mCH3, n = 1–4, m = 0–3). The anti-proliferative activities
of these complexes were also examined in a panel of 10 human cancer cell lines from
lung, prostate, and breast origin. The results showed varying degrees of activity in the
cell lines tested. In some cell lines, the synthesized complexes were as effective as
cisplatin or less effective, while in others, the synthesized complexes were more effective
than cisplatin. Although these complexes have improved solubility in organic solvents
and two have some solubility in water; their anti-proliferative activity is greatly
diminished compared to the dialkoxy series.
The third series was then prepared by oxidation of the Pt(II) dialkoxy series to
Pt(IV), which resulted in seven [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)]
complexes. The solubility of these Pt(IV) complexes in organic solvents were improved,
but they still have poor solubility in water. The anti-proliferative activities of these
complexes were also examined in the same panel of cancer cell lines. Similar to the Pt(II)
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precursors, these Pt(IV) complexes are generally more effective than cisplatin. Pt(IV)1C–Pt(IV)-3C were less active than the Pt(II) counterparts and Pt(IV)-4C had similar
activity to Pt(II)-4C. Pt(IV)-5C and Pt(IV)-6C were more active than their Pt(II)
counterparts in both the 1 h and the 48h treatment. Pt(II)-8C could not be tested due to
poor solubility, but the increased solubility of Pt(IV) complexes allowed for the testing of
Pt(IV)-8C, which had high anti-proliferative activity for both the 1 h and the 48 h
treatments.
Analysis of cell death revealed that Pt(IV)-4C and Pt(IV)-5C induced DNA
damage in A549 and DU145 cells, which led to activation of apoptosis with some
necrotic response. These findings demonstrate that the Pt(IV) complexes have the
potential to be used as anticancer drugs and warrant further investigation.
6.2 Future directions
The two Pt(II) series described were prepared by utilizing the 4,4′ positions on the
2,2′-bipyridyl ligand. Other series can be made by changing the functional group at these
positions. A few compounds with —COOR and phosphate groups at the 4,4′ positions
have been prepared, but their anti-proliferative activities have not been thoroughly
investigated. Examination of their anti-proliferative activities may provide useful
information on the structure-activity relationship.
New platinum complexes are continuously being made through modifications of
existing compounds by employing methods to alter the leaving groups and/or the nonleaving groups.1 The structure of the 2,2′-bipyridyl ligand offers many opportunities for
functionalization to create new compounds. However, it would be interesting to explore
the effects of replacing the chloride leaving groups with other types of leaving groups on
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the activity of the 2,2′-bipyridyl platinum complexes. Compounds in which the chloride
leaving groups were replaced by a pyrophosphate group have been shown to have better
or comparable activity to cisplatin and having a different mechanism of action than DNA
binding.2,3 These compounds were also demonstrated to be effective in cisplatin
resistance cancer cells. This would be an interesting option to modify the disubstituted2,2′-bipyridyl platinum(II) and platinum(IV) complexes. Alternatively, modification of
the axial ligands of the Pt(IV) complexes may result in improvements.4
In addition to the synthesis of new compounds, further investigation of the three
synthesized series should be done. Some of the results presented are only from one or
two trials; thus they need to be repeated to confirm the results. Also, a major concern
with cisplatin is intrinsic or acquired resistance; thus, these complexes should be tested in
cisplatin resistant cells.
Cisplatin induced DNA damage activates many signaling pathways. Although
activation of p53 and MAPKs by Pt(II)-4C have been demonstrated, it is not exactly
clear how they are involved. Thus, their upstream and downstream signaling should be
examined. Additionally, the use of a chemical inhibitor may not provide accurate
information since they can interact with other biological molecules. Consequently, results
obtained with the p53 and MAPK inhibitors should be confirmed with knockout
experiments.
Since the Pt(IV) complexes are also highly effective and various data indicate that
they induce apoptosis, the p53 and MAPK experiments done for the Pt(II)-4C should be
repeated with Pt(IV)-4C or Pt(IV)-5C. Although the Pt(II)-dioligooxyethylene series are
not as effective as the other two series, Pt(II)-4O,2C should be examined further since it
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is water soluble and had comparable activity to cisplatin in some of the tested cell lines.
Perhaps combination treatment with phytochemicals4–6 or photochemical internalizationmediated delivery may increase the effectiveness of these complexes.7,9 Lastly, instead of
directly modifying the complexes to improve solubility, it might be beneficial to explore
delivery methods such as incorporation into a macromolecular delivery system.10–12
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APPENDIX 1
SUPPORTING INFORMATION FOR CHAPTER 2
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Figure 2S – 1. 13C NMR spectra of ligands and Pt(II)-complexes recorded in A) DMSOd6 and B) CDCl3 at temperatures indicated in the experimental section (* solvent peak).
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Figure 2S – 2. DSC thermograms of A) Pt-3C, B) Pt-5C, C) Pt-6C, and D) Pt-8C
obtained in nitrogen at heating and cooling rates of 10 °C/min.
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APPENDIX 2
SUPPORTING INFORMATION FOR CHAPTER 3

Figure 3S – 1. Flow cytometric analysis of γH2AX. (A) A549 cells treated for 6 h with
25 µM Pt(II)-4C, (B) DU145 cells treated for 1 h with 25 µM Pt(II)-4C, and (D) fold
change in the fluorescence signals compared to control. Histograms are representative of
three experiments.

177

Figure 3S – 2. Effects of MAPK inhibitors on Pt(II)-4C induced cell death in DU145
cells. The cells were treated with increasing concentrations of Pt(II)-4C in the absence
and presence of 50 µM of MAPK inhibitors (PD: ERK inhibitor, SB: p38 inhibitor, SP:
JNK inhibitor) for 48 h. Results are representative of two independent experiments done
in quadruplicates.
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SUPPORTING INFORMATION FOR CHAPTER 4

Figure 4S – 1. 1H NMR of tosylate compounds recorded in CDCl3 at room temperature.
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Figure 4S –2. 1H (top) and 13C (bottom) NMR spectra of compound L-2O,1C recorded
in DMSO-d6 at room temperature.
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Figure 4S –3. 1H (top) and 13C (bottom) NMR spectra of compound L-3O,2C recorded
in CDCl3 at room temperature.
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Figure 4S –4. 1H (top) and 13C (bottom) NMR spectra of compound L-4O,2C recorded
in CDCl3 at room temperature.
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Figure 4S –5. 1H (top) and 13C (bottom) NMR spectra of compound L-4O,4C recorded
in CDCl3 at room temperature.
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Figure 4S –6. 1H (top) and 13C (bottom) NMR spectra of compound L-5O,1C recorded
in CDCl3 at room temperature.
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Figure 4S –7. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-2O,1C
recorded in DMSO-d6 at room temperature.
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Figure 4S –8. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-3O,2C
recorded in CDCl3 at room temperature.
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Figure 4S –9. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-4O,2C
recorded in CDCl3 at room temperature.
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Figure 4S –10. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-4O,4C
recorded in CDCl3 at room temperature.
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Figure 4S –11. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-5O,1C
recorded in CDCl3 at room temperature.
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Figure 5S –1. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-1C recorded
in DMSO-d6 at room temperature.
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Figure 5S –2. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-2C recorded
in DMSO-d6 at room temperature.
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Figure 5S – 3. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-3C recorded
in DMSO-d6 at room temperature.
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Figure 5S – 4. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-4C recorded
in DMSO-d6 at room temperature.
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Figure 5S – 5. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-5C recorded
in CDCl3 at room temperature.
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Figure 5S – 6. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-6C recorded
in CDCl3 at room temperature.
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Figure 5S – 7. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-8C recorded
in CDCl3 at room temperature.
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